

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Wednesday, September 22, 2004

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L10	L5 AND L8	82
<input type="checkbox"/>	L9	L5 AND L6	249
<input type="checkbox"/>	L8	cyclin	8181
<input type="checkbox"/>	L7	CYCLIN	8181
<input type="checkbox"/>	L6	SV40	26490
<input type="checkbox"/>	L5	VP22	524
<input type="checkbox"/>	L4	L3 AND VP22	79
<input type="checkbox"/>	L3	530/300,350.CCLS.	16971
<input type="checkbox"/>	L2	L1 AND VP22	70
<input type="checkbox"/>	L1	(435/69.1.CCLS.)	19136

END OF SEARCH HISTORY

Hit List

Search Forms

Search Results

Help

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

User Searches

Preferences

Logout

Search Results - Record(s) 1 through 82 of 82 returned.

☐ 1. Document ID: US 20040151696 A1

Using default format because multiple data bases are involved.

L10: Entry 1 of 82

File: PGPB

Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151696

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040151696 A1

TITLE: Oncolytic adenovirus

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Johnson, Leisa	Lafayette	CA	US	
Fattaey, Ali	San Francisco	CA	US	
Hermiston, Terry	Corte Madera	CA	US	
Shen, Yuqiao	Orinda	CA	US	
Laquerre, Sylvie	Conshohocken	PA	US	

US-CL-CURRENT: [424/93.2](#); [435/235.1](#), [435/456](#)

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20040146944 A1

L10: Entry 2 of 82

File: PGPB

Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146944

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040146944 A1

TITLE: Reverse protein delivery into cells on coded microparticles

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fang, Ye	Painted Post	NY	US	
Webb, Brian L.	Painted Post	NY	US	

US-CL-CURRENT: [435/7.2](#)

ABSTRACT:

Systems, methods and kits that utilize uniquely coded microparticles for performing protein assays are provided. The uniquely coded microparticles are used as a substrate for reverse protein delivery into cells. The microparticles and methods offer the possibility of studying the biological functions of either a single protein of interest in multiple cell types per assay or multiple proteins in a single cell type.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040142900 A1

L10: Entry 3 of 82

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142900
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040142900 A1

TITLE: Uses of transport proteins

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Normand, Nadia Michelle	Surrey		GB	
Brewis, Neil Douglas	Surrey		GB	
Phelan, Anne	Kent		GB	

US-CL-CURRENT: 514/44; 435/455

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 20040137622 A1

L10: Entry 4 of 82

File: PGPB

Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137622
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137622 A1

TITLE: Modular transfection systems

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Schmidt, Hanns-Martin	Koln	DE
Altrogge, Ludger	Pulheim	DE
Lenz, Dietmar	Koln	DE
Riemen, Gudula	Langenfeld	DE
Brosterhus, Helmut	Kirchhunden	DE
Lorbach, Elke	Koln	DE
Helfrich, Juliana	Koln	DE
Hein, Katharina	Koln	DE
Gremse, Marion	Koln	DE
Males, Tarjana	Hilden	DE
Christine, Rainer	Koln	DE
Siebenkotten, Gregor	Freehen-Konigsdorf	DE
Ortmann, Bodo	Koln	DE
Klacs, Andrea	Koln	DE

US-CL-CURRENT: 435/455

ABSTRACT:

The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals. The present inventions also includes corresponding pharmaceutical preparations, especially for use in gene therapy as well as the use of such transfection agents as component in kits.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20040072319 A1

L10: Entry 5 of 82

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072319

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072319 A1

TITLE: Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nash, Piers	Ontario		CA	
Pawson, Anthony	Ontario		CA	

Tang, Xiaojing Ontario CA
Tyers, Michael Ontario CA

US-CL-CURRENT: 435/226; 435/320.1, 435/325

ABSTRACT:

The invention relates to methods for identifying compounds that modulate ubiquitin-dependent proteolysis, and compounds identified using the methods. The invention also relates to a novel peptide motif referred to as the "CPD motif", molecules derived from the CPD motif, and uses of the CPD motif and molecules.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20040038303 A1

L10: Entry 6 of 82

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038303
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038303 A1

TITLE: Biologic modulations with nanoparticles

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Unger, Gretchen M.	Chaska	MN	US	

US-CL-CURRENT: 435/7.1; 530/350, 530/387.1, 530/396, 536/123

ABSTRACT:

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 7. Document ID: US 20040028693 A1

L10: Entry 7 of 82

File: PGPB

Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040028693
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040028693 A1

TITLE: Molecular vaccine linking intercellular spreading protein to an antigen

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wu, Tzyy Choou	Brookeville	MD	US	
Hung, Chien-Fu	Baltimore	MD	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homologue or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20040028607 A1

L10: Entry 8 of 82

File: PGPB

Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040028607

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040028607 A1

TITLE: Methods of modulating tubulin deacetylase activity

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Verdin, Eric M.	San Francisco	CA	US	
North, Brian J.	San Francisco	CA	US	
Ulrich, Scott M.	Ithaca	NY	US	

US-CL-CURRENT: 424/1.11; 435/19

ABSTRACT:

The present invention provides methods for identifying agents that modulate a level or an activity of tubulin deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating tubulin deacetylase activity in a cell. The invention further provides methods of modulating cellular proliferation by modulating the activity of tubulin deacetylase.

☐ 9. Document ID: US 20040023391 A1

L10: Entry 9 of 82

File: PGPB

Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023391
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023391 A1

TITLE: Method and device for protein delivery into cells

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fang, Ye	Painted Post	NY	US	
Lai, Fang	Painted Post	NY	US	
Picard, Laurent A.G.	Corning	NY	US	
Webb, Brian L.	Painted Post	NY	US	

US-CL-CURRENT: 435/458; 435/366

ABSTRACT:

Methods for performing surface-mediated protein delivery into living cells, and fabricating protein-transfected cell cluster arrays are provided. The method comprises providing a protein-containing mixture; depositing said protein-containing mixture onto a surface at defined locations; affixing the protein-containing mixture to the surface as microspots; and plating cells onto the surface in sufficient density and under conditions for the proteins to be delivered into the cells. The protein-containing mixture comprises any suitable amino acid sequence, including peptides, proteins, protein-domains, antibodies, or protein-nucleic acid conjugates, etc., with a carrier reagent. Protein-transfected cell arrays may be used for rapid and direct, screening of protein or enzymatic functions or any given intracellular protein interaction in the natural environment of a living cell, as well as for high-throughput screening of other biological and chemical analytes, which affect the functions of these proteins.

☐ 10. Document ID: US 20040022769 A1

L10: Entry 10 of 82

File: PGPB

Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040022769
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040022769 A1

TITLE: Methods and compositions to induce antitumor response

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFace, Drake M.	San Diego	CA	US	

US-CL-CURRENT: 424/93.2; 435/235.1, 435/320.1, 435/456

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 11. Document ID: US 20040002455 A1

L10: Entry 11 of 82

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 12. Document ID: US 20030232781 A1

L10: Entry 12 of 82

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232781

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030232781 A1

TITLE: Modulation of gene expression using insulator binding proteins

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.			US	
Wolffe, Elizabeth J.			US	

US-CL-CURRENT: 514/44; 424/94.61, 435/455

ABSTRACT:

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions including insulator domains for targeted regulation of a gene or transgene are provided.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 13. Document ID: US 20030229202 A1

L10: Entry 13 of 82

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229202

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229202 A1

TITLE: Membrane penetrating peptides and uses thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guo, Yong	Fresh Meadows	NY	US	
Morse, Clarence C.	Asbury	NJ	US	
Yao, Zhengbin	Sugar Land	TX	US	
Keesler, George A.	Hillsborough	NJ	US	

US-CL-CURRENT: 530/350; 435/455

ABSTRACT:

The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More

particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 14. Document ID: US 20030199002 A1

L10: Entry 14 of 82

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199002
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030199002 A1

TITLE: Clk-2 nucleic acids, polypeptides and uses thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hekimi, Siegfried	Montreal	MD	CA	
Benard, Claire	Montreal		CA	
Jiang, Ning	Montreal		CA	
Kebir, Hania	Montreal		CA	
McCright, Brenton	Gaithersburg		US	
Lakowski, Bernard	Paris		FR	

US-CL-CURRENT: 435/7.2; 435/193, 435/320.1, 435/325, 435/69.7, 536/23.2

ABSTRACT:

The present invention relates to nucleotide sequences of clk-2 genes, particularly human clk-2, and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof. The present invention also relates to methods and compositions designed for the treatment, management, or prevention of disorders associated with abnormal expression and/or activity of clk-2 nucleic acids and/or proteins. In one embodiment, the invention encompasses a method of treating or preventing a disorder associated with decreased apoptosis (e.g., cancer, autoimmune disorders) or decreased telomere length (e.g., rapid aging or advanced age) by administering to a subject in need thereof an effective amount of an agent that promotes clk-2 activity. In another embodiment, invention encompasses a method of treating or preventing a disorder associated with increased apoptosis (e.g., neurodegenerative disorders) and increased telomere length (e.g., cancer) such as by administering to a subject in need thereof an effective amount of an agent that decreases clk-2 function. Diagnostic methods and methods for screening for therapeutically useful agents are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 15. Document ID: US 20030194727 A1

L10: Entry 15 of 82

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Jin-Soo	Yuseong-gu		KR	
Park, Kyung-Soon	Yuseong-gu		KR	
Lee, Dong-Ki	Yuseong-gu		KR	
Seol, Wongi	Yuseong-gu		KR	
Lee, Horim	Chungcheongnam-do		KR	
Lee, Seong-Il	Yuseong-gu		KR	
Yang, Hyo-Young	Yuseong-gu		KR	
Lee, Yangsoon	Yuseong-gu		KR	
Jang, Young-Soon	Yuseong-gu		KR	

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1,
435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 16. Document ID: US 20030180777 A1

L10: Entry 16 of 82

File: PGPB

Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180777
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030180777 A1

TITLE: Rapid identification of transcriptional regulatory domains

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartsevich, Victor	Albany	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/7.2

ABSTRACT:

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

Compositions and methods for high-throughput assay for transcriptional regulatory domains in mammalian cells are provided. In certain embodiments, libraries of random amino acid sequences are assayed for transcriptional regulatory activity. In additional embodiments, cDNA libraries are assayed. Libraries are fused to a DNA-binding domain that is targeted to a reporter gene, and modulation of expression of the reporter gene is assayed. Accordingly, regulatory domains having both positive and negative transcriptional regulatory activity can be identified.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 17. Document ID: US 20030170216 A1

L10: Entry 17 of 82

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170216

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170216 A1

TITLE: SYN3 compositions and methods

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ihnat, Peter M.	Brooklyn	NY	US	
Witchey-Lakshmanan, Leonore C.	Piscataway	NJ	US	
Sandweiss, Varda	Forest Hills	NY	US	
Ugwu, Sydney O.	Chicago	IL	US	

US-CL-CURRENT: 424/93.21; 514/44

ABSTRACT:

Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 18. Document ID: US 20030166141 A1

L10: Entry 18 of 82

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Case, Casey C.	San Mateo	CA	US
Cox, George N. III	Louisville	CO	US
Eisenberg, Stephen P.	Boulder	CO	US
Liu, Qiang	Foster City	CA	US
Rebar, Edward J.	El Cerrito	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 20030152945 A1

L10: Entry 19 of 82

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152945 A1

TITLE: Cell cycle progression proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deak, Peter	Cambridge		GB	
Glover, David Moore	Sandy		GB	
Midgley, Carol	Milton Keynes		GB	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 20. Document ID: US 20030148973 A1

L10: Entry 20 of 82

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148973
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148973 A1

TITLE: MAGE-A1 peptides for treating or preventing cancer

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Emtage, Peter	Boston	MA	US	
Karunakaran, Liza	Toronto	NY	CA	
Pedyczak, Arthur	Toronto		CA	
Barber, Brian H.	Hawthorne		US	

US-CL-CURRENT: 514/44; 424/185.1, 424/93.2, 536/23.1

ABSTRACT:

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 21. Document ID: US 20030113919 A1

L10: Entry 21 of 82

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113919

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030113919 A1

TITLE: Immunogenic targets for melanoma

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Emtage, Peter	Sunnyvale	CA	US	
Karunakaran, Liza	Thornhill	NY	CA	
Pedyczak, Artur	Pickering		CA	
Barber, Brian	White Plains		US	

US-CL-CURRENT: 435/456; 435/235.1, 435/320.1

ABSTRACT:

The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 22. Document ID: US 20030108880 A1

L10: Entry 22 of 82

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 23. Document ID: US 20030099944 A1

L10: Entry 23 of 82

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030099944
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030099944 A1

TITLE: Combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton		CA	

US-CL-CURRENT: 435/6; 424/204.1, 435/5, 514/263.38, 514/263.4

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compositions and assays for the

identification and use of such inhibitors are provided as are methods of use of the inhibitors

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 24. Document ID: US 20030087817 A1

L10: Entry 24 of 82

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087817

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087817 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cox, George Norbert III	Louisville	CO	US	
Case, Casey Christopher	San Mateo	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric Edward	Boulder	CO	US	
Spratt, Sharon Kaye	Vacaville	CA	US	

US-CL-CURRENT: 514/12; 435/455

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 25. Document ID: US 20030087411 A1

L10: Entry 25 of 82

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 26. Document ID: US 20030082552 A1

L10: Entry 26 of 82

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082552

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082552 A1

TITLE: Modulation of gene expression using localization domains

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	Richmond	CA	US	
Urnov, Fyodor	Richmond	CA	US	
Lai, Albert	Berkeley	CA	US	
Raschke, Eva	San Francisco	CA	US	
Wolffe, Elizabeth J.			US	

US-CL-CURRENT: 435/6; 435/317.1, 435/455

ABSTRACT:

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions comprising localization domains, and fusions of localization domains with DNA binding domains and, optionally regulatory domains, are provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 27. Document ID: US 20030060457 A1

L10: Entry 27 of 82

File: PGPB

Mar 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030060457

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030060457 A1

TITLE: Cellular proteins as targets for the treatment of pathogens resistant to drugs

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

that target pathogen-encoded proteins

PUBLICATION-DATE: March 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton		CA	

US-CL-CURRENT: 514/211.08; 514/263.4, 514/285, 514/414, 514/456, 514/473, 514/518

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of gene expression, replication and reactivation in pathogenic agents. Compositions and assays for the identification and use of such inhibitors are provided, as are methods of use of the inhibitors

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Drawn Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 28. Document ID: US 20030059851 A1

L10: Entry 28 of 82

File: PGPB

Mar 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030059851

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030059851 A1

TITLE: Protein quantitation with cell imaging densitometry

PUBLICATION-DATE: March 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smith, Steven Jay	Bronx	NY	US	

US-CL-CURRENT: 435/7.2; 435/40.5, 435/7.23

ABSTRACT:

A method for quantitating cellular proteins in tissue, by means of a cell imaging densitometer in conjunction with immunohistological staining and a reference standard, is provided. Unlike prior art methods, which provide ordinal measures of relative amounts of protein among different cells, the method enables the quantitation of antigenic proteins in terms of absolute mass of protein/tumor or protein/patient, molecules of protein per cell, and volume or fraction of a tissue sample expressing the protein of interest. The method is useful for research purposes in the study of protein expression, and is shown to improve the accuracy of clinical histopathological analysis of tumor tissue sections for diagnosis and prognosis. The method is expected to be useful for prescribing in situ treatment dosages. The demonstrated resulting improvement in the correlation between tissue levels and blood levels of tumor-associated proteins should facilitate minimally-invasive monitoring of cancer progression and therapeutic response.

☐ 29. Document ID: US 20030054409 A1

L10: Entry 29 of 82

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054409
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030054409 A1

TITLE: Novel complex-forming proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jerome, Valerie	Coelbe		DE	
Sedlacek, Hans-Harald	Marburg		DE	
Mueller, Rolf	Marburg		DE	

US-CL-CURRENT: 435/7.1; 435/183, 435/320.1, 435/325, 435/69.5, 435/69.7, 530/350, 530/351

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

☐ 30. Document ID: US 20030054000 A1

L10: Entry 30 of 82

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054000
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030054000 A1

TITLE: Anti-pathogen system and methods of use thereof

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dowdy, Steven F.	Clayton	MO	US	

US-CL-CURRENT: 424/94.63; 435/226, 530/327, 530/350, 536/23.4, 536/24.33

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Drawn Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 31. Document ID: US 20030049649 A1

L10: Entry 31 of 82

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049649
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049649 A1

TITLE: Targeted modification of chromatin structure

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	San Pablo	CA	US	
Wolffe, Elizabeth J.	Richmond	CA	US	
Collingwood, Trevor			US	
Snowden, Andrew			US	

US-CL-CURRENT: 435/6; 435/199, 435/455, 435/468

ABSTRACT:

Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Drawn Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 32. Document ID: US 20030049602 A1

L10: Entry 32 of 82

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 33. Document ID: US 20030036163 A1

L10: Entry 33 of 82

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

☐ 34. Document ID: US 20030022330 A1

L10: Entry 34 of 82

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022330
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022330 A1

TITLE: APOA2-interacting proteins and use thereof

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/183; 435/226, 435/7.1

ABSTRACT:

Protein complexes are provided comprising APOA2 and one or more APOA2-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA2 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 35. Document ID: US 20030013169 A1

L10: Entry 35 of 82

File: PGPB

Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013169
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030013169 A1

TITLE: Transcription factor E2F DNA-binding domain inhibitor peptides and their use

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Muller, Rolf	Marburg		DE	
Kontermann, Roland E.	Marburg		DE	
Montigiani, Silvia	Siena		IT	

US-CL-CURRENT: 435/184; 530/330

ABSTRACT:

The present invention provides peptides which bind to the DNA binding domain of transcription factor E2F, and inhibit cell cycle progression. Peptides include FWLRFT (SEQ ID NO:1); WVRWHF (SEQ ID NO:2); WHFIFW (SEQ ID NO:3); IWLSGLSRGVVVSFP (SEQ ID NO:4); and GSRILTFRSGSWYAS (SEQ ID NO:5) and derivatives based upon these sequences. Compositions and the use of the peptides in inhibiting cell cycle progression, such as in uncontrolled cell proliferation, are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 36. Document ID: US 20030008373 A1

L10: Entry 36 of 82

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008373

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008373 A1

TITLE: APOA1-interacting proteins and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	
Szankasi, Philippe	Salt Lake City	UT	US	
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/226; 435/183, 435/7.1

ABSTRACT:

Protein complexes are provided comprising APOA1 and one or more APOA1-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA1 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 37. Document ID: US 20030008324 A1

L10: Entry 37 of 82

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 38. Document ID: US 20020197691 A1

L10: Entry 38 of 82

File: PGPB

Dec 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020197691
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020197691 A1

TITLE: FLT4-interacting proteins and use thereof

PUBLICATION-DATE: December 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/7.23

ABSTRACT:

Protein complexes are provided comprising FLT4 and one or more FLT4-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with FLT4 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 39. Document ID: US 20020187143 A1

L10: Entry 39 of 82

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187143
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187143 A1

TITLE: Methods and compositions for reducing immune response

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFace, Drake M.	San Diego	CA	US	
Rahman, Amena	San Diego	CA	US	
Shabram, Paul W.	Olivenhain	CA	US	
Tsai, Van T.	San Diego	CA	US	

US-CL-CURRENT: 424/140.1; 435/320.1, 536/23.72

ABSTRACT:

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Desc.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 40. Document ID: US 20020177692 A1

L10: Entry 40 of 82

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177692
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177692 A1

TITLE: BCL-XL-interacting protein and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/184, 435/287.2, 435/320.1, 435/325, 435/69.7

ABSTRACT:

Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

members thereof are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 41. Document ID: US 20020177207 A1

L10: Entry 41 of 82

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177207
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177207 A1

TITLE: Tsg101-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Janice	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/196; 435/199, 435/226

ABSTRACT:

Protein complexes are provided comprising Tsg101 and one or more protein interactors of Tsg101. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Tsg101 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 42. Document ID: US 20020177177 A1

L10: Entry 42 of 82

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177177
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177177 A1

TITLE: Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bernards, Rene	Alconde		NL	
Zwijnsen, Renate	Utrecht		NL	

US-CL-CURRENT: 435/7.23; 514/14, 514/15, 514/16, 530/326, 530/327, 530/328

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumors, for assays for compounds useful in the prevention of tumors and compounds obtainable by such assays.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 43. Document ID: US 20020177152 A1

L10: Entry 43 of 82

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 44. Document ID: US 20020173026 A1

L10: Entry 44 of 82

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/199; 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 45. Document ID: US 20020165352 A1

L10: Entry 45 of 82

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165352

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020165352 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 46. Document ID: US 20020164666 A1

L10: Entry 46 of 82

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164666

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164666 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.23; 435/183, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 47. Document ID: US 20020164575 A1

L10: Entry 47 of 82

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164575

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164575 A1

TITLE: Gene identification

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Case, Casey C.	San Mateo	CA	US
Urnov, Fyodor	Richmond	CA	US

US-CL-CURRENT: 435/4; 435/6

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HWMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 48. Document ID: US 20020160940 A1

L10: Entry 48 of 82

File: PGPB

Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160940

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020160940 A1

TITLE: Modulation of endogenous gene expression in cells

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Wolffe, Alan	Richmond	CA	US	
Urnov, Fyodor	Richmond	CA	US	
Lai, Albert	Richmond	CA	US	
Snowden, Andrew	Alameda	CA	US	
Tan, Siyuan	El Cerrito	CA	US	
Gregory, Philip			US	

US-CL-CURRENT: 514/6; 435/455

ABSTRACT:

Disclosed herein are methods and compositions for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HWMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 49. Document ID: US 20020155988 A1

L10: Entry 49 of 82

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155988
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155988 A1

TITLE: Uses of transport proteins

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Normand, Nadia Michelle	Surrey		GB	
Brewis, Neil Douglas	Surrey		GB	
Phelan, Anne	Kent		GB	

US-CL-CURRENT: 514/2; 435/7.23

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 50. Document ID: US 20020155432 A1

L10: Entry 50 of 82

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	
Weichselbaum, Ralph R.	Chicago	IL	US	
Roizman, Bernard	Chicago	IL	US	

US-CL-CURRENT: 435/5; 424/199.1, 424/205.1, 424/229.1, 435/320.1, 435/69.1

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising

administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 51. Document ID: US 20020150557 A1

L10: Entry 51 of 82

File: PGPB

Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150557

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020150557 A1

TITLE: Selectively replicating viral vectors

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ramachandra, Muralidhara	San Diego	CA	US	
Shabram, Paul W.	Olivenhain	CA	US	

US-CL-CURRENT: 424/93.2; 424/456, 435/320.1

ABSTRACT:

The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 52. Document ID: US 20020115215 A1

L10: Entry 52 of 82

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115215

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020115215 A1

TITLE: Targeted modification of chromatin structure

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	Orinda	CA	US	
Collingwood, Trevor	San Pablo	CA	US	

US-CL-CURRENT: 435/455; 435/468, 435/6

ABSTRACT:

Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 53. Document ID: US 20020106378 A1

L10: Entry 53 of 82

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106378

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020106378 A1

TITLE: Materials and methods for intracellular transport and their uses

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Oxtd		GB	
Elliott, Gillian Daphne	Oxtd		GB	

US-CL-CURRENT: 424/186.1; 530/350

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 54. Document ID: US 20020094529 A1

PGPUB-DOCUMENT-NUMBER: 20020094529
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094529 A1

TITLE: Gene identification

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Urnov, Fyodor	Richmond	CA	US	

US-CL-CURRENT: 435/6; 435/4, 435/455

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Drawings
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 55. Document ID: US 20020081736 A1

L10: Entry 55 of 82

File: PGPB

Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081736
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081736 A1

TITLE: Nucleic acid delivery

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conroy, Susan E.	London	CA	GB	
Engler, Heidrun	San Diego	CA	US	
Maneval, Daniel C.	San Diego		US	

US-CL-CURRENT: 435/455; 514/44, 514/53, 514/58

ABSTRACT:

The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression

vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 56. Document ID: US 20020081614 A1

L10: Entry 56 of 82

File: PGPB

Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081614

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020081614 A1

TITLE: Functional genomics using zinc finger proteins

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Zhang, Lei	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/7.21, 702/19

ABSTRACT:

0 The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 57. Document ID: US 20020072119 A1

L10: Entry 57 of 82

File: PGPB

Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072119

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020072119 A1

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Laquerre, Sylvie	Walnut Creek	CA	US	
Hermiston, Terry	Corte Madera	CA	US	

US-CL-CURRENT: 435/456; 424/93.6, 435/235.1

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 58. Document ID: US 20020068706 A1

L10: Entry 58 of 82

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068706

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020068706 A1

TITLE: INHIBITORS OF CELL-CYCLE PROGRESSION AND USES RELATED THERETO

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
GYURIS, JENO	WINCHESTER	MA	US	
LAMPHERE, LOU	BOSTON	MA	US	
BEACH, DAVID H.	HUNTINGTON BAY	NY	US	

US-CL-CURRENT: 514/44; 435/455, 536/23.4, 536/23.72, 536/24.1

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

Full	Title	Cita	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 59. Document ID: US 20020037280 A1

L10: Entry 59 of 82

File: PGPB

Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037280

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020037280 A1

TITLE: Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lieber, Andre	Seattle	WA	US	

Steinwaerder, Dirk S.	Hamburg	WA	DE
Carlson, Cheryl A.	Seattle	WA	US
Mi, Jie	Seattle		US

US-CL-CURRENT: 424/93.21; 435/235.1, 435/320.1, 435/456

ABSTRACT:

This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).

Full	Title	Cite	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 60. Document ID: US 6780590 B2

L10: Entry 60 of 82

File: USPT

Aug 24, 2004

US-PAT-NO: 6780590

DOCUMENT-IDENTIFIER: US 6780590 B2

TITLE: Gene identification

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

30 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 61. Document ID: US 6777185 B2

L10: Entry 61 of 82

File: USPT

Aug 17, 2004

US-PAT-NO: 6777185

DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Cite	Front	Review	Classification	Date	Reference	Claims	HWMC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 62. Document ID: US 6746848 B2

L10: Entry 62 of 82

File: USPT

Jun 8, 2004

US-PAT-NO: 6746848

DOCUMENT-IDENTIFIER: US 6746848 B2

TITLE: Protein quantitation with cell imaging densitometry

DATE-ISSUED: June 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Smith; Steven Jay	Bronx	NY	10463	

US-CL-CURRENT: 435/7.23; 435/7.21, 435/960, 435/967, 436/518, 436/63, 436/64

ABSTRACT:

A method for quantitating cellular proteins in tissue, by means of a cell imaging densitometer in conjunction with immunohistological staining and a reference standard, is provided. Unlike prior art methods, which provide ordinal measures of

relative amounts of protein among different cells, the method enables the quantitation of antigenic proteins in terms of absolute mass of protein/tumor or protein/patient, molecules of protein per cell, and volume or fraction of a tissue sample expressing the protein of interest. The method is useful for research purposes in the study of protein expression, and is shown to improve the accuracy of clinical histopathological analysis of tumor tissue sections for diagnosis and prognosis. The method is expected to be useful for prescribing in situ treatment dosages. The demonstrated resulting improvement in the correlation between tissue levels and blood levels of tumor-associated proteins should facilitate minimally-invasive monitoring of cancer progression and therapeutic response.

21 Claims, 23 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 63. Document ID: US 6734167 B2

L10: Entry 63 of 82

File: USPT

May 11, 2004

US-PAT-NO: 6734167
DOCUMENT-IDENTIFIER: US 6734167 B2

TITLE: Uses of transport proteins

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Surry			GB
Normand; Nadia Michelle	Boulogne-Billancourt			FR
Brewis; Neil Douglas	Surry			GB
Phelan; Anne	Kent			GB

US-CL-CURRENT: 514/12; 424/204.1, 424/231.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 64. Document ID: US 6686196 B2

L10: Entry 64 of 82

File: USPT

Feb 3, 2004

US-PAT-NO: 6686196
DOCUMENT-IDENTIFIER: US 6686196 B2

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

TITLE: Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

DATE-ISSUED: February 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lieber; Andre	Seattle	WA		
Steinwaerder; Dirk S.	Hamburg			DE
Carlson; Cheryl A.	Seattle	WA		
Mi; Jie	Seattle	WA		

US-CL-CURRENT: 435/320.1; 424/93.2, 435/455, 435/456

ABSTRACT:

This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).

26 Claims, 32 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 27

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 65. Document ID: US 6660259 B2

L10: Entry 65 of 82

File: USPT

Dec 9, 2003

US-PAT-NO: 6660259

DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Laquerre; Sylvie	Walnut Creek	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is

cytopathic to susceptible hyperproliferative cells, such as neoplastic cells.
Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 66. Document ID: US 6649158 B1

L10: Entry 66 of 82

File: USPT

Nov 18, 2003

US-PAT-NO: 6649158
DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 67. Document ID: US 6645501 B2

L10: Entry 67 of 82

File: USPT

Nov 11, 2003

US-PAT-NO: 6645501
DOCUMENT-IDENTIFIER: US 6645501 B2

TITLE: Anti-pathogen system and methods of use thereof

DATE-ISSUED: November 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dowdy; Steven F.	Clayton	MO		

US-CL-CURRENT: 424/192.1; 424/195.11, 424/196.11

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

27 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 68. Document ID: US 6635476 B1

L10: Entry 68 of 82

File: USPT

Oct 21, 2003

US-PAT-NO: 6635476

DOCUMENT-IDENTIFIER: US 6635476 B1

TITLE: Targeted vectors

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murphy; Richard B.	San Diego	CA		

US-CL-CURRENT: 435/320.1; 424/199.1, 424/93.1, 424/93.2, 435/235.1

ABSTRACT:

This invention provides therapeutic and diagnostic agent delivery vehicles, including viral vectors, that are complexed to a targeting moiety by coordinate covalent linkages mediated by a transition metal ion. The complex is typically formed with a transition metal ion that is in a kinetically labile oxidation state; after the complex is formed, the oxidation state of the transition metal ion is changed to one that renders the complex kinetically stable. The use of a coordinate covalent linkage to attach the targeting moiety to the delivery vehicle provides the ability to readily attach a different targeting moiety to a delivery vehicle without modifying the delivery vehicle itself. This flexibility is achieved without sacrificing stability of the complex.

26 Claims, 2 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 69. Document ID: US 6607882 B1

L10: Entry 69 of 82

File: USPT

Aug 19, 2003

US-PAT-NO: 6607882

DOCUMENT-IDENTIFIER: US 6607882 B1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox, III; George N.	Louisville	CO		
Case; Casey C.	San Mateo	CA		
Eisenberg; Stephen P.	Boulder	CO		
Jarvis; Eric E.	Boulder	CO		
Spratt; Sharon K.	Vacaville	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/455, 435/468, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

32 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 70. Document ID: US 6599692 B1

L10: Entry 70 of 82

File: USPT

Jul 29, 2003

US-PAT-NO: 6599692

DOCUMENT-IDENTIFIER: US 6599692 B1

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	San Francisco	CA		

US-CL-CURRENT: 435/4; 435/6, 536/23.1

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

55 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 71. Document ID: US 6534261 B1

L10: Entry 71 of 82

File: USPT

Mar 18, 2003

US-PAT-NO: 6534261

DOCUMENT-IDENTIFIER: US 6534261 B1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox, III; George Norbert	Louisville	CO		
Case; Casey Christopher	San Mateo	CA		
Eisenberg; Stephen P.	Boulder	CO		
Jarvis; Eric Edward	Boulder	CO		
Spratt; Sharon Kaye	Vacaville	CA		

US-CL-CURRENT: 435/6; 435/29, 536/23.5, 536/24.1

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

85 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 72. Document ID: US 6495526 B2

L10: Entry 72 of 82

File: USPT

Dec 17, 2002

US-PAT-NO: 6495526

DOCUMENT-IDENTIFIER: US 6495526 B2

TITLE: Inhibitors of cell-cycle progression and uses related thereto

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gyuris; Jeno	Winchester	MA		
Lamphere; Lou	Boston	MA		
Beach; David H.	Huntington Bay	NY		

US-CL-CURRENT: 514/44; 536/23.4, 536/23.72, 536/24.1

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

42 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 73. Document ID: US 6495346 B1

L10: Entry 73 of 82

File: USPT

Dec 17, 2002

US-PAT-NO: 6495346

DOCUMENT-IDENTIFIER: US 6495346 B1

TITLE: Complex-forming proteins

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jerome; Valerie	Colbe			DE
Sedlacek; Hans-Harald	Marburg			DE
Muller; Rolf	Marburg			DE

US-CL-CURRENT: 435/69.7; 424/85.1, 424/85.2, 435/69.5, 435/69.52, 530/351, 536/23.4, 536/23.5, 536/23.51

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the

component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

12 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Cita	Front	Review	Classification	Date	Reference		Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 74. Document ID: US 6485977 B1

L10: Entry 74 of 82

File: USPT

Nov 26, 2002

US-PAT-NO: 6485977
DOCUMENT-IDENTIFIER: US 6485977 B1

TITLE: Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collmer; Alan	Ithaca	NY		
Beer; Steven V.	Ithaca	NY		

US-CL-CURRENT: 435/455; 435/320.1, 435/325, 435/456, 435/69.1, 435/69.7, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.

11 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Cita	Front	Review	Classification	Date	Reference		Claims	KWIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 75. Document ID: US 6464976 B1

L10: Entry 75 of 82

File: USPT

Oct 15, 2002

US-PAT-NO: 6464976
DOCUMENT-IDENTIFIER: US 6464976 B1

TITLE: Methods and compositions for reducing immune response

DATE-ISSUED: October 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		
Rahman; Amena	San Diego	CA		
Shabram; Paul W.	Olivenhain	CA		
Tsai; Van T.	San Diego	CA		

US-CL-CURRENT: 424/140.1; 424/131.1, 424/159.1, 424/233.1, 424/278.1, 424/93.1,
435/7.1, 514/885, 530/351, 604/4.01, 604/5.01, 604/5.02

ABSTRACT:

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.

4 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 76. Document ID: US 6451579 B1

L10: Entry 76 of 82

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579
DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6,
435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g.

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 77. Document ID: US 6350572 B1

L10: Entry 77 of 82

File: USPT

Feb 26, 2002

US-PAT-NO: 6350572
DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijzen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4, 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 78. Document ID: US 6251398 B1

L10: Entry 78 of 82

File: USPT

Jun 26, 2001

US-PAT-NO: 6251398

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxtd			GB
Elliott; Gillian Daphne	Oxtd			GB

US-CL-CURRENT: 424/186.1; 424/192.1, 424/204.1, 424/208.1, 424/248.1, 424/263.1,
435/235.1, 435/252.3, 435/317.1, 435/325, 530/350, 530/826, 536/23.4

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Cite	Front	Review	Classification	Date	Reference	Claims	RMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 79. Document ID: US 6221355 B1

L10: Entry 79 of 82

File: USPT

Apr 24, 2001

US-PAT-NO: 6221355

DOCUMENT-IDENTIFIER: US 6221355 B1

TITLE: Anti-pathogen system and methods of use thereof

DATE-ISSUED: April 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dowdy; Steven F.	Clayton	MO		

US-CL-CURRENT: 424/192.1; 424/204.1, 424/208.1, 530/387.3, 530/388.3, 536/23.4

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system

effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

21 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Cite	Front	Review	Classification	Date	Reference	Claims	MMIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 80. Document ID: US 6086900 A

L10: Entry 80 of 82

File: USPT

Jul 11, 2000

US-PAT-NO: 6086900
DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3, 435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Cite	Front	Review	Classification	Date	Reference	Claims	MMIC	Draw Des
------	-------	------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 81. Document ID: US 6017735 A

L10: Entry 81 of 82

File: USPT

Jan 25, 2000

US-PAT-NO: 6017735
DOCUMENT-IDENTIFIER: US 6017735 A

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.11&ref=10&dbname=PGPB,USPT,US...> 9/22/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/69.7; 435/252.3, 435/317.1, 435/320.1, 435/325, 435/69.3, 530/350,
536/23.4, 536/23.5

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.

19 Claims, 10 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 6

Full	Title	Cita	Front	Review	Classification	Date	Reference			Claims	MMMC	Drawing Des
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 82. Document ID: US 20040142900 A1, WO 200147960 A1, AU 200122079 A, EP 1240190 A1, US 20020155988 A1, JP 2003519159 W, MX 2002006168 A1, US 6734167 B2

L10: Entry 82 of 82

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2001-418224
 DERWENT-WEEK: 200449
 COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Inhibiting cancer cell proliferation by exposing cells to a composition of fusion proteins comprising VP22 polypeptides coupled to cell cycle progression regulators, and further exposing cells to cell death stimulators

INVENTOR: BREWIS, N D; NORMAND, N M ; O'HARE, P F J ; PHELAN, A ; OHARE, P F J

PRIORITY-DATA: 1999GB-0030519 (December 24, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040142900 A1</u>	July 22, 2004		000	A61K048/00
<u>WO 200147960 A1</u>	July 5, 2001	E	023	C07K014/035
<u>AU 200122079 A</u>	July 9, 2001		000	C07K014/035
<u>EP 1240190 A1</u>	September 18, 2002	E	000	C07K014/035
<u>US 20020155988 A1</u>	October 24, 2002		000	A01N037/18
<u>JP 2003519159 W</u>	June 17, 2003		024	A61K047/48
<u>MX 2002006168 A1</u>	January 1, 2003		000	A61K047/48
<u>US 6734167 B2</u>	May 11, 2004		000	A61K038/00

INT-CL (IPC): A01 N 37/18; A61 K 31/7088; A61 K 38/00; A61 K 47/48; A61 K 48/00; A61 P 9/10; A61 P 17/02; A61 P 17/06; A61 P 35/00; C07 K 14/035; C12 N 15/85; G01 N 33/574

ABSTRACTED-PUB-NO: WO 200147960A

BASIC-ABSTRACT:

NOVELTY - Reducing proliferation of cells by exposing them to proteins with the transport function of herpes virus VP22 coupled to cell cycle progression regulator, or to nucleic acids encoding the proteins, further exposing cells to an agent to stimulate cell death and optionally exposing cells to an agent that prevents export of administered agents from cell.

DETAILED DESCRIPTION - Reducing (M1) proliferation of cells comprises:

(a) exposing the cells to a composition comprising a polypeptide which comprises an amino acid sequence with the transport function of herpes viral VP22 protein, and is coupled to one or several functionally active proteins or peptides (P1) which can regulate cell cycle progression or their functional analogues, or exposing cells to therapeutic compositions comprising nucleic acids encoding the proteins(s);

(b) exposing the cells to an agent (A1) to further stimulate cell death, the agent being a drug which can induce cell cycle arrest, cytotoxic chemotherapeutic drug commonly used as a part of a treatment of malignant disease, DNA damaging agent, an agent which increases cellular sensitivity to DNA damage, or cytotoxic amounts of radiation; and optionally after the step (a) and/or step (b); and

(c) further exposing the cells to an agent (A2) that prevents export from the cell of any one of the agents administered in the above steps.

An INDEPENDENT CLAIM is also included for the preparation (I) which comprises a coupling product between a protein with the transport function of VP22 and a protein which can regulate cell cycle progression, (A1) and optionally (A2), in combination with an excipient.

ACTIVITY - Antipsoriatic; cytostatic; dermatological; virucidal.

MECHANISM OF ACTION - Apoptosis inducer; cyclin-dependent kinase inhibitor (claimed); cell proliferation suppressor.

No supporting data is given.

USE - Reducing proliferation of hyper-proliferating cells e.g., cancer cells. (I) is useful for manufacturing a medicament to reduce or treat cell proliferation e.g., cancer cell proliferation (claimed).

(I) is useful for reducing or treating cell proliferation, in tumor cells present in tumor cell mass, non-malignant cells e.g., benign tumor cells such as genital warts, smooth muscle cells present in restenosis, proliferating skin cells e.g., skin cancer, psoriasis or eczema skin cells, or proliferating cells of scar tissue.

Full	Title	Cite	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw. Des.
------	-------	------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------


Terms	Documents
L5 AND L8	82

Display Format: **Change Format**

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for VP22 Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 114 of 114

One

Text Version

1: Chhabra A, Mehrotra S, Chakraborty NG, Mukherji B, Dorsky DL. Related Articles, I

Cross-presentation of a human tumor antigen delivered to dendritic cells by H VP22-mediated protein translocation.
Eur J Immunol. 2004 Oct;34(10):2824.
PMID: 15368298 [PubMed - in process]

2: Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, He L, Wu TC, Chen CA, Hsieh CY. Related Articles, I

Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
Eur J Immunol. 2004 Jul;34(7):1892-900.
PMID: 15214037 [PubMed - indexed for MEDLINE]

3: Jarver P, Langel U. Related Articles, I

The use of cell-penetrating peptides as a tool for gene regulation.
Drug Discov Today. 2004 May 1;9(9):395-402. Review.
PMID: 15081956 [PubMed - indexed for MEDLINE]

4: Suzuki K, Murtuza B, Brand NJ, Varela-Carver A, Fukushima S, Yacoub MH. Related Articles, I

Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport.
J Mol Cell Cardiol. 2004 Apr;36(4):603-6.
PMID: 15081320 [PubMed - in process]

5: Qiu Z, Harms JS, Zhu J, Splitter GA. Related Articles, I

Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpes simplex virus VP22.
J Virol. 2004 Apr;78(8):4224-33.
PMID: 15047837 [PubMed - indexed for MEDLINE]

6: Falk K, Aspehaug V, Vlasak R, Endresen C. Related Articles, I

Identification and characterization of viral structural proteins of infectious salmon anemia virus.
J Virol. 2004 Mar;78(6):3063-71.
PMID: 14990725 [PubMed - indexed for MEDLINE]

7: Brady RO. Related Articles, I

Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
Acta Paediatr Suppl. 2003 Dec;92(443):19-24.
PMID: 14989461 [PubMed - indexed for MEDLINE]

8: Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, Boyd DA, Wu TC. Related Articles, I

Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby


Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

cells and protective immunity.
Hum Gene Ther. 2004 Feb;15(2):167-77.
PMID: 14975189 [PubMed - in process]


- 9: [Barbe-Tuana FM, Machado DC, Saitovitch D.](#) Related Articles, 1

 **Modified location of the major histocompatibility protein Kb by co-delivery w VP22 protein.**
Biomol Eng. 2004 Jan;21(1):27-31.
PMID: 14715317 [PubMed - indexed for MEDLINE]


- 10: [Roeder GE, Parish JL, Stern PL, Gaston K.](#) Related Articles, 1

 **Herpes Simplex Virus VP22-Human Papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.**
Biotechnol Appl Biochem. 2004 Jan 7 [Epub ahead of print]
PMID: 14709162 [PubMed - as supplied by publisher]


- 11: [Zavaglia D, Normand N, Brewis N, O'Hare P, Favrot MC, Coll JL.](#) Related Articles, 1

 **VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mic**
Mol Ther. 2003 Nov;8(5):840-5.
PMID: 14599818 [PubMed - indexed for MEDLINE]


- 12: [Kuelto LA, Middaugh CR.](#) Related Articles, 1

 **Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems.**
J Pharm Sci. 2003 Sep;92(9):1754-72. Review.
PMID: 12949995 [PubMed - indexed for MEDLINE]


- 13: [Stroh C, Held J, Samraj AK, Schulze-Osthoff K.](#) Related Articles, 1

 **Specific inhibition of transcription factor NF-kappaB through intracellular protein delivery of I kappaBalpha by the Herpes virus protein VP22.**
Oncogene. 2003 Aug 14;22(34):5367-73.
PMID: 12917639 [PubMed - indexed for MEDLINE]


- 14: [van Leeuwen H, Okuwaki M, Hong R, Chakravarti D, Nagata K, O'Hare P.](#) Related Articles, 1

 **Herpes simplex virus type 1 tegument protein VP22 interacts with TAF-I proteins and inhibits nucleosome assembly but not regulation of histone acetylation by INHAT.**
J Gen Virol. 2003 Sep;84(Pt 9):2501-10.
PMID: 12917472 [PubMed - indexed for MEDLINE]


- 15: [Kong BH, Wang WX, Liu CS, Ma DX, Qu X.](#) Related Articles, 1

 **[Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo]**
Zhonghua Fu Chan Ke Za Zhi. 2003 Apr;38(4):195-8. Chinese.
PMID: 12885362 [PubMed - in process]


- 16: [Rutjes SA, Bosma PJ, Rohn JL, Noteborn MH, Wesseling JG.](#) Related Articles, 1


 **Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.**
J Mol Med. 2003 Sep;81(9):558-65. Epub 2003 Jul 16.
PMID: 12879152 [PubMed - indexed for MEDLINE]

- 17: [Lundberg M, Wikstrom S, Johansson M.](#) Related Articles, 1


 **Cell surface adherence and endocytosis of protein transduction domains.**
Mol Ther. 2003 Jul;8(1):143-50.


PMID: 12842437 [PubMed - indexed for MEDLINE]


-  **18:** [Kong B, Wang W, Liu C, Song L, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Wang B, Wei MQ, Yang Q.](#) [Related Articles, I](#)

 **Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GC suicide gene therapy for ovarian cancer.**
In Vivo. 2003 Mar-Apr;17(2):153-6.
PMID: 12792977 [PubMed - indexed for MEDLINE]


-  **19:** [Namiki S, Tomida T, Tanabe M, Iino M, Hirose K.](#) [Related Articles, I](#)


 **Intracellular delivery of glutathione S-transferase into mammalian cells.**
Biochem Biophys Res Commun. 2003 Jun 6;305(3):592-7.
PMID: 12763035 [PubMed - indexed for MEDLINE]


-  **20:** [Kretz A, Wybranietz WA, Hermening S, Lauer UM, Isenmann S.](#) [Related Articles, I](#)

 **HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo.**
Mol Ther. 2003 May;7(5 Pt 1):659-69.
PMID: 12718909 [PubMed - indexed for MEDLINE]


-  **21:** [Boenicke L, Chu K, Pauls R, Tams C, Kruse ML, Kurdow R, Schniewind B, Bohle A, Kremer B, Kalthoff H.](#) [Related Articles, I](#)


 **Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.**
J Mol Med. 2003 Mar;81(3):205-13. Epub 2003 Mar 18.
PMID: 12682729 [PubMed - indexed for MEDLINE]


-  **22:** [Brignati MJ, Loomis JS, Wills JW, Courtney RJ.](#) [Related Articles, I](#)


 **Membrane association of VP22, a herpes simplex virus type 1 tegument protein.**
J Virol. 2003 Apr;77(8):4888-98.
PMID: 12663795 [PubMed - indexed for MEDLINE]


-  **23:** [Weitzman MD.](#) [Related Articles, I](#)


 **VP22 flips the switch on cell death.**
Mol Ther. 2003 Feb;7(2):146-7. No abstract available.
PMID: 12638542 [PubMed - indexed for MEDLINE]


-  **24:** [Walters JN, Sexton GL, McCaffery JM, Desai P.](#) [Related Articles, I](#)


 **Mutation of single hydrophobic residue I27, L35, F39, L58, L65, L67, or L77 at the N terminus of VP5 abolishes interaction with the scaffold protein and prevents closure of herpes simplex virus type 1 capsid shells.**
J Virol. 2003 Apr;77(7):4043-59.
PMID: 12634364 [PubMed - indexed for MEDLINE]

-  **25:** [Brewis ND, Phelan A, Normand N, Choolun E, O'Hare P.](#) [Related Articles, I](#)











 **Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis.**
Mol Ther. 2003 Feb;7(2):262-70.
PMID: 12597915 [PubMed - indexed for MEDLINE]










-  **26:** [Zavaglia D, Favrot MC, Eymen B, Tenaud C, Coll JL.](#) [Related Articles, I](#)

 **Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.**
Gene Ther. 2003 Feb;10(4):314-25.
PMID: 12595890 [PubMed - indexed for MEDLINE]

-  **27:** [Roy I, Holle L, Song W, Holle E, Wagner T, Yu X.](#) [Related Articles, I](#)

Efficient translocation and apoptosis induction by adenovirus encoded VP22

-  **p53 fusion protein in human tumor cells in vitro.**
Anticancer Res. 2002 Nov-Dec;22(6A):3185-9.
PMID: 12530063 [PubMed - indexed for MEDLINE]
-  **28: Lyman MG, Demmin GL, Banfield BW.** Related Articles, 1
The attenuated pseudorabies virus strain Bartha fails to package the tegumen proteins Us3 and VP22.
J Virol. 2003 Jan;77(2):1403-14.
PMID: 12502856 [PubMed - indexed for MEDLINE]
-  **29: Cashman SM, Sadowski SL, Morris DJ, Frederick J, Kumar-Singh R.** Related Articles, 1
Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors--implications for gene therapy.
Mol Ther. 2002 Dec;6(6):813-23.
PMID: 12498777 [PubMed - indexed for MEDLINE]
-  **30: Kong B, Wang W, Liu C, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Jiang S.** Related Articles, 1
[Anti-tumor effect of lentivirus-mediated MUC1 antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice]
Zhonghua Yi Xue Za Zhi. 2002 Sep 10;82(17):1207-10. Chinese.
PMID: 12475412 [PubMed - indexed for MEDLINE]
-  **31: Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC.** Related Articles, 1
HIV-1 Vpr displays natural protein-transducing properties: implications for pathogenesis.
Virology. 2002 Oct 10;302(1):95-105.
PMID: 12429519 [PubMed - indexed for MEDLINE]
-  **32: Ye D, Xu D, Singer AU, Juliano RL.** Related Articles, 1
Evaluation of strategies for the intracellular delivery of proteins.
Pharm Res. 2002 Sep;19(9):1302-9.
PMID: 12403066 [PubMed - indexed for MEDLINE]
-  **33: Hutchinson I, Whiteley A, Browne H, Elliott G.** Related Articles, 1
Sequential localization of two herpes simplex virus tegument proteins to punctate nuclear dots adjacent to ICP0 domains.
J Virol. 2002 Oct;76(20):10365-73.
PMID: 12239313 [PubMed - indexed for MEDLINE]
-  **34: Miranda-Saksena M, Boadle RA, Armati P, Cunningham AL.** Related Articles, 1
In rat dorsal root ganglion neurons, herpes simplex virus type 1 tegument for in the cytoplasm of the cell body.
J Virol. 2002 Oct;76(19):9934-51.
PMID: 12208970 [PubMed - indexed for MEDLINE]
-  **35: Qian C, Sangro B, Prieto J.** Related Articles, 1
New strategies to enhance gene therapy efficiency.
Gastroenterology. 2002 Aug;123(2):639-42. No abstract available.
PMID: 12145817 [PubMed - indexed for MEDLINE]
-  **36: Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M, Kubicka S.** Related Articles, 1
Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors.
Gastroenterology. 2002 Aug;123(2):608-18.
PMID: 12145813 [PubMed - indexed for MEDLINE]

-  **37:** [Fuchs W, Klupp BG, Granzow H, Hengartner C, Brack A, Mundt A, Enquist L W, Mettenleiter TC.](#) Related Articles, I
Physical interaction between envelope glycoproteins E and M of pseudorabies virus and the major tegument protein UL49.
 J Virol. 2002 Aug;76(16):8208-17.
 PMID: 12134026 [PubMed - indexed for MEDLINE]
-  **38:** [Sciortino MT, Taddeo B, Poon AP, Mastino A, Roizman B.](#) Related Articles, I
Of the three tegument proteins that package mRNA in herpes simplex virion, one (VP22) transports the mRNA to uninfected cells for expression prior to infection.
 Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8318-23.
 PMID: 12060774 [PubMed - indexed for MEDLINE]
-  **39:** [Zender L, Kuhnel F, Kock R, Manns M, Kubicka S.](#) Related Articles, I
VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo.
 Cancer Gene Ther. 2002 Jun;9(6):489-96.
 PMID: 12032659 [PubMed - indexed for MEDLINE]
-  **40:** [Morris SJ, Smith H, Sweet C.](#) Related Articles, I
Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmation that neuraminidase induces apoptosis and indications that other proteins may have a role.
 Arch Virol. 2002 May;147(5):961-79.
 PMID: 12021867 [PubMed - indexed for MEDLINE]
-  **41:** [Martin A, O'Hare P, McLauchlan J, Elliott G.](#) Related Articles, I
Herpes simplex virus tegument protein VP22 contains overlapping domains: cytoplasmic localization, microtubule interaction, and chromatin binding.
 J Virol. 2002 May;76(10):4961-70.
 PMID: 11967313 [PubMed - indexed for MEDLINE]
-  **42:** [Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graeppler F, Bitzer M, Stahler P, Gregor M, Lauer UM.](#) Related Articles, I
Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene.
 Gene Ther. 2001 Nov;8(21):1654-64.
 PMID: 11895004 [PubMed - indexed for MEDLINE]
-  **43:** [Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M.](#) Related Articles, I
Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination.
 Virology. 2002 Mar 1;294(1):47-59.
 PMID: 11886264 [PubMed - indexed for MEDLINE]
-  **44:** [van Leeuwen H, Elliott G, O'Hare P.](#) Related Articles, I
Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress.
 J Virol. 2002 Apr;76(7):3471-81.
 PMID: 11884571 [PubMed - indexed for MEDLINE]
-  **45:** [Diefenbach RJ, Miranda-Saksena M, Diefenbach E, Holland DJ, Boadle RA, Armati PJ, Cunningham AL.](#) Related Articles, I
Herpes simplex virus tegument protein US11 interacts with conventional kinesin heavy chain.
 J Virol. 2002 Apr;76(7):3282-91.

PMID: 11884553 [PubMed - indexed for MEDLINE]

46: [O'Donnell LA, Clemmer JA, Czymmek K, Schmidt CJ.](#)

Related Articles, I

**Marek's disease virus VP22: subcellular localization and characterization of carboxyl terminal deletion Mutations.**

Virology. 2002 Jan 20;292(2):235-40.

PMID: 11878926 [PubMed - indexed for MEDLINE]

47: [Soden J, Stevens A, Ray DW.](#)

Related Articles, I

**Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation.**

J Endocrinol. 2002 Mar;172(3):615-25.

PMID: 11874710 [PubMed - indexed for MEDLINE]

48: [Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M, Wu TC.](#)

Related Articles, I

**Cancer immunotherapy using Sindbis virus replicon particles encoding a VP antigen fusion.**

Hum Gene Ther. 2002 Mar 1;13(4):553-68.

PMID: 11874633 [PubMed - indexed for MEDLINE]

49: [Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC.](#)

Related Articles, I

**Improving DNA vaccine potency by linking Marek's disease virus type 1 VP to an antigen.**

J Virol. 2002 Mar;76(6):2676-82.

PMID: 11861834 [PubMed - indexed for MEDLINE]

50: [Lundberg M, Johansson M.](#)

Related Articles, I

**Positively charged DNA-binding proteins cause apparent cell membrane translocation.**

Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71.

PMID: 11846414 [PubMed - indexed for MEDLINE]

51: [Lai Z, Brady RO.](#)

Related Articles, I

**Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector.**

J Neurosci Res. 2002 Feb 1;67(3):363-71.

PMID: 11813241 [PubMed - indexed for MEDLINE]

52: [Marples B, Greco O, Joiner MC, Scott SD.](#)

Related Articles, I

**Molecular approaches to chemo-radiotherapy.**

Eur J Cancer. 2002 Jan;38(2):231-9. Review.

PMID: 11803140 [PubMed - indexed for MEDLINE]

53: [Dorange F, Tischer BK, Vautherot JF, Osterrieder N.](#)

Related Articles, I

**Characterization of Marek's disease virus serotype 1 (MDV-1) deletion mutants that lack UL46 to UL49 genes: MDV-1 UL49, encoding VP22, is indispensable for virus growth.**

J Virol. 2002 Feb;76(4):1959-70.

PMID: 11799190 [PubMed - indexed for MEDLINE]

54: [Bennett RP, Dalby B, Guy PM.](#)

Related Articles, I


**Protein delivery using VP22.**


Nat Biotechnol. 2002 Jan;20(1):20. No abstract available. Erratum in: Nat Biotechnol 2002 Apr;20(4):338.


PMID: 11753353 [PubMed - indexed for MEDLINE]

55: [del Rio T, Werner HC, Enquist LW.](#)


Related Articles, I

-  The pseudorabies virus VP22 homologue (UL49) is dispensable for virus growth in vitro and has no effect on virulence and neuronal spread in rodents
J Virol. 2002 Jan;76(2):774-82.
PMID: 11752167 [PubMed - indexed for MEDLINE]


 **56:** [Morris MC, Depollier J, Mery J, Heitz F, Divita G.](#) Related Articles, 1

-  A peptide carrier for the delivery of biologically active proteins into mamma cells.
Nat Biotechnol. 2001 Dec;19(12):1173-6.
PMID: 11731788 [PubMed - indexed for MEDLINE]


 **57:** [Derer W, Easwaran HP, Leonhardt H, Cardoso MC.](#) Related Articles, 1

-  A novel approach to induce cell cycle reentry in terminally differentiated mu cells.
FASEB J. 2002 Jan;16(1):132-3. Epub 2001 Nov 29.
PMID: 11729099 [PubMed - indexed for MEDLINE]


 **58:** [Blouin A, Blaho JA.](#) Related Articles, 1


-  Assessment of the subcellular localization of the herpes simplex virus structu protein VP22 in the absence of other viral gene products.
Virus Res. 2001 Dec 4;81(1-2):57-68.
PMID: 11682125 [PubMed - indexed for MEDLINE]


 **59:** [Geiss BJ, Tavis JE, Metzger LM, Leib DA, Morrison LA.](#) Related Articles, 1


-  Temporal regulation of herpes simplex virus type 2 VP22 expression and phosphorylation.
J Virol. 2001 Nov;75(22):10721-9.
PMID: 11602713 [PubMed - indexed for MEDLINE]


 **60:** [Ren X, Harms JS, Splitter GA.](#) Related Articles, 1


-  Tyrosine phosphorylation of bovine herpesvirus 1 tegument protein VP22 correlates with the incorporation of VP22 into virions.
J Virol. 2001 Oct;75(19):9010-7.
PMID: 11533164 [PubMed - indexed for MEDLINE]


 **61:** [Aints A, Guven H, Gahrton G, Smith CI, Dilber MS.](#) Related Articles, 1

-  Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting.
Gene Ther. 2001 Jul;8(14):1051-6.
PMID: 11526452 [PubMed - indexed for MEDLINE]


 **62:** [Wills KN, Atencio JA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO, Johnson DE.](#) Related Articles, 1

-  Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.
J Virol. 2001 Sep;75(18):8733-41.
PMID: 11507218 [PubMed - indexed for MEDLINE]






















 **63:** [Kotsakis A, Pomeranz LE, Blouin A, Blaho JA.](#) Related Articles, 1











-  Microtubule reorganization during herpes simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein.
J Virol. 2001 Sep;75(18):8697-711.
PMID: 11507215 [PubMed - indexed for MEDLINE]

 **64:** [Ren X, Harms JS, Splitter GA.](#) Related Articles, 1

-  Bovine herpesvirus 1 tegument protein VP22 interacts with histones, and the carboxyl terminus of VP22 is required for nuclear localization.
J Virol. 2001 Sep;75(17):8251-8.

PMID: 11483770 [PubMed - indexed for MEDLINE]

-  **65:** Lundberg M, Johansson M. Related Articles, 1
 **Is VP22 nuclear homing an artifact?**
Nat Biotechnol. 2001 Aug;19(8):713-4. No abstract available.
PMID: 11479552 [PubMed - indexed for MEDLINE]
-  **66:** Oliveira SC, Harms JS, Afonso RR, Splitter GA. Related Articles, 1
 **A genetic immunization adjuvant system based on BVP22-antigen fusion.**
Hum Gene Ther. 2001 Jul 1;12(10):1353-9.
PMID: 11440628 [PubMed - indexed for MEDLINE]
-  **67:** Ford KG, Souberbielle BE, Darling D, Farzaneh F. Related Articles, 1
 **Protein transduction: an alternative to genetic intervention?**
Gene Ther. 2001 Jan;8(1):1-4. Review.
PMID: 11402295 [PubMed - indexed for MEDLINE]
-  **68:** Spengler M, Niesen N, Grose C, Ruyechan WT, Hay J. Related Articles, 1
 **Interactions among structural proteins of varicella zoster virus.**
Arch Virol Suppl. 2001;(17):71-9.
PMID: 11339553 [PubMed - indexed for MEDLINE]
-  **69:** Liu CS, Kong B, Xia HH, Ellem KA, Wei MQ. Related Articles, 1
 **VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.**
J Gene Med. 2001 Mar-Apr;3(2):145-52.
PMID: 11318113 [PubMed - indexed for MEDLINE]
-  **70:** Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Related Articles, 1
 **Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen.**
J Immunol. 2001 May 1;166(9):5733-40.
PMID: 11313416 [PubMed - indexed for MEDLINE]
-  **71:** Falnes PO, Wesche J, Olsnes S. Related Articles, 1
 **Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.**
Biochemistry. 2001 Apr 10;40(14):4349-58.
PMID: 11284691 [PubMed - indexed for MEDLINE]
-  **72:** Normand N, van Leeuwen H, O'Hare P. Related Articles, 1
 **Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery.**
J Biol Chem. 2001 May 4;276(18):15042-50. Epub 2001 Jan 18.
PMID: 11278656 [PubMed - indexed for MEDLINE]
-  **73:** Schwartz JJ, Zhang S. Related Articles, 1
 **Peptide-mediated cellular delivery.**
Curr Opin Mol Ther. 2000 Apr;2(2):162-7. Review.
PMID: 11249637 [PubMed - indexed for MEDLINE]
-  **74:** Donnelly M, Elliott G. Related Articles, 1
 **Fluorescent tagging of herpes simplex virus tegument protein VP13/14 in virion infection.**
J Virol. 2001 Mar;75(6):2575-83.
PMID: 11222680 [PubMed - indexed for MEDLINE]
-  **75:** Rajcani J, Durmanova V. Related Articles, 1

-  **Early expression of herpes simplex virus (HSV) proteins and reactivation of latent infection.**
Folia Microbiol (Praha). 2000;45(1):7-28. Review.
PMID: 11200675 [PubMed - indexed for MEDLINE]
-  **76:** Cheng WF, Hung CH, Chai CY, Hsu KF, Ho L, Ling M, Wu TC. Related Articles, 1
Enhancement of sindbis virus self-replicating RNA vaccine potency by linka of herpes simplex virus type 1 VP22 protein to antigen.
J Virol. 2001 Mar;75(5):2368-76.
PMID: 11160740 [PubMed - indexed for MEDLINE]
-  **77:** Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. Related Articles, 1
CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VI comparison with responses to tegument and envelope glycoproteins.
J Virol. 2000 Dec;74(23):11422-5.
PMID: 11070045 [PubMed - indexed for MEDLINE]
-  **78:** Lai Z, Han L, Zirzow G, Brady RO, Reiser J. Related Articles, 1
Intercellular delivery of a herpes simplex virus VP22 fusion protein from cel infected with lentiviral vectors.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11297-302.
PMID: 11027330 [PubMed - indexed for MEDLINE]
-  **79:** Pomeranz LE, Blaho JA. Related Articles, 1
Assembly of infectious Herpes simplex virus type 1 virions in the absence of full-length VP22.
J Virol. 2000 Nov;74(21):10041-54.
PMID: 11024133 [PubMed - indexed for MEDLINE]
-  **80:** Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF. Related Articles, 1
Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL (VP22) and UL48 (VP16) genes: high-level expression and characterization MDV-1 VP22 and VP16.
J Gen Virol. 2000 Sep;81(Pt 9):2219-30.
PMID: 10950980 [PubMed - indexed for MEDLINE]
-  **81:** Kueltzo LA, Normand N, O'Hare P, Middaugh CR. Related Articles, 1
Conformational lability of herpesvirus protein VP22.
J Biol Chem. 2000 Oct 27;275(43):33213-21.
PMID: 10913125 [PubMed - indexed for MEDLINE]
-  **82:** Aints A, Dilber MS, Smith CL. Related Articles, 1
Intercellular spread of GFP-VP22.
J Gene Med. 1999 Jul-Aug;1(4):275-9.
PMID: 10738560 [PubMed - indexed for MEDLINE]
-  **83:** Wybranietz WA, Prinz F, Spiegel M, Schenk A, Bitzer M, Gregor M, Lauer UM. Related Articles, 1
Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines.
J Gene Med. 1999 Jul-Aug;1(4):265-74.
PMID: 10738559 [PubMed - indexed for MEDLINE]
-  **84:** Harms JS, Ren X, Oliveira SC, Splitter GA. Related Articles, 1
Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations.
J Virol. 2000 Apr;74(7):3301-12.
PMID: 10708447 [PubMed - indexed for MEDLINE]

85: [Elliott G, O'Hare P.](#)

[Related Articles, I](#)



Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division.

J Virol. 2000 Mar;74(5):2131-41.

PMID: 10666242 [PubMed - indexed for MEDLINE]

86: [Brewis N, Phelan A, Webb J, Drew J, Elliott G, O'Hare P.](#)

[Related Articles, I](#)



Evaluation of VP22 spread in tissue culture.

J Virol. 2000 Jan;74(2):1051-6.

PMID: 10623773 [PubMed - indexed for MEDLINE]

87: [Derer W, Easwaran HP, Knopf CW, Leonhardt H, Cardoso MC.](#)

[Related Articles, I](#)



Direct protein transfer to terminally differentiated muscle cells.

J Mol Med. 1999 Aug;77(8):609-13.

PMID: 10543392 [PubMed - indexed for MEDLINE]

88: [Luft FC.](#)

[Related Articles, I](#)



Can VP22 resurrect gene therapy?

J Mol Med. 1999 Aug;77(8):575-6. No abstract available.

PMID: 10543389 [PubMed - indexed for MEDLINE]

89: [Pomeranz LE, Blaho JA.](#)

[Related Articles, I](#)



Modified VP22 localizes to the cell nucleus during synchronized herpes simplex virus type 1 infection.

J Virol. 1999 Aug;73(8):6769-81.

PMID: 10400775 [PubMed - indexed for MEDLINE]

90: [Elliott G, O'Reilly D, O'Hare P.](#)

[Related Articles, I](#)



Identification of phosphorylation sites within the herpes simplex virus tegument protein VP22.

J Virol. 1999 Jul;73(7):6203-6.

PMID: 10364384 [PubMed - indexed for MEDLINE]

91: [Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CL, O'Hare P.](#)

[Related Articles, I](#)



Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.

Gene Ther. 1999 Jan;6(1):12-21.

PMID: 10341871 [PubMed - indexed for MEDLINE]

92: [Elliott G, O'Hare P.](#)

[Related Articles, I](#)



Intercellular trafficking of VP22-GFP fusion proteins.

Gene Ther. 1999 Jan;6(1):149-51.

PMID: 10341888 [PubMed - indexed for MEDLINE]

93: [Murphy AL, Murphy SJ.](#)

[Related Articles, I](#)



Catch VP22: the hitch-hiker's ride to gene therapy?

Gene Ther. 1999 Jan;6(1):4-5. No abstract available.

PMID: 10341869 [PubMed - indexed for MEDLINE]

94: [Elliott G, O'Hare P.](#)

[Related Articles, I](#)























Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection.

J Virol. 1999 May;73(5):4110-9.

PMID: 10196307 [PubMed - indexed for MEDLINE]

95: [Fang B, Xu B, Koch P, Roth JA.](#)

[Related Articles, I](#)

-  **Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cells.**
Gene Ther. 1998 Oct;5(10):1420-4.
PMID: 9930348 [PubMed - indexed for MEDLINE]
-  **96: Morrison EE, Stevenson AJ, Wang YF, Meredith DM.** Related Articles, 1
 **Differences in the intracellular localization and fate of herpes simplex virus tegument proteins early in the infection of Vero cells.**
J Gen Virol. 1998 Oct;79 (Pt 10):2517-28.
PMID: 9780059 [PubMed - indexed for MEDLINE]
-  **97: Koelle DM, Frank JM, Johnson ML, Kwok WW.** Related Articles, 1
 **Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cell-infiltrating human genital herpes lesions.**
J Virol. 1998 Sep;72(9):7476-83.
PMID: 9696844 [PubMed - indexed for MEDLINE]
-  **98: Morrison EE, Wang YF, Meredith DM.** Related Articles, 1
 **Phosphorylation of structural components promotes dissociation of the herpes simplex virus type 1 tegument.**
J Virol. 1998 Sep;72(9):7108-14.
PMID: 9696804 [PubMed - indexed for MEDLINE]
-  **99: Elliott G, O'Hare P.** Related Articles, 1
 **Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules.**
J Virol. 1998 Aug;72(8):6448-55.
PMID: 9658087 [PubMed - indexed for MEDLINE]
-  **100: Phelan A, Elliott G, O'Hare P.** Related Articles, 1
 **Intercellular delivery of functional p53 by the herpesvirus protein VP22.**
Nat Biotechnol. 1998 May;16(5):440-3.
PMID: 9592391 [PubMed - indexed for MEDLINE]
-  **101: Liang X, Chow B, Babiuk LA.** Related Articles, 1
 **Study of immunogenicity and virulence of bovine herpesvirus 1 mutants deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in calves.**
Vaccine. 1997 Jul;15(10):1057-64.
PMID: 9269047 [PubMed - indexed for MEDLINE]
-  **102: Elliott G, O'Hare P.** Related Articles, 1
 **Intercellular trafficking and protein delivery by a herpesvirus structural protein.**
Cell. 1997 Jan 24;88(2):223-33.
PMID: 9008163 [PubMed - indexed for MEDLINE]
-  **103: McLauchlan J.** Related Articles, 1
 **The abundance of the herpes simplex virus type 1 UL37 tegument protein in virus particles is closely controlled.**
J Gen Virol. 1997 Jan;78 (Pt 1):189-94.
PMID: 9010303 [PubMed - indexed for MEDLINE]
-  **104: Elliott G, O'Reilly D, O'Hare P.** Related Articles, 1
 **Phosphorylation of the herpes simplex virus type 1 tegument protein VP22.**
Virology. 1996 Dec 1;226(1):140-5.
PMID: 8941333 [PubMed - indexed for MEDLINE]
-  **105: Leslie J, Rixon FJ, McLauchlan J.** Related Articles, 1



Overexpression of the herpes simplex virus type 1 tegument protein VP22 increases its incorporation into virus particles.

Virology. 1996 Jun 1;220(1):60-8.

PMID: 8659129 [PubMed - indexed for MEDLINE]

106: [Elliott G, Mouzakis G, O'Hare P.](#)

[Related Articles, 1](#)



VP16 interacts via its activation domain with VP22, a tegument protein of herpes simplex virus, and is relocated to a novel macromolecular assembly coexpressing cells.

J Virol. 1995 Dec;69(12):7932-41.

PMID: 7494306 [PubMed - indexed for MEDLINE]

107: [Dargan DJ, Patel AH, Subak-Sharpe JH.](#)

[Related Articles, 1](#)



PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked.

J Virol. 1995 Aug;69(8):4924-32.

PMID: 7609061 [PubMed - indexed for MEDLINE]

108: [Liang X, Chow B, Li Y, Raggo C, Yoo D, Attah-Poku S, Babiuk LA.](#)

[Related Articles, 1](#)



Characterization of bovine herpesvirus 1 UL49 homolog gene and product: bovine herpesvirus 1 UL49 homolog is dispensable for virus growth.

J Virol. 1995 Jun;69(6):3863-7.

PMID: 7745736 [PubMed - indexed for MEDLINE]

109: [Koptidesova D, Kopacek J, Zelnik V, Ross NL, Pastorekova S, Pastorek J.](#)

[Related Articles, 1](#)



Identification and characterization of a cDNA clone derived from the Marek disease tumour cell line RPL1 encoding a homologue of alpha-transinducin factor (VP16) of HSV-1.

Arch Virol. 1995;140(2):355-62.

PMID: 7710361 [PubMed - indexed for MEDLINE]

110: [Coulter LJ, Moss HW, Lang J, McGeoch DJ.](#)

[Related Articles, 1](#)



A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted.

J Gen Virol. 1993 Mar;74 (Pt 3):387-95.

PMID: 8383174 [PubMed - indexed for MEDLINE]

111: [Elliott GD, Meredith DM.](#)

[Related Articles, 1](#)



The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49.

J Gen Virol. 1992 Mar;73 (Pt 3):723-6.

PMID: 1312128 [PubMed - indexed for MEDLINE]

112: [Meredith DM, Lindsay JA, Halliburton IW, Whittaker GR.](#)

[Related Articles, 1](#)



Post-translational modification of the tegument proteins (VP13 and VP14) of herpes simplex virus type 1 by glycosylation and phosphorylation.

J Gen Virol. 1991 Nov;72 (Pt 11):2771-5.

PMID: 1658203 [PubMed - indexed for MEDLINE]

113: [Baker TS, Newcomb WW, Booy FP, Brown JC, Steven AC.](#)

[Related Articles, 1](#)



Three-dimensional structures of maturable and abortive capsids of equine herpesvirus 1 from cryoelectron microscopy.

J Virol. 1990 Feb;64(2):563-73.

PMID: 2153224 [PubMed - indexed for MEDLINE]

114: [Knopf KW, Kaerner HC.](#)

[Related Articles, 1](#)



Virus-specific basic phosphoproteins associated with herpes simplex virus 1
a (HSV-1) particles and the chromatin of HSV-1-infected cells.

J Gen Virol. 1980 Feb;46(2):405-14.

PMID: 6247428 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 14 2004 18:26:21



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for

Limits

Preview/Index

History

Clipboard

Details


Show:

About Entrez

Text Version

☐ 1: Gene Ther. 1999 Jan;6(1):4-5.

[Related Articles,](#)



Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

Catch VP22: the hitch-hiker's ride to gene therapy?

Murphy AL, Murphy SJ.

PMID: 10341869 [PubMed - indexed for MEDLINE]

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Show:

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 21 2004 15:38:44

Connecting via Winsock to STN
Welcome to STN International! Enter x:x
***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:26:57 ON 22 SEP 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'AQUALINE' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 14:27:08 ON 22 SEP 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 14:27:08 ON 22 SEP 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'CAPLUS' ENTERED AT 14:27:08 ON 22 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:27:08 ON 22 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Proquest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'FOMAD' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'HEALSAFE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'NIOSHTIC' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:27:08 ON 22 SEP 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 14:27:08 ON 22 SEP 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 14:27:08 ON 22 SEP 2004

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 14:27:08 ON 22 SEP 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 14:27:08 ON 22 SEP 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 14:27:08 ON 22 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:27:08 ON 22 SEP 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 14:27:08 ON 22 SEP 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S VP22

49 FILES SEARCHED...

L1 2504 VP22

=> DUP REM L1

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING IS APPROXIMATELY 51% COMPLETE FOR L1

PROCESSING IS APPROXIMATELY 94% COMPLETE FOR L1

PROCESSING COMPLETED FOR L1

L2 1383 DUP REM L1 (1121 DUPLICATES REMOVED)

=> S L2 AND PY<=1999

'1999' NOT A VALID FIELD CODE

3 FILES SEARCHED...

6 FILES SEARCHED...

8 FILES SEARCHED...

10 FILES SEARCHED...

14 FILES SEARCHED...

20 FILES SEARCHED...

'1999' NOT A VALID FIELD CODE

26 FILES SEARCHED...

28 FILES SEARCHED...

29 FILES SEARCHED...

'1999' NOT A VALID FIELD CODE

34 FILES SEARCHED...

L3 199 L2 AND PY<=1999

=> D L3 1-199

L3 ANSWER 1 OF 199 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved. (2004) on STN

AN 95:59072 AGRICOLA

DN IND20479688

TI Identification and characterization of a cDNA clone derived from the Marek's disease tumour cell line RPL1 encoding a homologue of alpha-transinducing factor (VP16) of HSV-1.

AU Koptidesova, D.; Kopacek, J.; Zelnik, V.; Ross, N.L.J.; Pastorekova, S.; Pastorek, J.

CS Slovak Academy of Sciences, Bratislava, Slovak Republic.

AV DNAL (448.3 Ar23)

SO Archives of virology, ***1995*** Vol. 140, No. 2. p. 355-362

Publisher: Wien, Austria : Springer-Verlag.

CODEN: ARVIDF; ISSN: 0304-8608

NTE Includes references

CY Austria

DT Article

FS Non-U.S. Imprint other than FAO

LA English

L3 ANSWER 2 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN

AN 1998:53870 BIOBUSINESS

DN 1005693

TI Intercellular delivery of functional p53 by the herpesvirus protein

VP22

AU Phelan A Elliott G O'Hare P

CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 0TL, UK.

SO Nature Biotechnology, (***1998***) Vol.16, No.5, p.440-443.

ISSN: 1087-0156.

DT ARTICLE

FS NONUNIQUE

LA English

L3 ANSWER 3 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN

AN 1998:48224 BIOBUSINESS

DN 1000047

TI Delivering p53 with herpesvirus protein.

AU Anon
 SO Applied Genetics News, (***1998***) Vol.18, No.11, June, p.2.
 ISSN: 0271-7107.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 4 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 1998:48128 BIOBUSINESS
 DN 0999951
 TI Invitrogen gets cell transport molecule from Phogen.
 AU Anon
 SO Pharmaceutical Business News, (***1998***) Vol.14, No.316, May 11,
 p.26.
 ISSN: 0956-0661.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 5 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 1998:44319 BIOBUSINESS
 DN 0996142
 TI Phogen's ***VP22*** tech piggy-backs proteins into target cells.
 AU Anon
 SO European Biotechnology Newsletter, (***1998***) No.267, May 21, p.12.
 ISSN: 0765-2046.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 6 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 97:33268 BIOBUSINESS
 DN 0890803
 TI Phogen JV explores potential of herpesvirus drug delivery.
 AU Anon
 SO Genetic Engineering News, (***1997***) Vol.17, No.6, March 15, p.4.
 ISSN: 0270-6377.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 7 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 97:32996 BIOBUSINESS
 DN 0890531
 TI Cantab and MCCC will develop herpesvirus drug delivery.
 AU Anon
 SO Genetic Technology News, (***1997***) Vol.17, No.4, April, p.12.
 ISSN: 0272-9032.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 8 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 97:30348 BIOBUSINESS
 DN 0887883
 TI Cantab joins forces with MCCC to form biotech company.
 AU Anon
 SO Pharmaceutical Business News, (***1997***) Vol.13, No.287, March 12,
 p.18.
 ISSN: 0956-0661.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 9 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 97:27599 BIOBUSINESS
 DN 0885134
 TI ***VP22*** : A new movement in protein transport.
 AU Marshall A; Castellino A
 CS Dep. Cell Biol. Anatomy, Cornell Univ. Med. Coll., 1300 York Ave., New

SO York, NY 10021, USA.
 Nature Biotechnology, (***1997***) Vol.15, No.3, March, p.205.
 ISSN: 1087-0156.
 DT ARTICLE
 FS UNIQUE
 LA English

L3 ANSWER 10 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation.
 on STN
 AN 97:24738 BIOBUSINESS
 DN 0882273
 TI Could cold sores be gene therapy's best friend?
 AU Coghlan A
 SO New Scientist, (***1997***) Vol.153, No.2069, Feb. 15, P.25.
 ISSN: 0262-4079.
 FS UNIQUE
 LA ENGLISH

L3 ANSWER 11 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
 AN 0183317 BIOCOMMERCE FS Abstract
 CO Phogen Ltd (41282), UK
 Washington University (3086), USA
 Idun Pharmaceuticals Inc (28890), USA
 SO Pharmaceutical Business News, 10 SEP 1999, vol. 349, Page(s) 22.
 TC (Company information)

L3 ANSWER 12 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
 AN 0180669 BIOCOMMERCE FS Abstract
 CO Phogen Ltd (41282), UK
 Cantab Pharmaceuticals plc (26256), UK
 Marie Curie Cancer Care (MCCC) (41041), UK
 Xenova Group plc (29007), UK
 SO Scrip, 26 MAY 1999, vol. 2440, Page(s) 14.
 Pharma Marketletter, 24 MAY 1999, vol. 2621, Page(s) 6.
 TC (Company information)

L3 ANSWER 13 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
 AN 0178060 BIOCOMMERCE FS Abstract
 CO Phogen Ltd (41282), UK
 Cantab Pharmaceuticals plc (26256), UK
 Marie Curie Cancer Care (MCCC) (41041), UK
 Xenova Group plc (29007), UK
 SO Scrip, 22 JAN 1999, vol. 2405, Page(s) 22.
 Pharmaceutical Business News, 22 JAN 1999, vol. 15334, Page(s) 26.
 TC (Company information)

L3 ANSWER 14 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
 AN 0177649 BIOCOMMERCE FS Abstract
 CO Phogen Ltd (41282), UK
 Karolinska Institute (KI) (602), Sweden
 Marie Curie Cancer Care (MCCC) (41041), UK
 Cantab Pharmaceuticals plc (26256), UK
 NASDAQ Stock Market (33303), USA
 Xenova Group plc (29007), UK
 SO Phogen Press Release, 11 JAN 1999
 TC (Company information)

L3 ANSWER 15 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
 AN 0176533 BIOCOMMERCE FS Abstract
 CO Phogen Ltd (41282), UK
 Cantab Pharmaceuticals Research Ltd (26181), UK
 Marie Curie Cancer Care (MCCC) (41041), UK
 Chemo-Sero-Therapeutic Research Institute, The (Kaketsuken) (2351), Japan
 Xenova Research Ltd (49192), UK
 SO Genetic Engineering News, 01 NOV 1998, vol. 1819, Page(s) 1,22,39,42.
 TC General Review

L3 ANSWER 16 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
 AN 0173423 BIOCOMMERCE FS Abstract
 CO Phogen Ltd (41282), UK
 Cantab Pharmaceuticals plc (26256), UK
 Marie Curie Cancer Care (MCCC) (41041), UK
 Invitrogen Corp (17791), USA
 Marie Curie Research Institute (15418), UK
 Xenova Group plc (29007), UK
 SO Pharm Science & Technology Today, JUN 1998, vol. 13, Page(s) 92-93.

TC General Review

L3 ANSWER 17 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0171772 BIOCOMMERCE FS Abstract
CO Marie Curie Research Institute (15418), UK
Texas A&M University (4987), USA
SO Nature Biotechnology, MAY 1998, vol. 165, Page(s) 418-419, 440-443.
Chemistry in Britain, AUG 1998, vol. 348, Page(s) 19.
TC (Institute information)

L3 ANSWER 18 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0170624 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Invitrogen Corp (17791), USA
SO Scrip, 15 MAY 1998, vol. 2335, Page(s) 29.
Genetic Technology News, 13 MAY 1998, vol. 1819, Page(s) 3.
In Vivo, MAY 1998, vol. 165, Page(s) 74-75.
TC (Company information)

L3 ANSWER 19 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0169739 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Cantab Pharmaceuticals plc (26256), UK
Marie Curie Research Institute (15418), UK
Xenova Group plc (29007), UK
SO Cantab Pharmaceuticals Press Release, 08 MAY 1998, vol. 320, Page(s) 1, 8.
BioWorld International, 20 MAY 1998, vol. 165, Page(s) 440-443.
Nature Biotechnology, MAY 1998, vol. 2335, Page(s) 29.
Scrip, 15 MAY 1998, vol. 136, Page(s) 30.
BioVenture View, JUN 1998, vol. 267, Page(s) 12.
European Biotechnology Newsletter, 21 MAY 1998, vol. 2, 340, Page(s) 724.
Gene Therapy, 03 JUN 1998, vol. 1811, Page(s) 2.
Applied Genetics News, JUN 1998
TC (Company information)

L3 ANSWER 20 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0152695 BIOCOMMERCE FS Abstract
CO Cantab Pharmaceuticals plc (26256), UK
Marie Curie Cancer Care (MCCC) (41041), UK
Phogen Ltd (41282), UK
Xenova Group plc (29007), UK
SO Cantab Pharmaceuticals Press Release, 27 FEB 1997, vol. 210, Page(s) 24.
Times, 28 FEB 1997, vol. 2213, Page(s) 1, 3.
BioWorld International, 05 MAR 1997, vol. 43, Page(s) 10.
Scrip, 11 MAR 1997, vol. 2410, Page(s) 178.
Gene Therapy, MAR 1997, vol. 68, Page(s) 28.
Marketletter, 10 MAR 1997, vol. 13287, Page(s) 8-9.
R&D Focus Drug News, 10 MAR 1997, vol. 6, Page(s) 18.
Pharmaceutical Business News, 12 MAR 1997, vol. 710, Page(s) 202.
Chemistry and Industry, 17 MAR 1997, vol. 611, Page(s) 8.
BIA Bulletin, MAY 1997, vol. 2412, Page(s) 28.
Marketletter, 04 MAY 1998, vol. 421, Page(s) 6-7.
Pharmaceutical Ventures, 10 MAR 1997, vol. 176, Page(s) 10.
R&D Focus Drug News, 31 MAR 1997, vol. 44, Page(s) 4.
Marketletter, 24 MAR 1997, vol. 519, Page(s) 7.
European Biotechnology Newsletter, 20 MAR 1997, vol. 174, Page(s) 14.
Biotechnology Newswatch, 03 MAR 1997, vol. 335, Page(s) 13.
Cancer Weekly, 10 MAR 1997, vol. 95, Page(s) 9-10.
Gene Therapy Weekly, 10 MAR 1997, vol. 104, Page(s) 4.
Genetic Engineering News, 15 MAR 1997, Page(s) 272.
Gene Therapy, APR 1997, Page(s) 3.
BioWorld Financial Watch, 12 MAY 1997, Page(s) 8.
Pharmaceutical Times, APR 1997, Page(s) 12.
Genetic Technology News, APR 1997, Page(s) 10.
Chemistry in Britain, MAY 1997, Page(s) 10.
Pharmaceutical Technology Europe, MAY 1997, Page(s) 11.
BioPharm, APR 1997, Page(s) 4.
Nature UK Product Review, MAY 1997, Page(s) 8.
BIA Bulletin, MAY 1998, Page(s) 10.
BioPharm Showcase, JUL 1998
TC (Company information)

L3 ANSWER 21 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004383604 BIOENG
DN 4597965
TI Intercellular Spread of GFP- ***VP22***

AU Aints, A; Dilber, MS; Smith, CIE*
 CS Center for Biotechnology, Department of Biosciences at Novum, Karolinska
 Institutet, Haelsovaegen 7, S-14157, Huddinge, Sweden,
 [mailto:edvard.smith@cbit.ki.se]
 SO Journal of Gene Medicine [J. Gene Med.]. Vol. 1, no. 4, pp. 275-279.
 Jul-Aug 1999.
 ISSN: 1099-498X
 DT Journal
 LA English
 SL English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 22 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004383603 BIOENG
 DN 4597964
 TI Quantification of ****VP22**** -GFP Spread by Direct Fluorescence in 15
 Commonly Used Cell Lines
 AU Wybranietz, WA; Prinz, F; Spiegel, M; Schenk, A; Bitzer, M; Gregor, M;
 Lauer, UM
 CS Internal Medicine I, Medical University Clinic Tuebingen, Otfried
 Mueller-Str. 10, D-72076 Tuebingen, Germany,
 [mailto:wolfgang.wybranietz@uni-tuebingen.de]
 SO Journal of Gene Medicine [J. Gene Med.]. Vol. 1, no. 4, pp. 265-274.
 Jul-Aug 1999.
 ISSN: 1099-498X
 DT Journal
 LA English
 SL English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 23 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004373949 BIOENG
 DN 4449126
 TI Intercellular trafficking of ****VP22**** -GFP fusion proteins
 AU Elliott, G; O'Hare, P*
 CS Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 0TL, UK
 SO Gene Therapy [Gene Ther.]. Vol. 6, no. 1, pp. 149-151. Jan 1999.
 ISSN: 0969-7128
 DT Journal
 LA English
 SL English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 24 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004373932 BIOENG
 DN 4449109
 TI Intercellular delivery of thymidine kinase prodrug activating enzyme by
 the herpes simplex virus protein, ****VP22****
 AU Dilber, MS; Phelan, A; Aints, A; Mohamed, AJ; Elliott, G; Edvard Smith,
 CI; O'Hare, P*
 CS Marie Curie Research Institute, The Chart, Oxted, Surrey, RH8 0TL, UK
 SO Gene Therapy [Gene Ther.]. Vol. 6, no. 1, pp. 12-21. Jan 1999.
 ISSN: 0969-7128
 DT Journal
 LA English
 SL English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 25 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004371099 BIOENG
 DN 4424908
 TI Transduction of full-length TAT fusion proteins into mammalian cells:
 TAT-p27 super(Kip1) induces cell migration
 AU Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA;
 Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF*
 CS Howard Hughes Medical Institute and Division of Molecular Oncology, Depts
 of Pathology and Medicine, Washington University School of Medicine, St.
 Louis, MO 63110, USA, [mailto:dowdy@pathology.wustl.edu]
 SO Nature Medicine [Nat. Med.]. Vol. 4, no. 12, pp. 1449-1452. Dec 1998.
 ISSN: 1078-8956
 DT Journal
 LA English
 OS Medical and Pharmaceutical Biotechnology Abstracts; Oncogenes & Growth
 Factors Abstracts

L3 ANSWER 26 OF 199 BIOENG COPYRIGHT on STN 2004 CSA

AN 2004366843 BIOENG
 DN 4633200
 TI Protein therapy - delivery guaranteed
 AU Bayley, H
 CS Department of medical biochemistry and genetics at the Texas A&M Health Science Center, College Station, TX 77843-1114, USA, [mailto:bayley@tamu.edu]
 SO Nature Biotechnology [Nat. Biotechnol.]. Vol. 17, no. 11, pp. 1066-1067. Nov 1999.
 ISSN: 1087-0156
 DT Journal; General Review
 LA English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 27 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004359291 BIOENG
 DN 4411655
 TI Intercellular trafficking of ***VP22*** -GFP fusion proteins is not observed in cultured mammalian cells
 AU Fang, B; Xu, B; Koch, P; Roth, JA
 CS Section of Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Box 109, 1515 Holcombe Boulevard, Houston, TX 77030, USA
 SO Gene Therapy [Gene Ther.]. Vol. 5, no. 10, pp. 1420-1424. Oct 1998.
 ISSN: 0969-7128
 DT Journal
 LA English
 SL English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 28 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004356753 BIOENG
 DN 4344192
 TI Intercellular delivery of functional p53 by the herpesvirus protein ***VP22***
 AU Phelan, A; Elliott, G; O'Hare, P*
 CS Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 OTL, UK
 SO Nature Biotechnology [NAT. BIOTECHNOL.]. Vol. 16, no. 5, pp. 440-443. May 1998.
 ISSN: 1087-0156
 DT Journal
 LA English
 SL English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 29 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
 AN 2004356752 BIOENG
 DN 4344191
 TI Ferrying proteins to the other side [Drug delivery through the plasma membrane]
 AU Fernandez, Tania; Bayley, Hagan*
 CS Department of Medical Biochemistry and Genetics at the Texas A&M Health Science Center, College Station, TX 77843, USA
 SO Nature Biotechnology [NAT. BIOTECHNOL.]. Vol. 16, no. 5, pp. 418-420. May 1998.
 ISSN: 1087-0156
 DT Journal; General Review
 LA English
 OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 30 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
 AN 2000:277810 BIOSIS
 DN PREV200000277810
 TI Herpesvirus pre-(viral DNA replication) enveloped particles.
 AU Dargan, Derrick James [Inventor, Reprint author]; Patel, Arvind Hirabhai [Inventor]; Subak-Sharpe, John Herbert [Inventor]
 CS Glasgow, UK
 ASSIGNEE: Medical Research Council
 PI US 5994116 November 30, 1999
 SO Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 30, 1999) Vol. 1228, No. 5. e-file.
 CODEN: OGUPE7. ISSN: 0098-1133.
 DT Patent
 LA English
 ED Entered STN: 6 Jul 2000

Last Updated on STN: 7 Jan 2002

- L3 ANSWER 31 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2000:792 BIOSIS
DN PREV200000000792
TI Direct protein transfer to terminally differentiated muscle cells.
AU Derer, Wolfgang; Easwaran, Hariharan P.; Knopf, Charles W.; Leonhardt,
Heinrich; Cardoso, M. Cristina [Reprint author]
CS Franz Volhard Clinic, Max Delbrueck Center, Wiltbergstrasse 50, D-13125,
Berlin, Germany
SO Journal of Molecular Medicine (Berlin), (Aug., 1999) Vol. 77, No. 8, pp.
609-613. print.
ISSN: 0946-2716.
DT Article
LA English
ED Entered STN: 23 Dec 1999
Last Updated on STN: 31 Dec 2001
- L3 ANSWER 32 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1999:345893 BIOSIS
DN PREV199900345893
TI Modified ***VP22*** localizes to the cell nucleus during synchronized
herpes simplex virus type 1 infection.
AU Pomeranz, Lisa E.; Blaho, John A. [Reprint author]
CS Department of Microbiology, Mount Sinai School of Medicine, One Gustave L.
Levy Place, New York, NY, 10029-6574, USA
SO Journal of Virology, (Aug., 1999) Vol. 73, No. 8, pp. 6769-6781. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999
- L3 ANSWER 33 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1999:323440 BIOSIS
DN PREV199900323440
TI Identification of phosphorylation sites within the herpes simplex virus
tegument protein ***VP22***.
AU Elliott, Gillian [Reprint author]; O'Reilly, Dawn; O'Hare, Peter
CS Virus Assembly Group, Marie Curie Research Institute, The Chart, Oxted,
Surrey, RH1 OTL, UK
SO Journal of Virology, (July, 1999) Vol. 73, No. 7, pp. 6203-6206. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999
- L3 ANSWER 34 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1999:310764 BIOSIS
DN PREV199900310764
TI ***VP22*** translocates heterologous proteins into tissue culture
cells.
AU Bennett, Robert P. [Reprint author]; Dalby, Brian [Reprint author]; Guy,
Pamela M. [Reprint author]
CS Invitrogen Corporation, Carlsbad, CA, USA
SO FASEB Journal, (April 23, 1999) Vol. 13, No. 7, pp. A1555. print.
Meeting Info.: Annual Meeting of the American Societies for Experimental
Biology on Biochemistry and Molecular Biology 99. San Francisco,
California, USA. May 16-20, 1999. American Societies for Experimental
Biology.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 17 Aug 1999
Last Updated on STN: 17 Aug 1999
- L3 ANSWER 35 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1999:298221 BIOSIS
DN PREV199900298221

TI Preliminary structural characterization of ****vp22**** , a protein
 AU expressing novel intercellular trafficking activity.
 CS Kueltzo, L. [Reprint author]; O'Hare, P.; Middaugh, C. R. [Reprint author]
 SO Department of Pharmaceutical Chemistry, University of Kansas, Lawrence,
 KS, 66047, USA
 FASEB Journal, (April 23, 1999) Vol. 13, No. 7, pp. A1393. print.
 Meeting Info.: Annual Meeting of the American Societies for Experimental
 Biology on Biochemistry and Molecular Biology 99. San Francisco,
 California, USA. May 16-20, 1999. American Societies for Experimental
 Biology.
 CODEN: FAJOEC. ISSN: 0892-6638.
 DT Conference; (Meeting)
 LA Conference; Abstract; (Meeting Abstract)
 ED English
 Entered STN: 12 Aug 1999
 Last Updated on STN: 12 Aug 1999

L3 ANSWER 36 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1999:238923 BIOSIS
 DN PREV199900238923
 TI Live-cell analysis of a green fluorescent protein-tagged herpes simplex
 virus infection.
 AU Elliott, Gillian [Reprint author]; O'Hare, Peter
 CS Marie Curie Research Institute, The Chart, Oxted, Surrey, RH1 0TL, UK
 SO Journal of Virology, (May, 1999) Vol. 73, No. 5, pp. 4110-4119. print.
 CODEN: JOVIAM. ISSN: 0022-538X.
 DT Article
 LA English
 ED Entered STN: 17 Jun 1999
 Last Updated on STN: 17 Jun 1999

L3 ANSWER 37 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1998:490859 BIOSIS
 DN PREV199800490859
 TI Differences in the intracellular localization and fate of herpes simplex
 virus tegument proteins early in the infection of Vero cells.
 AU Morrison, Ewan E.; Steven, Alex J.; Wang, Yi-Fen; Meredith, David M.
 CS [Reprint author]
 Mol. Med. Unit, Univ. Leeds, St. James's Univ. Hosp., Beckett St., Leeds
 LS9 7TF, UK
 SO Journal of General Virology, (Oct., 1998) Vol. 79, No. 10, pp. 2517-2528.
 print.
 CODEN: JGVIAI. ISSN: 0022-1317.
 DT Article
 LA English
 ED Entered STN: 18 Nov 1998
 Last Updated on STN: 18 Nov 1998

L3 ANSWER 38 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1998:411472 BIOSIS
 DN PREV199800411472
 TI Phosphorylation of structural components promotes dissociation of the
 herpes simplex virus type 1 tegument.
 AU Morrison, Ewan E.; Wang, Yi-Fen; Meredith, David M. [Reprint author]
 CS Molecular Med. Unit, Univ. Leeds, Clinical Sci. Build., St. James Univ.
 Hosp., Leeds LS9 7TF, UK
 SO Journal of Virology, (Sept., 1998) Vol. 72, No. 9, pp. 7108-7114. print.
 CODEN: JOVIAM. ISSN: 0022-538X.
 DT Article
 LA English
 ED Entered STN: 21 Sep 1998
 Last Updated on STN: 21 Sep 1998

L3 ANSWER 39 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1998:405088 BIOSIS
 DN PREV199800405088
 TI Recognition of herpes simplex virus type 2 tegument proteins by CD4 T
 cells infiltrating human genital herpes lesions.
 AU Koelle, David M. [Reprint author]; Frank, Jeannine M.; Johnson, Matthew
 L.; Kwok, William W.
 CS Fred Hutchinson Cancer Res. Center, Room D3-100, 1100 Fairview Ave. North,
 P.O. Box 19024, Seattle, WA 98109, USA

SO Journal of Virology, (Sept., 1998) Vol. 72, No. 9, pp. 7476-7483. print.
 CODEN: JOVIAM. ISSN: 0022-538X.
 DT Article
 LA English
 ED Entered STN: 21 Sep 1998
 Last Updated on STN: 21 Sep 1998

L3 ANSWER 40 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1998:372651 BIOSIS
 DN PREV199800372651
 TI Herpes simplex virus type 1 tegument protein ***VP22*** induces the
 stabilization and hyperacetylation of microtubules.
 AU Elliott, Gillian [Reprint author]; O'Hare, Peter
 CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 0TL, UK
 SO Journal of Virology, (Aug., 1998) Vol. 72, No. 8, pp. 6448-6455. print.
 CODEN: JOVIAM. ISSN: 0022-538X.
 DT Article
 LA English
 ED Entered STN: 27 Aug 1998
 Last Updated on STN: 27 Aug 1998

L3 ANSWER 41 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1997:290802 BIOSIS
 DN PREV199799590005
 TI Protein transport: The nonclassical ins and outs.
 AU Cleves, Ann E.
 CS Dep. Biochemistry Biophysics, Univ. California, San Francisco, CA
 94143-0534, USA
 SO Current Biology, (1997) Vol. 7, No. 5, pp. R318-R320.
 CODEN: CUBLE2. ISSN: 0960-9822.
 DT Article
 LA English
 ED Entered STN: 9 Jul 1997
 Last Updated on STN: 9 Jul 1997

L3 ANSWER 42 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1997:118416 BIOSIS
 DN PREV199799417619
 TI The abundance of the herpes simplex virus type 1 UL37 tegument protein in
 virus particles in closely controlled.
 AU McLauchlan, John
 CS MRC Virol. Unit, Church st., Glasgow G11 5JR, UK
 SO Journal of General Virology, (1997) Vol. 78, No. 1, pp. 189-194.
 CODEN: JGVIAJ. ISSN: 0022-1317.
 DT Article
 LA English
 ED Entered STN: 10 Mar 1997
 Last Updated on STN: 10 Mar 1997

L3 ANSWER 43 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1997:107423 BIOSIS
 DN PREV199799406626
 TI Intercellular trafficking and protein delivery by a herpesvirus structural
 protein.
 AU Elliott, Gillian; O'Hare, Peter
 CS Marie Curie Res. Inst., The Chart, Oxted, Surrey RH8 0TL, UK
 SO Cell, (1997) Vol. 88, No. 2, pp. 223-233.
 CODEN: CELLB5. ISSN: 0092-8674.
 DT Article
 LA English
 ED Entered STN: 10 Mar 1997
 Last Updated on STN: 10 Mar 1997

L3 ANSWER 44 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1997:30445 BIOSIS
 DN PREV199799336848
 TI Phosphorylation of the herpes simplex virus type 1 tegument protein
 VP22
 AU Elliott, Gillian [Reprint author]; O'Reilly, Dawn; O'Hare, Peter
 CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 0TL, UK
 SO Virology, (1996) Vol. 226, No. 1, pp. 140-145.

DT CODEN: VIRLAX. ISSN: 0042-6822.
 LA Article
 ED English
 Entered STN: 28 Jan 1997
 Last Updated on STN: 25 Mar 1997

L3 ANSWER 45 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1996:341870 BIOSIS
 DN PREV199699064226
 TI Overexpression of the herpes simplex virus type 1 tegument protein
 VP22 increases its incorporation into virus particles.
 AU Leslie, J.; Rixon, F. J.; McLauchlan, J. [Reprint author]
 CS MRC Virology Unit, Inst. Virology, Church Street, Glasgow G11 5JR, UK
 SO Virology, (1996) Vol. 220, No. 1, pp. 60-68.
 CODEN: VIRLAX. ISSN: 0042-6822.
 DT Article
 LA English
 ED Entered STN: 26 Jul 1996
 Last Updated on STN: 26 Jul 1996

L3 ANSWER 46 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1996:30491 BIOSIS
 DN PREV199698602626
 TI VP16 interacts via its activation domain with ***VP22***, a tegument
 protein of herpes simplex virus, and is relocated to a novel
 macromolecular assembly in coexpressing cells.
 AU Elliott, Gillian [Reprint author]; Mouzakitidis, Gerasimos; O'Hare, Peter
 CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 0TL, UK
 SO Journal of Virology, (1995) Vol. 69, No. 12, pp. 7932-7941.
 CODEN: JOVIAM. ISSN: 0022-538X.
 DT Article
 LA English
 ED Entered STN: 12 Jan 1996
 Last Updated on STN: 12 Jan 1996

L3 ANSWER 47 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1995:364073 BIOSIS
 DN PREV199598378373
 TI PREPS: Herpes simplex virus type 1-specific particles produced by infected
 cells when viral DNA replication is blocked.
 AU Dargan, D. J. [Reprint author]; Patel, A. H.; Subak-sharpe, J. H.
 CS Med. Res. Council, Virol Unit, Univ. Glasgow, Church St., Glasgow G11 5JR,
 UK
 SO Journal of Virology, (1995) Vol. 69, No. 8, pp. 4924-4932.
 CODEN: JOVIAM. ISSN: 0022-538X.
 DT Article
 LA English
 ED Entered STN: 30 Aug 1995
 Last Updated on STN: 30 Aug 1995

L3 ANSWER 48 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1994:272819 BIOSIS
 DN PREV199497285819
 TI Detection and identification of Vibrio parahaemolyticus in fecal samples
 of outbreak patients by in vitro amplification of thermostable direct
 haemolysin gene fragment.
 AU Lee, Chiayin [Reprint author]; Pan, Shwu-Fen; Lee, Yeong-Sheng; Lee,
 Chih-Lung
 CS Graduate Inst. Agric. Chem., Natl. Taiwan Univ., Taipei, Taiwan
 SO Journal of the Chinese Agricultural Chemical Society, (1994) Vol. 32, No.
 1, pp. 103-112.
 CODEN: CKNHAA. ISSN: 0578-1736.
 DT Article
 LA Chinese
 ED Entered STN: 24 Jun 1994
 Last Updated on STN: 24 Jun 1994

L3 ANSWER 49 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 1993:235606 BIOSIS
 DN PREV199395126781
 TI A mutant of herpes simplex virus type 1 in which the UL13 protein kinase

gene is disrupted.

AU Coulter, L. J.; Moss, H. W. M.; Lang, J.; McGeoch, D. J. [Reprint author]
CS Inst. Virology, Univ. Glasgow, Church Street, Glasgow G11 5JR, UK
SO Journal of General Virology, (1993) Vol. 74, No. 3, pp. 387-395.
CODEN: JGVIAI. ISSN: 0022-1317.
DT Article
LA English
ED Entered STN: 7 May 1993
Last Updated on STN: 7 May 1993

L3 ANSWER 50 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1992:234456 BIOSIS
DN PREV199293122481; BA93:122481
TI THE HERPES SIMPLEX VIRUS TYPE 1 TEGUMENT PROTEIN ***VP22*** IS ENCODED
BY GENE UL49.
AU ELLIOTT G D [Reprint author]; MEREDITH D M
CS DEP MICROBIOL, UNIV OF LEEDS, LEEDS LS2 9JT, UK
SO Journal of General Virology, (1992) Vol. 73, No. 3, pp. 723-726.
CODEN: JGVIAI. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 10 May 1992
Last Updated on STN: 10 May 1992

L3 ANSWER 51 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1992:56110 BIOSIS
DN PREV199293036085; BA93:36085
TI POST-TRANSLATIONAL MODIFICATION OF THE TEGUMENT PROTEINS VP13 AND VP14 OF
HERPES SIMPLEX VIRUS TYPE 1 BY GLYCOSYLATION AND PHOSPHORYLATION.
AU MEREDITH D M [Reprint author]; LINDSAY J A; HALLIBURTON I W; WHITTAKER G R
CS DEP MICROBIOL, UNIV LEEDS, LEEDS LS2 9JT, UK
SO Journal of General Virology, (1991) Vol. 72, No. 11, pp. 2771-2776.
CODEN: JGVIAI. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 13 Jan 1992
Last Updated on STN: 13 Jan 1992

L3 ANSWER 52 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1990:139691 BIOSIS
DN PREV199089078502; BA89:78502
TI THREE-DIMENSIONAL STRUCTURES OF MATURABLE AND ABORTIVE CAPSIDS OF EQUINE
HERPESVIRUS 1 FROM CRYOELECTRON MICROSCOPY.
AU BAKER T S [Reprint author]; NEWCOMB W W; BOOY F P; BROWN J C; STEVEN A C
CS LAB PHYSIOL BIOL, NATL INST ARTHRITIS MUSCULOSKELETAL SKIN DIS, BUILDING
6, ROOM 114, BETHESDA, MD 20892, USA
SO Journal of Virology, (1990) Vol. 64, No. 2, pp. 563-573.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990

L3 ANSWER 53 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 1980:179973 BIOSIS
DN PREV198069054969; BA69:54969
TI VIRUS SPECIFIC BASIC PHOSPHO PROTEINS ASSOCIATED WITH HERPES SIMPLEX VIRUS
TYPE 1 PARTICLES AND THE CHROMATIN OF HERPES SIMPLEX VIRUS TYPE 1 INFECTED
CELLS.
AU KNOPF K-W [Reprint author]; KAERNER H C
CS GER CANCER RES CENT, INST VIRUS RES, 6900 HEIDELBERG, W GER
SO Journal of General Virology, (1980) Vol. 46, No. 2, pp. 405-414.
CODEN: JGVIAI. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH

L3 ANSWER 54 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1999-05246 BIOTECHDS

TI Intercellular trafficking of ***VP22*** -GFP fusion proteins;
 VP22 -green fluorescent protein fusion protein with the
 ability to mediate intercellular protein transport
 AU Elliot G; *O'Hare P
 CS Marie-Curie-Res.Inst.Oxtd
 LO Marie Curie Research Institute, The Chart, Oxtd, Surrey RH8 OTL, UK.
 SO Gene Ther.; (***1999***) 6, 1, 149-51
 CODEN: GETHEC ISSN: 0969-7128
 DT Journal
 LA English

L3 ANSWER 55 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1999-02756 BIOTECHDS
 TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex
 virus;
 herpes simplex virus recombinant ***VP22*** protein preparation,
 virus vector-mediated gene transfer and expression in host cell, used
 for infection recombinant vaccine or nucleic acid vaccine
 AU Burke R L; Tigges M A
 PA Chiron
 LO Emeryville, CA, USA.
 PI WO 9855145 ***10 Dec 1998***
 AI WO 1998-US10664 26 May 1998
 PRAI US 1997-47359 2 Jun 1997
 DT Patent
 LA English
 OS WPI: 1999-059878 [05]

L3 ANSWER 56 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1999-01646 BIOTECHDS
 TI Using baculo virus to deliver nucleic acid to hepatocytes;
 thymidine-kinase gene transfer, antisense and ribozyme for virus
 infection and liver cancer gene therapy
 AU McGarvey M J; Thomas H C
 PA Imperial-Coll.Innovations
 LO London, UK.
 PI WO 9848842 ***5 Nov 1998***
 AI WO 1998-GB1249 29 Apr 1998
 PRAI GB 1997-8698 29 Apr 1997
 DT Patent
 LA English
 OS WPI: 1999-009390 [01]

L3 ANSWER 57 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1998-11220 BIOTECHDS
 TI Use of the microtubule binding function and transport properties of
 herpes virus ***VP22*** protein;
 to study and manipulate mammal cell structure, growth, division and
 death in vitro and in vivo
 AU Elliot G D
 PA Phogen
 LO Cambridge, UK.
 PI WO 9842742 ***1 Oct 1998***
 AI WO 1998-GB873 23 Mar 1998
 PRAI GB 1997-5903 21 Mar 1997
 DT Patent
 LA English
 OS WPI: 1998-531948 [45]

L3 ANSWER 58 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1998-09556 BIOTECHDS
 TI New coupled or fusion polypeptides;
 herpes virus ***VP22*** protein and p53 fusion protein preparation
 by plasmid p49532p+10 vector expression in microorganism or mammal
 cell, used for disease therapy or gene therapy, etc.
 AU O'Hare P F J; Elliott G D
 PA Marie-Curie-Cancer-Care
 LO London, UK.
 PI WO 9832866 ***30 Jul 1998***
 AI WO 1998-GB207 23 Jan 1998
 PRAI GB 1997-16398 1 Aug 1997; GB 1997-1363 23 Jan 1997
 DT Patent
 LA English
 OS WPI: 1998-427962 [36]

L3 ANSWER 59 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN

AN 1998-08690 BIOTECHDS
 TI Ferrying proteins to the other side;
 membrane translocating protein fusion protein for potential use in
 gene therapy or as recombinant vaccine
 AU Fernandez T; Bayley H
 CS Univ.Texas-A+M
 LO Department of Medical Biochemistry and Genetics, Texas A+M Health Science
 Center, College Station, TX 77843, USA.
 Email: bayley@tamu.edu
 SO Nat.Biotechnol.; (***1998***) 16, 5, 418-20
 CODEN: NABIF ISSN: 1087-0156
 DT Journal
 LA English

L3 ANSWER 60 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1998-04880 BIOTECHDS
 TI New antiviral agent against herpes, disrupts binding of ***VP22*** to
 VP16 or gB;
 virucide causing disruption of herpes simplex virus type-1 protein
 association
 AU McLaughlan J; McGeoch D J; Hope R G; Rixon H W M
 PA Med.Res.Counc.
 LO London, UK.
 PI WO 9804708 ***5 Feb 1998***
 AI WO 1997-GB2036 28 Jul 1997
 PRAI GB 1996-15726 26 Jul 1996
 DT Patent
 LA English
 OS WPI: 1998-130696 [12]

L3 ANSWER 61 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1997-06513 BIOTECHDS
 TI Use of herpes simplex virus type-1 major tegument portion, ***VP22***
 ;
 as a transport protein in a fusion protein, for tissue-specific gene
 expression, using a virus vector, lipofection, transfection or
 microinjection, in e.g. gene therapy
 AU O'Hare P F J; Elliott G D
 PA O'Hare P F J; Elliott G D
 LO Oxted, UK.
 PI WO 9705265 ***13 Feb 1997***
 AI WO 1996-GB1831 25 Jul 1996
 PRAI GB 1996-1570 26 Jan 1996; GB 1995-15568 28 Jul 1995
 DT Patent
 LA English
 OS WPI: 1997-145701 [13]

L3 ANSWER 62 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
 AN 1985-05303 BIOTECHDS
 TI Construction of a shuttle vector which replicates stably in Vibrio
 parahemolyticus and Escherichia coli;
 plasmid characterization (conference paper)
 AU Ando T; Arai T
 LO Department of Microbiology, Keio University School of Medicine Tokyo,
 Japan.
 SO Transferable Antibiot.Resist.; (***1984***) 5 Meet., 347-52
 DT Journal
 LA English

L3 ANSWER 63 OF 199 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 1999:29479978 BIOTECHNO
 TI Can ***VP22*** resurrect gene therapy?
 AU Luft F.C.
 CS F.C. Luft, Franz-Volhard-Klinik, Humboldt University of Berlin,
 Wiltbergstrasse 50, D-13125 Berlin-Buch, Germany.
 E-mail: luft@fvk-berlin.de
 SO Journal of Molecular Medicine, (***1999***), 77/8 (575-576), 6
 reference(s)
 CODEN: JMLME8 ISSN: 0946-2716
 DT Journal; (Short Survey)
 CY Germany, Federal Republic of
 LA English

L3 ANSWER 64 OF 199 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
 AN 1999:29043687 BIOTECHNO
 TI Catch ***VP22*** : The hitch-hiker's ride to gene therapy?

AU Murphy A.L.; Murphy S.J.
SO Gene Therapy, (***1999***), 6/1 (4-5), 7 reference(s)
CODEN: GETHEC ISSN: 0969-7128
DT Journal; (Short Survey)
CY United Kingdom
LA English

L3 ANSWER 65 OF 199 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1998:29043337 BIOTECHNO
TI New strategies for the genetic therapy of primary liver carcinoma
AU Lauer U.; Spiegel M.; Bitzer M.; Wybranietz W.A.; Gross Ch.D.; Prinz F.;
Graepler F.; Neubert W.J.; Gregor M.
CS Dr. U. Lauer, Abteilung Innere Medizin I, Med. Universitätsklinik
Tubingen, Otfried-Muller-Str. 10, D-72076 Tubingen, Germany.
SO Minimally Invasive Therapy and Allied Technologies, (***1998***), 7/6
(567-571), 26 reference(s)
CODEN: MITAFI ISSN: 1364-5706
DT Journal; Article
CY United Kingdom
LA English
SL English

L3 ANSWER 66 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:753364 CAPLUS
DN 131:347510
TI Gene therapy vectors utilizing recombination and their use in antitumor
therapy
IN Margison, Geoffrey Paul; Marples, Brian; Scott, Simon; Hendry, Jolyon
Hindson
PA Cancer Research Campaign Technology Limited, UK
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9960142	A2	19991125	WO 1999-GB1362	19990517 <--
	WO 9960142	A3	20000713		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2374248	AA	19991125	CA 1999-2374248	19990517 <--
	AU 9939375	A1	19991206	AU 1999-39375	19990517 <--
	AU 763714	B2	20030731		
	EP 1078091	A2	20010228	EP 1999-922263	19990517
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	NZ 508671	A	20030530	NZ 1999-508671	19990517
PRAI	GB 1998-10423	A	19980515		
	WO 1999-GB1362	W	19990517		

L3 ANSWER 67 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:390423 CAPLUS
DN 131:39724
TI Cytotoxin fusion proteins for use in killing of cells infected by
pathogens
IN Dowdy, Steven F.
PA Washington University, USA
SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929721	A1	19990617	WO 1998-US26358	19981210 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,			

UA, UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2314267 AA 19990617 CA 1998-2314267 19981210 <--
 AU 9918182 A1 19990628 AU 1999-18182 19981210 <--
 EP 1037911 A1 20000927 EP 1998-963079 19981210
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 US 6221355 B1 20010424 US 1998-208966 19981210
 JP 2002505077 T2 20020219 JP 2000-524312 19981210
 PRAI US 1997-69012P P 19971210
 US 1998-82402P P 19980420
 WO 1998-US26358 W 19981210
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 68 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:166641 CAPLUS
 DN 130:205911
 TI Fusion proteins of transcriptional activators carrying peptides promoting
 cell uptake and a regulated expression system using them
 IN Dowdy, Steven F.; Jessee, Joel A.
 PA Washington University, USA
 SO PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910376	A1	19990304	WO 1998-US16887	19980814 <--
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1005486	A1	20000607	EP 1998-939402	19980814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513987	T2	20010911	JP 2000-507702	19980814
US 2003040038	A1	20030227	US 1998-134793	19980814
US 2004146889	A1	20040729	US 2003-680576	20031006
PRAI US 1997-56713P	P	19970822		
US 1998-134793	A1	19980814		
WO 1998-US16887	W	19980814		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 69 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:621324 CAPLUS
 DN 129:240848
 TI Increasing the efficiency of uptake of transforming DNA complexes with
 polycations using peptides
 IN Hawley-Nelson, Pamela; Lan, Jianqing; Shih, Pojen; Jessee, Joel A.;
 Ciccarone, Valentina C.; Evans, Krista L.; Schifferli, Kevin P.; Gebeyehu,
 Guililat
 PA Life Technologies, Inc., USA
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9840502	A1	19980917	WO 1998-US5232	19980316 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6051429	A	20000418	US 1997-818200	19970314
AU 9865622	A1	19980929	AU 1998-65622	19980316 <--
EP 1007699	A1	20000614	EP 1998-911737	19980316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, FI			
JP	2001517939	T2	20011009	JP 1998-539899
PRAI	US 1997-818200	A	19970314	19980316
	US 1995-477354	B2	19950607	
	US 1996-658130	A2	19960604	
	WO 1998-US5232	W	19980316	

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L3 ANSWER 70 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:175378 CAPLUS
TI ***VP22*** : A new movement in protein transport
AU Marshall, Andrew; Castellino, Alexander
CS Dep. Cell Biol. Anatomy, Cornell Univ. Med. Coll., New York, NY, 10021, USA
SO Nature Biotechnology (***1997***), 15(3), 205
CODEN: NABIF9; ISSN: 1087-0156
PB Nature Publishing Co.
DT Journal; News Announcement
LA English
- L3 ANSWER 71 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:571796 CAPLUS
DN 121:171796
TI Nucleotide sequence of a 55 kbp region from the right end of the genome of a pathogenic African swine fever virus isolate (malawi LIL20/1)
AU Dixon, Linda K.; Twigg, Stephen R. F.; Baylis, Sally A.; Vydelingum, Soopayah; Bristow, Christine; Hammond, Jef M.; Smith, Geoffrey L.
CS AFRC Inst. Animal Health, Pirbright Lab., Woking, GU24 0NF, UK
SO Journal of General Virology (***1994***), 75(7), 1655-84
CODEN: JGVIAV; ISSN: 0022-1317
DT Journal
LA English
- L3 ANSWER 72 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:320903 CAPLUS
DN 120:320903
TI Analysis of antibody responses to predominant linear epitopes of Theiler's murine encephalomyelitis virus
AU Inoue, Atsushi; Choe, Yong Kyung; Kim, Byung S.
CS Med. Sch., Northwest. Univ., Chicago, IL, 60611, USA
SO Journal of Virology (***1994***), 68(5), 3324-33
CODEN: JOVIAM; ISSN: 0022-538X
DT Journal
LA English
- L3 ANSWER 73 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:445358 CAPLUS
DN 115:45358
TI Purification of the structural proteins of herpes simplex virus type 1 by reversed-phase high-performance liquid chromatography
AU Whittaker, G. R.; Meredith, D. M.
CS Dep. Microbiol., Univ. Leeds, Leeds, LS2 9JT, UK
SO Archives of Virology (***1990***), 114(3-4), 271-6
CODEN: ARVIDF; ISSN: 0304-8608
DT Journal
LA English
- L3 ANSWER 74 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:403337 CAPLUS
DN 99:3337
TI Important role of protease of baculovirus inclusion bodies in the infection process
AU Kozlov, E. A.; Levitina, T. L.; Gusak, N. M.; Unguryanu, N.; Serebryanyi, S. B.
CS Inst. Mol. Biol. Genet., Kiev, USSR
SO Molekulyarnaya Biologiya (Kiev) (***1982***), 31, 32-5
CODEN: MLKBAQ; ISSN: 0375-9415
DT Journal
LA Russian
- L3 ANSWER 75 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1999(06):5040 CEABA-VTB FS B
DN CEABA: 1999:3212891
TI Phogen s herpes protein technology boosts anticancer gene therapy
CS Phogen, Cambridge, UK

SO Pharm. Bus. News (***1999***) 15(334), p.26
 CODEN: PBNEEH ISSN: 0956-0661
 DT Journal
 LA English

L3 ANSWER 76 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
 AN 1998(07):0028 CEABA-VTB FS B
 DN CEABA: 1998:5225896
 TI Invitrogen gets cell transport molecule from Phogen
 CS Invitrogen, USA
 SO Pharm. Bus. News (***1998***) 14(316), p.26
 CODEN: PBNEEH ISSN: 0956-0661
 DT Journal
 LA English

L3 ANSWER 77 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
 AN 1998(06):5537 CEABA-VTB FS B
 DN CEABA: 1998:2431892
 TI Cancer gene therapy: guardian gene restored
 AU Newell, J. (UK)
 SO Chem. Br. (***1998***) 34(8), p.19
 CODEN: CHMBAY ISSN: 0009-3106
 DT Journal
 LA English

L3 ANSWER 78 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
 AN 1997(07):5539 CEABA-VTB FS B
 DN CEABA: 1997:7484891
 TI Could cold sores be gene therapy s best friend?
 AU Coghlan, A.
 SO New Sci. (***1997***) 153(2069), p.25
 CODEN: NWSCAL ISSN: 0028-6664
 DT Journal
 LA English

L3 ANSWER 79 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
 AN 1997(06):8691 CEABA-VTB FS B
 DN CEABA: 1997:3712899
 TI Hitchhiker s guide to gene therapy
 CS Phogen, UK
 SO Chem. Ind. (London) (***1997***) (6), p.202
 CODEN: CHINAG ISSN: 0009-3068
 DT Journal
 LA English

L3 ANSWER 80 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
 AN 1997(06):7870 CEABA-VTB FS B
 DN CEABA: 1997:3336891
 TI Phogen to focus on herpes drug delivery
 CS Phogen, Cambridge, UK
 SO Biotechnol. Newswatch (***1997***), p.14
 ISSN: 0275-3685
 DT Journal
 LA English

L3 ANSWER 81 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
 AN 1997(06):4294 CEABA-VTB FS B
 DN CEABA: 1997:1558891
 TI Drug delivery by herpes virus protein
 SO Lab. News (London) (***1997***), p.5
 ISSN: 0266-7169
 DT Journal
 LA English

L3 ANSWER 82 OF 199 CIN COPYRIGHT 2004 ACS on STN
 AN 28(23):23048P CIN
 TI Deals
 SO BioCentury, 24 May 1999 (19990524), 7(30, Pt. 2), p. B3. ISSN: 1097-7201;
 CODEN: BICEFS.
 LA English

L3 ANSWER 83 OF 199 CIN COPYRIGHT 2004 ACS on STN
 AN 28(5):4140W CIN
 TI Other research news
 SO BioCentury, 18 Jan 1999 (19990118), 7(5, Pt. 2), p. B16. ISSN: 1097-7201;
 CODEN: BICEFS.

LA English

L3 ANSWER 84 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 27(27):30609E CIN
TI Phogen's ***VP22*** tech piggy-backs proteins into target cells
SO Eur. Biotechnol. Newsl., 21 May 1998 (19980521), 267, p. 12. ISSN: 0765-2046; CODEN: EBNWEI.
LA English

L3 ANSWER 85 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 27(20):23072W CIN
TI Other research news
SO BioCentury, 4 May 1998 (19980504), 6(39, Pt. 2), p. B13. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L3 ANSWER 86 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 27(20):22759P CIN
TI Sales & marketing
SO BioCentury, 4 May 1998 (19980504), 6(39, Pt. 2), p. B6. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L3 ANSWER 87 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(18):20632X CIN
TI Phogen JV explores potential of herpesvirus drug delivery
SO Genet. Eng. News, 15 Mar 1997 (970315), 17(6), p. 4. ISSN: 0270-6377; CODEN: GENNDX.
LA English

L3 ANSWER 88 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(14):16215W CIN
TI Hitchhiker's guide to gene therapy
SO Chem. Ind. (London), 17 Mar 1997 (970317), (6), p. 202. ISSN: 0009-3068; CODEN: CHINAG.
LA English

L3 ANSWER 89 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(13):15349F CIN
TI Cantab joins forces with MCCC to form biotech company
SO Pharm. Bus. News, 12 Mar 1997 (970312), 13(287), p. 18. ISSN: 0956-0661; CODEN: PBNEEH.
LA English

L3 ANSWER 90 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(13):15271Z CIN
TI Cantab forms joint venture to develop protein for drug and gene delivery
SO Biotechnol. News, 6 Mar 1997 (970306), 17(6), p. 4. ISSN: 0273-3226; CODEN: BINWEY.
LA English

L3 ANSWER 91 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(12):13742E CIN
TI ***VP22*** : a new movement in protein transport
SO Nat. Biotechnol., Mar 1997 (970300), 15(3), p. 205. ISSN: 1087-0156; CODEN: NABIF9.
LA English

L3 ANSWER 92 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY78333 peptide DGENE
TI New membrane permanent peptide complexes for medical imaging, diagnostics and therapy -
IN Piwnica-worms D
PA (UNIW) UNIV WASHINGTON.
PI ***WO 9967284 A2 19991229 65p***
AI WO 1999-US13660 19990618
PRAI US 1998-90087 19980620
DT Patent
LA English
OS 2000-160576 [14]
DESC Herpes simplex virus ***VP22*** protein SEQ ID NO:5.

L3 ANSWER 93 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW67755 Protein DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce

IN a cytotoxic T cell response
 PA Burke R L; Tigges M A
 PI (CHIR) CHIRON CORP.
 WO 9855145 A1 19981210 94p
 AI WO 1998-US10664 19980526
 PRAI US 1997-47359 19970602
 DT Patent
 LA English
 OS 1999-059878 [05]
 CR N-PSDB: AAV81471
 DESC HSV-2 ***VP22*** protein.

L3 ANSWER 94 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW95100 peptide DGENE
 TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration

IN Beach D H; Gyuris J; Lamphere L
 PA (MITO-N) MITOTIX INC.
 PI ***WO 9906540 A2 19990211 88p***
 AI WO 1998-US15759 19980729
 PRAI US 1997-902572 19970729
 DT Patent
 LA English
 OS 1999-153770 [13]
 CR N-PSDB: AAX26228
 DESC HIV-1 ***VP22*** polypeptide C-terminal domain.

L3 ANSWER 95 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAW95099 Protein DGENE
 TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration

IN Beach D H; Gyuris J; Lamphere L
 PA (MITO-N) MITOTIX INC.
 PI ***WO 9906540 A2 19990211 88p***
 AI WO 1998-US15759 19980729
 PRAI US 1997-902572 19970729
 DT Patent
 LA English
 OS 1999-153770 [13]
 CR N-PSDB: AAX26227
 DESC HIV-1 ***VP22*** polypeptide.

L3 ANSWER 96 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY27404 Protein DGENE
 TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors or inflammation -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K

PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945126 A2 19990910 149p***
 AI WO 1999-GB672 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-540852 [45]
 CR N-PSDB: AAZ07807
 DESC HSV-1 tegument protein ***vp22***

L3 ANSWER 97 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAY42292 Protein DGENE
 TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K

PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945127 A2 19990910 187p***
 AI WO 1999-GB674 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129

DT Patent
LA English
OS 1999-551046 [46]
CR N-PSDB: AAZ19784
DESC Herpes simplex virus type 1 (HSV-1) ***VP22*** tegument protein.

L3 ANSWER 98 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47199 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide D.

L3 ANSWER 99 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47198 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide C.

L3 ANSWER 100 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47197 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide B.

L3 ANSWER 101 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47196 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide A.

L3 ANSWER 102 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47195 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726

DT Patent
LA English
OS 1998-130696 [12]
DESC Herpes simplex virus truncated tegument protein ***VP22*** .

L3 ANSWER 103 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47194 Protein DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
CR N-PSDB: AAV17085
DESC Herpes simplex virus tegument protein ***VP22*** .

L3 ANSWER 104 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47205 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide J.

L3 ANSWER 105 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47204 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide I.

L3 ANSWER 106 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47203 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide H.

L3 ANSWER 107 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47202 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726

DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide G.

L3 ANSWER 108 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47201 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide F.

L3 ANSWER 109 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47200 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB -
useful for treating infections caused by herpes simplex, e.g. cold sores
and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide E.

L3 ANSWER 110 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW69718 protein DGENE
TI Coupled or fusion polypeptides, for transporting proteins into cells -
contain an amino acid sequence with the transport function of herpesviral
VP22 protein
IN Elliott G D; O'Hare P F J
PA (CURI-N) CURIE CANCER CARE MARIE.
PI ***WO 9832866 A1 19980730 39p***
AI WO 1998-GB207 19980123
PRAI GB 1997-16398 19970801
GB 1997-1363 19970123
DT Patent
LA English
OS 1998-427962 [36]
DESC Human p53 used in coupled proteins and fusion proteins.

L3 ANSWER 111 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW69717 protein DGENE
TI Coupled or fusion polypeptides, for transporting proteins into cells -
contain an amino acid sequence with the transport function of herpesviral
VP22 protein
IN Elliott G D; O'Hare P F J
PA (CURI-N) CURIE CANCER CARE MARIE.
PI ***WO 9832866 A1 19980730 39p***
AI WO 1998-GB207 19980123
PRAI GB 1997-16398 19970801
GB 1997-1363 19970123
DT Patent
LA English
OS 1998-427962 [36]
DESC Herpesviral ***VP22*** protein used in coupled proteins and fusion
proteins.

L3 ANSWER 112 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW81473 DNA DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex
virus - and vaccines containing vector encoding this polypeptide, induce
a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***

AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
DESC Primer GPUL49 3' for HSV-2 ***VP22*** gene.

L3 ANSWER 113 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV81472 DNA DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***
AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
DESC Primer GPUL49 5' for HSV-2 ***VP22*** gene.

L3 ANSWER 114 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV81471 DNA DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***
AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
CR P-PSDB: AAW67755
DESC HSV-2 ***VP22*** gene.

L3 ANSWER 115 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAX26227 DNA DGENE
TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI ***WO 9906540 A2 19990211 88p***
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR P-PSDB: AAW95099
DESC HIV-1 ***VP22*** polypeptide encoding DNA.

L3 ANSWER 116 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAX26228 DNA DGENE
TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI ***WO 9906540 A2 19990211 88p***
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR P-PSDB: AAW95100
DESC HIV-1 ***VP22*** polypeptide C-terminal domain encoding DNA.

L3 ANSWER 117 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ07807 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors or inflammation -

IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L;
 Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945126 A2 19990910 149p***
 AI WO 1999-GB672 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-540852 [45]
 CR P-PSDB: AAY27404
 DESC HSV-1 tegument protein ***VP22*** encoding DNA.

L3 ANSWER 118 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ07770 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues,
 particularly hypoxic cells, for treating e.g. tumors or inflammation -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L;
 Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945126 A2 19990910 149p***
 AI WO 1999-GB672 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-540852 [45]
 DESC HSV-1 tegument protein ***VP22*** 3' primer.

L3 ANSWER 119 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ07769 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues,
 particularly hypoxic cells, for treating e.g. tumors or inflammation -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L;
 Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945126 A2 19990910 149p***
 AI WO 1999-GB672 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-540852 [45]
 DESC HSV-1 tegument protein ***VP22*** 5' primer.

L3 ANSWER 120 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ19804 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues,
 particularly hypoxic cells, for treating e.g. tumors -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L;
 Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945127 A2 19990910 187p***
 AI WO 1999-GB674 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-551046 [46]
 DESC Herpes simplex type 1 (HSV-1) tegument protein ***VP22*** 3' PCR
 primer.

L3 ANSWER 121 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ19803 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues,
 particularly hypoxic cells, for treating e.g. tumors -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L;
 Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945127 A2 19990910 187p***
 AI WO 1999-GB674 19990305
 PRAI GB 1998-4841 19980306

GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-551046 [46]
 DESC Herpes simplex type 1 (HSV-1) tegument protein ***VP22*** 5' PCR primer.

L3 ANSWER 122 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ19796 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945127 A2 19990910 187p***
 AI WO 1999-GB674 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-551046 [46]
 DESC Human anchorless P450R 3' PCR primer.

L3 ANSWER 123 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ19795 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945127 A2 19990910 187p***
 AI WO 1999-GB674 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-551046 [46]
 DESC Human anchorless P450R 5' PCR primer.

L3 ANSWER 124 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAZ19784 DNA DGENE
 TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
 IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
 PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
 PI ***WO 9945127 A2 19990910 187p***
 AI WO 1999-GB674 19990305
 PRAI GB 1998-4841 19980306
 GB 1998-18103 19980819
 GB 1999-2081 19990129
 DT Patent
 LA English
 OS 1999-551046 [46]
 CR P-PSDB: AAY42292
 DESC Herpes simplex virus type 1 (HSV-1) ***VP22*** DNA.

L3 ANSWER 125 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAV17085 DNA DGENE
 TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
 IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
 PA (MEDI-N) MEDICAL RES COUNCIL.
 PI ***WO 9804708 A1 19980205 75p***
 AI WO 1997-GB2036 19970728
 PRAI GB 1996-15726 19960726
 DT Patent
 LA English
 OS 1998-130696 [12]
 CR P-PSDB: AAW47194
 DESC Herpes simplex virus UL49 gene.

L3 ANSWER 126 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAT10200 DNA DGENE
 TI Amplification and detection of specific gene fragment of *Vibrio*
parahaemolyticus - using two oligo:nucleotide(s) as a primer set to
 amplify the thermostable direct haemolysin gene
 IN Lii J; Pan S
 PA (LIIJ-I) LII J.
 PI ***TW 265366 A 19951211 9p***
 AI TW 1993-110632 19931215
 PRAI TW 1993-110632 19931215
 DT Patent
 LA Chinese
 OS 1996-086449 [09]
 DESC Thermostable direct haemolysin primer, ***VP22*** .

L3 ANSWER 127 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 1999:1564 IMSDRUGNEWS
 TITLE: drug delivery system, ***VP22*** herpesvirus protein
 Phogen agreement extended
 SOURCE: R&D Focus Drug News (***7 Jun 1999***).
 WORD COUNT: 38

L3 ANSWER 128 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 1998:1629 IMSDRUGNEWS
 TITLE: drug delivery system, ***VP22*** herpesvirus protein
 Phogen preclinical data
 SOURCE: R&D Focus Drug News (***25 May 1998***).
 WORD COUNT: 179

L3 ANSWER 129 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 97:894 IMSDRUGNEWS
 TITLE: drug delivery system, ***VP22*** herpesvirus protein
 Phogen preclinical data
 SOURCE: R&D Focus Drug News (***31 Mar 1997***).
 WORD COUNT: 154

L3 ANSWER 130 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 97:685 IMSDRUGNEWS
 TITLE: drug delivery system, ***VP22*** herpesvirus protein
 Phogen Cantab, Marie Curie Cancer Care joint venture
 SOURCE: R&D Focus Drug News (***10 Mar 1997***).
 WORD COUNT: 110

L3 ANSWER 131 OF 199 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BVH1LFT31 GenBank (R)
 GenBank ACC. NO. (GBN): Z54206
 GenBank VERSION (VER): Z54206.1 GI:995626
 CAS REGISTRY NO. (RN): 169022-06-4
 SEQUENCE LENGTH (SQL): 31444
 MOLECULE TYPE (CI): DNA; linear
 DIVISION CODE (CI): Viruses
 DATE (DATE): 23 Jan 1997
 DEFINITION (DEF): Bovine herpesvirus type 1 31-kb DNA (left genome end).
 SOURCE: Bovine herpesvirus 1.
 ORGANISM (ORGN): Bovine herpesvirus 1
 Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
 Alphaherpesvirinae; Varicellovirus
 NUCLEIC ACID COUNT (NA): 4507 a 10913 c 11443 g 4581 t
 REFERENCE: 1 (bases 1 to 1354)
 AUTHOR (AU): Fraefel,C.; Wirth,U.V.; Vogt,B.; Schwyzer,M.
 TITLE (TI): Immediate-early transcription over covalently joined
 genome ends of bovine herpesvirus 1: the circ gene
 JOURNAL (SO): Journal of virology., 67 (3), 1328-1333 (***1993***)
 OTHER SOURCE (OS): CA 118:227339
 REFERENCE: 2 (bases 1601 to 3100)
 AUTHOR (AU): Singh,M.; Fraefel,C.; Bello,L.J.; Lawrence,W.C.;
 Schwyzer,M.
 TITLE (TI): Identification and characterization of BICP27, an early
 protein of bovine herpesvirus 1 which may stimulate
 mRNA 3' processing

JOURNAL (SO): The Journal of general virology., 77 (Pt 4), 615-625 (****1996****)

OTHER SOURCE (OS): CA 124:282366

REFERENCE: 3 (bases 3101 to 8000)

AUTHOR (AU): Letchworth,G.J.; Lowery,D.E.; Schwyzer,M.

TITLE (TI): Sequence of the BHV-1 UL53 (gK), UL52 (helicase/primase), and UL51 genes

JOURNAL (SO): Unpublished

REFERENCE: 4 (bases 7818 to 9667)

AUTHOR (AU): Liang,X.; Tang,M.; Manns,B.; Babiuk,L.A.; Zamb,T.J.

TITLE (TI): Identification and deletion mutagenesis of the bovine herpesvirus 1 dUTPase gene and a gene homologous to herpes simplex virus UL49.5

JOURNAL (SO): Virology., 195 (1), 42-50 (****1993****)

OTHER SOURCE (OS): CA 119:153149

REFERENCE: 5 (bases 9662 to 11962)

AUTHOR (AU): Carpenter,D.E.; Misra,V.

TITLE (TI): Sequences of the bovine herpesvirus 1 homologue of herpes simplex virus type-1 alpha-trans-inducing factor (UL48)

JOURNAL (SO): Gene., 119 (2), 259-263 (****1992****)

OTHER SOURCE (OS): CA 119:42360

REFERENCE: 6 (bases 11963 to 15012)

AUTHOR (AU): LaBoissiere,S.; Trudel,M.; Simard,C.

TITLE (TI): Characterization and transcript mapping of a bovine herpesvirus type 1 gene encoding a polypeptide homologous to the herpes simplex virus type 1 major tegument proteins VP13/14

JOURNAL (SO): The Journal of general virology., 73 (Pt 11), 2941-2947 (****1992****)

OTHER SOURCE (OS): CA 119:89230

REFERENCE: 7 (bases 15007 to 22448)

AUTHOR (AU): Vlcek,C.; Paces,V.; Schwyzer,M.

TITLE (TI): Sequence of BHV-1 UL46 to UL41 genes

JOURNAL (SO): Unpublished

REFERENCE: 8 (bases 22099 to 23813)

AUTHOR (AU): Simard,C.; Bastien,N.; Trudel,M.

TITLE (TI): Sequencing and 5'- and 3'-end transcript mapping of the gene encoding the small subunit of ribonucleotide reductase from bovine herpesvirus type-1

JOURNAL (SO): Virology., 190 (2), 689-701 (****1992****)

OTHER SOURCE (OS): CA 119:89863

REFERENCE: 9 (bases 23481 to 31444)

AUTHOR (AU): Simard,C.; Langlois,I.; Styger,D.; Vogt,B.; Vlcek,C.; Chalifour,A.; Trudel,M.; Schwyzer,M.

TITLE (TI): Sequence analysis of the UL39, UL38 and UL37 homologs of bovine herpesvirus 1 and expression studies of UL40 and UL39, the subunits of ribonucleotide reductase

JOURNAL (SO): Virology (1995) In press

REFERENCE: 10 (bases 1 to 31444)

AUTHOR (AU): Schwyzer,M.; Styger,D.; Vogt,B.; Lowery,D.E.; Simard,C.; LaBoissiere,S.; Misra,V.; Vlcek,C.; Paces,V.

TITLE (TI): Gene contents in a 31-kb segment at the left genome end of bovine herpesvirus-1

JOURNAL (SO): Unpublished

REFERENCE: 11 (bases 1 to 31444)

AUTHOR (AU): Schwyzer,M.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (21-SEP-1995) Martin Schwyzer, Institute of Virology, Faculty of Veterinary, Medicine, University of Zurich, Winterthurerstr. 266a, Zurich, CH-8057, Switzerland

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..31444	/organism="Bovine herpesvirus 1" /strain="Cooper" /db-xref="taxon:10320" /clone="HindIII fragments N, J, M, I, E"
misc-signal	200..207	/note="octamer box"
repeat-region	235..430	/rpt-type=DIRECT /rpt-unit=235..248
mRNA	466..1280	/gene="circ" /standard-name="LR1.1"

gene	466..1280	/note="transcribed from alternative late promoter"
exon	473..1280	/evidence=experimental /gene="circ" /gene="circ" /standard-name="IER1.5" /note="IE transcription over covalently joined genome ends" /number=2
CDS	486..1229	/evidence=experimental /gene="circ" /note="product of IER1.5 and LR1.1; homolog of VZV ORF2 and EHV-1 ORF3" /codon-start=1 /product="circ" /protein-id="CAA90913.1" /db-xref="GI:995627" /db-xref="SPTREMBL:Q01342" /translation="MGARASAPAAAGPPPAHAVLL DALSGGTIDLPGGDEAVFVSCPTT RPVYHHMRRGRTAHTTPVHFVGRAYAILPCRKFM LYLMRGGAVYGYEPTTGLHRLADS LHDFLT TAGLQQRDLHCLDVTVLDAQMDPVTFTT PEILIELEADPAFPPPPSARARRS TLRRASMRRPARTFCPHQLLAEGSILDLC SPEQA AAPGCSLLPACDSGDAACPCDAGE TARDCTADAARAPSPGALSRYSSVRSVFF"
polyA-signal	1259..1264	/gene="circ"
polyA-signal	complement(1649..1654)	/note="IER1.5 and LR1.1"
CDS	complement(1658..2860)	/note="BICP27, UL53, UL52" /function="early protein affecting 3'mRNA processing" /note="homolog of ICP27 (UL54) of HSV-1" /codon-start=1 /product="BICP27" /protein-id="CAA90914.1" /db-xref="GI:995628" /db-xref="SPTREMBL:Q01354" /translation="MADPEIATLSTASESDDL SLFGSDREEDDEAPSLAPALRSVVGQ VRKRKLEGAEDEPMPAEPPEGAASGDGGPAEAP PARRARVRPRRPRRRPRRRQPAGE QRSRGPAAKREAAATSSHGGGGAAARSIGSSLR LARSLAEAAQRATAERTAVFAGA RLDLMRPVQNGGFRAAGVSPWAAVLDFGAEQFVP EGRRVTWETLMFHGRDLYRMFEVR PHAAQAARALRDLVLR SANLVDALASADECLTWC KFIATKNLRLRTKDPIVATAGAVL ENLRLKLAPFLRCYLGRGLPSLEELCAARRLSL ATCPASYMFVMLARLSRAVRSGAE CVPLLEVTVGDA PFEEYIPGTCVAGLIDALDTHK QACDSMTCKLVANFTLV PVVMHGK YFYCNEIF"
TATA-signal	complement(2985..2991)	/note="BICP27"
CDS	complement(3040..4038)	/note="glycoprotein K" /codon-start=1 /product="UL53" /protein-id="CAA90915.1" /db-xref="GI:995629" /db-xref="SPTREMBL:Q65816" /translation="MLLGGRTVNLAALALLTAHL ALALWVALAARCQRCACVRATARN GSLRWELRSPGAVYVWGGANNATLAADAPCRHAV VQHIPPGLLDGDEALHGRVRAVAG ARDCRAYLWCAQARGLLAWLLYVAFVYLRQERR MFGLCRNDADFLSPGGYTLNYAAA ALAAVVGHGPYTKLARLMCELSARRRALAVDFRL DPLGCAWRPRAALPLLAEGFARLG ARIAAAGSVGITHPCAAAYPLYLKIWAWVHVALF AGLELVSLLYRKPRRRGGTCAGDG GDGGESGIRKVCVNCCSTLLAGLLVKALYLAAIV GGVIALHLYEHNLRRLRLGAQT"
CDS	complement(4013..7237)	/note="component of DNA helicase/primase complex" /codon-start=1

		<pre> /product="UL52" /protein-id="CAA90916.1" /db-xref="GI:995630" /db-xref="SPTREMBL:Q65817" /translation="MDGPAALEDALQILYATDGC AIGFSLMLLTGQEEPGRGAYVVS NWPGRLAACLGGESPNVALALADARPLVAFYLL GGPPGGSAAATPRLARLRVHLQQR AGRARARRRTAPRQGPTRARAARAPRRGRHLCAA RGHDHALLVATEQLAPRTGRTADD ARYVEGQTTVRSALRARAPAGRRGLASLYIHHEHK TVAAYRRLYSNSGATPFWFLSKFG PGEKTLVLATRFYVFQAERAGDAATYDLQAVRDC LATYAVAAPPNPSGLAFDPLVSFA ALAAFCCRSYGARGAVAAGAPAYVAARIEADLAE VRCLREYIDHRRSLKVADPEFVA YVYLAYFEGFNRRQITEHLRAVTATEPPDGGEAL APRLAGVSRLRERAVDAFFRHVRA QFNVSQSYIEQNVAVAVVRLPPATAEAYARARTYA RLLAATANGPGRTICDGAALRAA LDHLEGQAARFGWVLHAPGAPSASAVPGPLDAA LRVGAPDGGASPDATPACCGVSKR LLELAAAAARDGAHPLDGLFGARGTAAPTPVYRV ELPRGHQAFVADGDDWAAVTSVA ALDPDEVAVEVAAAAAAAESGRDALVERDARLT ALLTERAACAAGRSRRSLGPAAP RDQYYVNRNELFNARLAVTNIVLDVDFRLKRPLP RGDLHGAMRSFRRGALAALAALFP EIAADAWPAHPCFFYKSACPSAAASNLGDDASP SWAAPDRDAGWDEYESALAREGEA QYSCEDVSDPAGARPEETGGAEGAGSAAALTTAC GCDDKMGFRVAVVPVAPYIIAGGP TLKGIARLVQHAVMLERPFAEAMSRYLRFDAFVD AAVYTHGHSRLRPFFGKPDASNV GRWLLPFYVVPERCDVAAFVAAHRDPHFFHFA APPAGGRREARRAHVGGYVSFFE RKAAVNRAAFHGVRVSLRRALAAVGVDGGDRGAV EEFIADVIEAELAPYMAEHYPQAA REYQGAGARLVAAKADWLLAQLVPARAGTAQGFG CLRAAHGAAQNKARSLVSLSVDS HDRLCASLIQQCFATKCGSNRLGTVFTVDLSGRA ARYAARGADC" /codon-start=1 /product="UL51" /protein-id="CAA90917.1" /db-xref="GI:995631" /db-xref="SPTREMBL:Q65818" /translation="MALQRLVGWLCGRGGGTRDA PQYEPLARRLSGPTLFRQLQEAVVA VSALLPAPLTVEDVARSDGTRRLAKAQLSARTY YICQRNIECLSKHQAACSDASITA VVTKHIQDAQRMRTCLAALLQMYHSVGAVEGTT DSMVDQAIRMAAESNIVMADVAVL ERALGIQAQGAGAEAAARASPTAVGAEARAPPPL PRQPAASAPVAVSPAPPVAPAEAA ATKPPSRAGRAAAAASSPAVLQLAA" </pre>
CDS	7236..7967	<pre> /note="UL51" /note="intergenic region between convergent UL51 and UL50" </pre>
polyA-signal	7976..7981	<pre> /note="UL50; noncanonical" </pre>
misc-feature	7982..8028	<pre> /function="deoxyuridine triphosphatase" </pre>
polyA-signal	complement(8029..8034)	<pre> /codon-start=1 /product="UL50" /protein-id="CAA90918.1" /db-xref="GI:995632" /db-xref="SPTREMBL:Q89932" /translation="MANSAAATTATMSGDRGILV VELNAEAAPWRLESCCEPDSLALW GPIAPAAKRDETAPSGSLLYSRLINLNMKAAAPG GYAIIMSQMRSGDTHMPRPPAVAV GIVDSGYSGILRAIVWAPESAAAAPPAGLALRLT LARLTTTLPRLIAVDDDANAGTEA GVEVPFFATFAPKRDEDAGYDIAMPYTAVLAPGE NLHVRLPVAYAADAHAAPYVFG SSCNLRGLIVLPTAWPPGEPFCRFVLRNVTQEPLV </pre>
CDS	complement(8045..9022)	

CDS	8970..9260	AAAGQRVAQLLLLARRLEWLPSGL NDREPFTSPRAAPPAPGAPRLRWRRVADLAAAV PPSARGPRGFGSTGL" /codon-start=1 /product="UL49.5" /protein-id="CAA90919.1" /db-xref="GI:995633" /db-xref="SPTREMBL:Q89806" /translation="MPRSPLIVAVVAAALFAIVR GRDPLLDAMRREGAMDFWSAGCYA RGVPLSEPPQALVVFYVALTAVMVAVALYAYGLC FRLMGASGPNKKESRGRG" /note="UL49.5" /note="UL49" /note="homolog of HSV-1 VP22 (tegument protein)" /codon-start=1 /product="UL49" /protein-id="CAA90920.1" /db-xref="GI:995634" /db-xref="SWISS-PROT:P30022" /translation="MARFHRPSEDEDDYEYSDLW VRENSLYDYESGSDDHVYEELRAA TSGPEPSGRRASVRACASAAAVQPAARGRDRAAA AGTTVAAPAAAPARRSSSRASSRP PRAAADPPVLRPATRGSSGGAGAVAVGPPRPAP PGANAVASGRPLAFSAAPKTPKAP WCGPTHAYNRTIFCEAVALVAAEYARQAAASVWD SDPPKSNERLDRMLKSAAIRILVC EGSGLLAAANDILAARAQRPAARGSTSGGESRLR GERARP" /note="UL49" /function="tegument protein which transactivates IE genes" /note="homolog of HSV-1 alphaTIF (Vmw65, VP16)" /codon-start=1 /product="BTIF" /protein-id="CAA90921.1" /db-xref="GI:995635" /db-xref="SPTREMBL:Q65819" /translation="MSGRIKTAGRALASQCGGAA AATMDPYDAIEAFDSSLGSPPLAA GPLYDGPSPARFALPPRPAPLAALLERMQAELG FPDGPALLRAMERWNEDLFSCLPT NADLYADAALLSADADAVVGAMYLAVPGDAERLD LNAHANQPLPAPPASEEGLPEYVA GVQAHFLAELRAREERYAGLFLGYCRALLQHLRA TAARGRGAAGAGAQAADRLRQLVAA RYYREASRLARLAFAHMYVATAREVSWRLHSQQS QAQGVFVSLYYAWPQRRQFTCLFH PVLFNHGVVALEDGFLDAAELRRLNYRRRELGLP LVRAGLVEVEVGPLVEEPPFSGSL PRALGFLNYQVRAKMGAPAEAGGRLAPERESYA RPRGAINYGTTPEAMLRPPSPSEV LPCDPAPAATVRVASPATHLAQPSAKGAAPAEF AALAGLAKPGPAPLAAAPAPFA AALALAEPAALAPAPLAAAPAEPAAVAGPSPA NPFGGTYDALLGDRLNQLLDF" /note="UL47" /note="UL48; noncanonical" /note="Major tegument protein (VP8)" /codon-start=1 /product="UL47" /protein-id="CAA90922.1" /db-xref="GI:995636" /db-xref="SWISS-PROT:P36338" /translation="MDAARDGRPERRRAVSGTYR THPFQPSARRSAGRPARCGRRGR GAPRVRRPRPYFQRPDEDTSEDENVYDYIDGDS SDSADDYDSYFTANRGNHAGD AMDTDAPPERAPEGGAPQDYLTAHLRAIEVLPES APHRSLLEARTVYAQQFPFRDL SAGSKAPAQRARRSLRGFPRGGGGQEPGPDDEG DDAADLREDLVPDEAYAHLEDER
polyA-signal	9231..9236	
TATA-signal	9288..9294	
CDS	9384..10160	
polyA-signal	10224..10229	
CDS	10275..11792	
TATA-signal	11892..11898	
polyA-signal	11892..11897	
CDS	11963..14182	

TATA-signal
CDS

14263..14269
14314..16560

LSEGPPLLNMEAAAAAAGERSVVEELFTYAPAQP
QVEVPLPRILEGRVRPSAFFAQM
LDALCRTPPNQDQVARERRAWEMAGTPHGLLITT
WSTVDPEFSIGGMVYGAPEGTRPR
LVWRRAMQAMALQYRLGVGGLCRAVDGAACRPL
RRCSFWRDALLRECATAIFCRGRG
ARAAPRRLPRPAVGLLAATQFTPPDASPHATLFR
GSMGLIYWHEL RVMLTAVPALCA
RYAGAGLQSAELYLLALRHSEAPGYTANERYALS
AYLTLFVALAERGLRWLYLAGAHL
LGPHPTAAAFREVRAKIPYERLPLGSATLHDAEV
ETVDSATFQEALAFSALAHVYGEA
YVAVRTATTLMAEYAVHAERRDVRQMTAAFLGV
GLIAQRLMGSLNLLLCVAGAAVY
GGRRVTVREGTLARYSLLADAALPLVRPVFLVEF
REARDGVMRELRPVPASPLAGK
RRVMELYSLDSIEALVGREPLGSRPVLGPLVDI
AEALADHPLVLTGDGRGPRLGGR"

/note="UL46"
/note="tegument protein"
/codon-start=1
/product="UL46"
/protein-id="CAA90923.1"
/db-xref="GI:995637"
/db-xref="SPTREMBL:Q65820"
/translation="MAWPAASRGLIERRAEKGCL
LPTLADATAAAVVALQEATEPLCG
APLFGAERAAALLGVRNAVPEALVLSAKDAD
DEYRLEYDRAAARVLAGARLSKDA
VWRAVIGSYWKYLKASSGADVNIDGAAGGAAMEQ
AQLTNVMLFAPTYARRASRSPFKH
KQDNAAYKTA AE LRGALRAVEKMYMYMRPGDPM
VESPDTEARLQEILAYAATAYRWL
LWFMDALDGTVLRKLGKRPSAAVGPREP RP PGEL
CERHLTGGPGIACGSGAALMLTAL
TAAVLALLLRVGAAWTESSWKSNTQGVTAIVAA
VELASAVHHHLQYLLNMAFVGAC
WLRAGVRDPYMI AAIRAQCRFAHFTGQLMPTMTS
ASWAALERGTASWFKLALLKSVA
HGAQTRYYSNIVESMRLGGSRGLLAPVRARPSGR
GRRCPQSLAARPLPSLPAAAAAPP
GSGSGSGSGSDSDLDLGFAPAVGVYASMRNLE
GAYADAGGPLSPAASAAAREAAVY
ENEGEGEFAPLPSAFAEDGSSDSADELAIDGMP
APPPRGGRGADELAIDGMPAPPP
RGGRGADELAIDGMPAPPPRGGRGASAGRLQYA
DSRAVSSDDDEDEGKDEDEKAGA
TAPLAADPESELARAMRRCSLRVPASAPAPAPAP
CTERPGNPTRSYSRSPRLRALDD
RHGLEALAAAGAAHTARHNRDVWQRF SRVCEAGD
DYENYDEARGAERGHLSACASRARP EVERVTSL"

polyA-signal
misc-feature

16594..16599
16600..16612

/note="UL47, UL46"
/note="intergenic region between
convergent UL46 and UL44; no BHV-1
homolog of HSV-1 UL45 found"

polyA-signal
CDS

complement(16613..16618
)
complement(16683..18209
)

/note="UL43, UL44"
/function="glycoprotein C"

/codon-start=1
/product="UL44"
/protein-id="CAA90924.1"
/db-xref="GI:995638"
/db-xref="SPTREMBL:Q65821"
/translation="MGPLGRAWLIAAIFAWALLS
ARRGLAEAEASPPSPSPPTET
ESSAGTTGATPPTPNSPDATPEDSTPGATTPVGT
PEPPSVSEHDPPVTNSTPPAPPE
DGRPGGAGNASRDGRPSGGGRPPRPSKAPPKE
RKWMLCEREAVAASYAEPLYVHCG
VADNATGGARLELWFQRVGRFRSTRGDDEAVRNP
FPRAPPVLLFVAQNGSIAYRSAEL
GDNYIFPSPADPRNLPLTVRSLTAATEGVYTWR
DMGTSQRKVVTVTTHRAPAVSVE
PQPALEGAGYAAVCRAAEYPPRSTRLHWFRNGY
PVEARHARDVFTVDDSGLFSRTSV

		LTLEDATPTAHPNLRCDVSWFQSANMERRYFAY GTPAVYRPPPELRVYFEGGEAVCEA RCVPEGRVSLRWTVRDGIAPSRTEQTVCAERPG LVNLRGVRLSTTDGPVDYTCTAT GYAPLPEFSATATYDASPLIGSPVLVSVVAVA CGLGAVGLLLVAASCLRRKARARL "
TATA-signal	complement(18301..18307)	/note="UL44"
CDS	complement(18388..19524)	/codon-start=1 /product="UL43" /protein-id="CAA90925.1" /db-xref="GI:995639" /db-xref="SPTREMBL:Q65822" /translation="MFASVRVSGCAGARAGCGPC ALAATGALVAMGHTHTGLMAAALAT VGRAQDPAAALALTATAAAALVCWRPAAQTLRRR LAPLGRLAQALAVAAALAVWATDP APAVLRGVTTGAAAAYVVGVPVHCAHFVTAASG TGAHFRTALLTMTCGLLGLSAGR WGARPEALAAAGAAAALVVAATDAAALEDTCY KIWRYAALRTLAPLGEAACPADPC GAREDAVPMRALARAAAELALSAAALAAAAALW APGRALGLEGGGRWRTRGAVLLSV AGGHGVALAEHLCLRYARADAADGALMAHVGICA LGAALPLCGADGGAPAALASAAAG TLVACVWRRRCGRGTARLAAAHVAKALHAALCFC VGACWVCADE"
polyA-signal	complement(19582..19587)	/note="UL42"
CDS	complement(19597..20823)	/function="processivity factor for DNA polymerase" /codon-start=1 /product="UL42" /protein-id="CAA90926.1" /db-xref="GI:995640" /db-xref="SPTREMBL:Q65823" /translation="MLQPPSHLRADEGEARLTAG LSDGGNGNPIASASLIGRQLADVS ALLSPFGASLRNAFLVFSREGMLVHSGLYDEQVY VAVPAEKFTSFQWAPARDDARAVF LANVDSRRGLLDAFRADKTRTVQNVAFKITGEPP ASVLTQVTYFREADALLQASLVKH ELGEYSIMLPTRGADLAVSLSRPQLSKLQAVAKD PNEAVVFAYRRARCLSAESASGRA SFAARHEGGESGAELQLALAPSAGSERIFARAQG GGRRAALLEVRCSSGAPDFRLELE SPSGFRRLQKVRQVGGDALVRFY LAPASAAMMS VSTAAPGLTVFFFCRPATATASA DDADDAEPAPRLPAKRPAASGQPRRGAGAGIQT DGAHPVAVSGBRARKRPRADAGAP GPSSGPDRGGEGGETP"
TATA-signal	complement(20903..20909)	/note="UL42"
CDS	21068..22447	/function="virion host shutoff factor" /codon-start=1 /product="UL41" /protein-id="CAA90927.1" /db-xref="GI:995641" /db-xref="SPTREMBL:Q65824" /translation="MGLFKLLRYAYGNRLVKHDA ITTPPGVMTPIAVDLWNVMYTLLE RFCGDAPGGVGDAATARCFLSLLRMLLKRSYYP IFVADRGIHGDRRATRGAKAIVAQ TMRAVGGSGRLGRLVSDDYTSEDEVLGAYEYPVP HADAAADDDEEATAKEFAGRASAG AARANAPKLAHRVCVSLIRFLGYAYVDAEEMAD DVCANLFHTNTVAHIYTTDTDMIL MGCDLILDAAPLFPPTLRCRDVLASLGLTYGQFL ATFVRCHTDLHQPPMLRSVQQVVR GLRRAAEAEPATTETESGSEPESELGRPGAGP RRRLPPAVDDPLKTTTTPATVEAHS VRMKYTSRYPPIAQTCADALRLLPASQTRGGVLE RKFKVHVVDTIAPMRGRWAVLKR VPQAQDAPDPRLVYDTIVSAVGSAAEADTLMGLF

		WKHIPTPPFAKVLADYWDEAPAG PGSRRTTRQ"
polyA-signal	22443..22448	/note="UL41"
mRNA	complement(22475..23602	/gene="UL40"
)	
gene	complement(22475..23602	/evidence=experimental
)	/gene="UL40"
polyA-signal	complement(22494..22499	/gene="UL40"
)	
mRNA	complement(22495..26048	/note="UL39, UL40"
)	/gene="UL39"
gene	complement(22495..26048	/evidence=experimental
)	/gene="UL39"
CDS	complement(22563..23507	/gene="UL40"
)	
		/function="ribonucleotide reductase small subunit" /codon-start=1 /product="UL40" /protein-id="CAA90928.1" /db-xref="GI:995642" /db-xref="SWISS-PROT:Q01319" /translation="MAEAADAATLTRKYKYFYET ECPDLHLRSLSVANRWLETEFPL ADDAKDVARLSGALEFYRFLFAFLSAADDLVNV NLGDLSELFTQKDILHYIEQESI EVVHSRVYSAIQLLLFRNDAVARAGYVEGALGDP AVRRKVDWLERRVAAAESVAEKYV LMILIEGIFSSSFAAIAYLRTHNLFVVTCTND LISRDEAVHTAASCCIFDNYLGGE RPPPARIYELFREAWKLSASLFGCAPRGSHILDV EASAYVEYSADRLLAAIQLPPLF GTPPPPTDFPLALMTAEKHTNFFERRSTNYTGTV INDL"
CDS	complement(23526..25889	/gene="UL39"
)	
		/function="ribonucleotide reductase large subunit" /codon-start=1 /product="UL39" /protein-id="CAA90929.1" /db-xref="GI:995643" /db-xref="SWISS-PROT:P50646" /translation="MASDAFMQTACPADAAEQLE AEHAWEAQLGCGAVPPPPAAASRP SRAAVAAYVGEVVDVDRMAQSRADERVYKCGQLV HLRVRARSVPLDDWLTSAELALVS EVAEPVRANRAFVEVSLRYFELTEYATLRALGLQ SALKYEEMYLAKLEGGAIESMGQF FVRIAATAATWTMREPAFGRALVGEGATWCAVFN AYLTALYRQLVVPATPIMLFAGRA RGSLASCYLLNPQVSSSTEAVEAITTEVARILLN RGGIGISFQSFDRAVSRDCKRGIM GALKLLDSMAMAINSDSERPTGICVYLEPWHCDV RAVLNMRGLLARDESTRCNLFSC LWVPDLLFDRLAHLEGGREGVWVTLFDDRASHLS RLHGPAFTAAYERLEREGLGVETV PVQDLAFLIVRSIVMTGSPFVMFKDACNRHYHMD TAGDALTGSNLCTEIVQRASPDH GVCNLASVNLPRCVREGGALAFDFAALSTAAA TAAIFVNAMMLGGQYPTKAARGV ARHRS LGIGFQGLHTLLLELGMDMLSPAARRLN EIAERLLLAVMATSATLCEYGCAP FEDFARSKFARGLMPFDGYEGVLSLPRAWARLR EKVARHGLYNAQFVALMPTVSSSQ VTEGSEGFSPVFTNMFSKVTMSGELLRPNLPLMR ALRKHFTREASRLGAVRALDREQW SVAAALGDLAPGHPLAKFKTAFEYDQERLIDLCA DRAPFVDQSQSMSLFVTEPMDGKV PASQIMNLLVYAYKKGLKTGLYYCKIRKATNGV FTGGDLVCSGCHL"
TATA-signal	complement(26119..26125	/note="UL39"
)	

polyA-signal complement(26202..26207 /note="UL38"
)
 CDS complement(26231..27655 /note="homolog of HSV-1 capsid
 protein VP19C"
 /codon-start=1
 /product="UL38"
 /protein-id="CAA90930.1"
 /db-xref="GI:995644"
 /db-xref="SPTREMBL:Q89542"
 /translation="MAAPNGSSSYIQIGNHLRMR
 LPAAAPPFSGVPAAAAAAAEASAA
 EAGVQSVTAPAVGGARGRAPRGYNPWAGGMLHVS
 DATVTIQNMSGIQIVTPRQIAVD
 PAGTAVLSPGGQPHIRLSRQVTLTDFCDPQLERP
 GAPVLTCLKHPADIIGLAAAAAPP
 RQFRDVEEAWRDLGDASSVGAVPPGGLRASLVSF
 SFLAAACAAEYGNRAAADALRAHL
 ISNSGDRRMALRLDRFYACLQAMIRCRAFPHQAL
 GCLGGLLSWTTQDKLASVTAVVCG
 AQEGARTDQAAHPRSTAHVPACAFLDVDAELRLE
 PAGVKFVYLVFVYTQRLEHEGFRA
 HVAVSKLNETTFASGLSYLLHRTRAENVLRGTAG
 DAAEVAGAADEFPLPALANSRAAY
 RCPVSRLGDCDATAFLPRWAPDAAGRPTRESCMY
 AAFARLGTLPHDSPRVTCRERYQ
 SCDVPVVKIEGLVWGTGDWVECFY"
)
 TATA-signal complement(27720..27726 /note="UL37"
)
 CDS 27871..30945 /note="tegument protein"
 /codon-start=1
 /product="UL37"
 /protein-id="CAA90931.1"
 /db-xref="GI:995645"
 /db-xref="SPTREMBL:Q89815"
 /translation="MSGDPVRALWAALERLDGEV
 AGPAALAEARAASVSEFLLASGPSS
 LDFVAPRWAAALQRAACRAYERLHTPDAAALLAENL
 PGLVLWRLPGAARDTADFMAGVRD
 LANSMIAEAPLGYLAAARLRATAAFGPVNMQRVV
 VEWASLFLEIYAREDAACVGVLP
 DPACRSPAGSAAVIRPLLQSRFRLLYDMPFFQAG
 LSALAHAAANWKVPMAAVARRAADA
 AAPPLARALFAVALVDEYFPEPDEDTAPGLAEA
 FAEIADLVPPEALVPAGEANAFAR
 SSHDVRVSAALAYRDPFVRGAAAGSVAARVRADA
 GLLADDTLLGRDAVAVHAGAVVRL
 LERAAARATPAALGRVAEHAAAVWDAVQASATPD
 QAVETLAAAGFTPGTCAMLERAVL
 AQLSRPEPRAPADVLQAVGCVAVAGGVLFKLFDA
 YGPSADYLAHYTATIANLHPYYAD
 VLPPLLGLPDGGLAQITIRHMAPRPRTDYVAAIRA
 ALAAEAAAADKRAASASARAAVEN
 SGDRAAGAAAREALLTWFDLRASERWGVAPPAA
 EAPPAAEAARS PAAGGASAAELAR
 AARALEFPRTDAVPAAVLRDPAFAPHFAAAVLSD
 VLVAADALPFSANGVAQLMALIAW
 ARDCGAGAVANVDGYRTKLSALAAAGLWPFVDASA
 PAPTTTQVRNAEAVLGELHTVATT
 AAECLPPEVRPPVPARPRVGGCVFLASMYLHAAF
 ARLQGYVAETEALAASMAAAVGDV
 AGAVARLGVLFDFCHASVPGQQLAIYATRGAPC
 ALGAWRSADLADAVRGARAEAAARA
 RAEVRVSLAALQRAAAQTTQALQECEAADARPPG
 GGLDDEHRALLAGHSALVRAQTAL
 ALAAGKLVAGAEAPGLHEVGRFLQRWDAIGAALG
 RALDDSAGERDVAELVARLRGVWD
 EVQEDRRVAAPGPPRSAANAAAAEEAVLALLEGY
 PEVRGDEGSPALLDARADVADWAG
 VDRGPLQRRASAGADAAAASAAANTAAGPWLTT
 DLLAEVDGVCASRPAAAR"

SEQUENCE (SEQ):

```

1 ggcccagccc ccgcgcgggg ggcgcgaggaga aaaaaaaaaat tttttccgcg cggcgcggtgc
61 attgcggcg ggccccggcg ggtgggggat gggcgcgag cgcgagggtta gggttggcac
121 actgccaaga tcaccaagca tgtgcgcggc catcttgctt ccaaactcat tagcataccc
181 cgccattat tccatttcta ttgcatacc caccgttga catgccgcca tattgtcct

```

241 cctccctcgc tctctctccc tgcgtctctcc tccctcgtct ctcctccctc gctcctctct
301 cctcgtctct cctccctcgc tctctctccc tgcgtctctc tccctcgtct ctcctccctc
361 gctcctctct cctcgtctct cctccctcgc tctctctccc tgcgtctctc tccctcgtct
421 ctctctccctc gctcctctctc aaaacactac cgcgggctc cgtctctact agcttcggcg
481 ccgtcatggg tgcccgcgcc tccgcgcctg ctgcccggcc gccccagcc cagctgttc
541 tactagatgc gctctccggg ggcacgattc acctgcctgg cggcgacgag gccgtctttg
601 tgtcctgccc gacgacgcgc cccgtgtacc accacatgcy ccgcggccgc acggccaca
661 ctacaccctg gacactcgtt gcacgcgcct atgccatctt gccctgccc cagtttatgc
721 tgtatctgat gcgcggtggt gccgtttacg gctacgagcc caccactggc ctgcaccgcc
781 tcgccgattc actgcacgac tttcttacta ctgccggact acagcagcga gacctacact
841 gcctcgatgt cacggtgctt gacgcgcaga tggacccggt gacgttcacc acccccgaga
901 tctcatcga gctcgaggcg gacccggcct tcccaccgcc gccctcggcc cgcgcgcgc
961 gctccacgt ggcggcgccg tctatgcgcc ggcggcgacg caccctctgc cccaccagc
1021 tgctagcaga gggctccatt ctggactctc gctcggcaga gcaagcggcg gcgcgggct
1081 gttcgtgct ccccgctgt gactctggag acgcgcgctg cccctgcgac gctggcgaga
1141 ccgcccgtga ctgtactgcc gatgccgcgc gcgctcccag ccccgccgc tttctctgct
1201 atagctccgt gcgctcgggtg tttcttttag gcgcggcgcc cgtgtggga catacattaa
1261 taaatgcagc gtttcttact ctactgtagt ggctggccgt ttgcttctt ttgggattgg
1321 caatttagcg ttccgtcgac gccacatctt ttgcctttct gtttcccgtt gcgtgcgct
1381 gtgtcgccga gccgacttgc cccgacaaca caggcaggca cgcggcccg cccccgcca
1441 ggcactattt gcgctcgggt gacttgagct tgactttgac tcgcttttgt gccgacgcc
1501 aattatttgc cttggcccg tgtgttcccc ccgcgcgcgc ttgtgccgc caagcccgcc
1561 cgcgcgatag cgcgcgcgc cctgtgtccc caacaagta tatacact cgagtatac
1621 gggttcaaat caatgttgac aggttgactt tattagctta gaagatctcg ttgcagtaaa
1681 agtattttcc gtgcatgtac acgggaacca gggtgaaatt agcgacgagc ttgcagtcga
1741 tgcgtgcga agcctgtttg tgtgtgtcca gggcatcgat gaggcccgcc acgcaggtcc
1801 cggggatgta ctctctgaaa ggcgcgtcgc ccacagtcac ctccaacagc ggcacgact
1861 ctgcgcgga gcgcaccgc cggcttagac gcgcaacat cacgaacatg tacgatgcgg
1921 ggcaggtggc gaggcttagc cggcgcgccg cgcagagctc ctccagcgag ggcagcccg
1981 gcccgcgcag gtagcagcgc agaaaaggcg cttagcttcag ccgcaggttt tccagcacgg
2041 cgccggccgt ggccacgata gggctcttgg tgccagggcg caagtctttg gtggcgatga
2101 acttgacca cgttaggcac tcgtcgccgc agggcagtg gcctaccagg ttgctgctgc
2161 gcagcaccag gtctcgagc gcccgcgcgc cctggcgccg gtgcgggcg accccaaca
2221 tgccgtagag gtcgcggccg tggaaactga gcgtctccca ggtgacgcgg cggccctcgg
2281 gaacgaattg ctccgcgcca agtccaaga cggctgccc tggcgacacg cccgctgcgc
2341 ggaacccgcc gttttgcacg ggccgcatga ggtccagtc cgcgcccg cagacggcg
2401 tgacgcgctc ggccgtggct cgtgcgcgc cttcgccaa gcttcgcgc gccagcg
2461 agctcccgat cgagcggcg gcggcgccc cgcgcgctg tgaagacgtc gcgagggcg
2521 cctcgctt ttgctgcggg ccgcgggacc gctgctctcc ggcgggctgt cttcggcgc
2581 ggcgcctgc gcggcgccgc ggcgcgacgc gagcccgcc cgcgggaggt gcttcggcg
2641 gaccgctgc gccgcttgc gcgccttgc ccggcggtc ggccggcatc ggctcgtct
2701 ccgcgccctc cagcttgcgc ttgcgaacct gcccaccac ggagcgcagg gcgggagcga
2761 gcgagggcg ctcgctgct tcttcgcgg gtagccgaa gaggctcaag tcgtcgtct
2821 cgtggccgt gctgaggggt gcgatctcg ggtccgccat gccgctgca ctcgcgggc
2881 tcgtcgtcg gccgggtgc tcgctgttc ggcggagcg tcggtgtct gcgtttctaa
2941 aagaggctc gcactccgc cctgttctc cactgagacc ggcattttat gttcgccgc
3001 cccaccctgc gcggcagcag cgcgcgccc tagggcggt cacgtctgc cgcagcgag
3061 ccgcagggc aggttgtgct cgtagtgcag cagcgcgat acgccccca cgatagcggc
3121 caggtagagc gcctttacga gcagcccgcc gagcagcgt gagcagcag taacgcacac
3181 ctttctgatc ccgctctgc cgcgctcgc gccatcgcc ggcacagtc ctcgcgcgc
3241 ccgcggcttg cgttacagca gcgagaccag ttccaatcc gcaaagagg gcagctgaac
3301 ctagcccgcc attttcaggt acagcggtga ggcggccgc caggggtgc ttatgccag
3361 gctgcccgg gccgcaatcc gcgcgcgag ccgcgcaaag cctccgcaa gcaggggag
3421 agcagcccgg gggcgccagg cgcagcccag ggggtcgagg cggaaagtc cagcaagcgc
3481 gcgcccggc gccgagagct cgcacatgag ccgcgcgagc ttcgtgtac ggccgtggcc
3541 gactacggcc gcgagcgcgc cggcgcgta gttgaggggt tagccggcg ggctgaggaa
3601 gtcggcgctg ttgcggcaaa gaccaaacat gcgcgctcc tggcgaggt acacgaacgc
3661 gacgtacagc agccatgcca gcaggccgccc gcgagcctgc gcgaccaca ggtaggcgcg
3721 gcaatcgcg gcccgggcca cggcgcgac gcggccgtgc agcgttctg cgcgctgag
3781 cagcccggg gggatgtgct gcacgacgg gcgtccggc gggcgctcg cgcgagcgt
3841 ggcgttgttc gcgcgcggc agacgtagac ggcgcgggg ctgcgagct cccagcgag
3901 cgagccgttg cgcgcgggtg cgcggagcga cgcacagcgc tggcagcggg cggcagcgc
3961 gaccacagc gccagcgcga ggtgggccc ggcagcgcg gcccgagag atccacggtg
4021 ccgcccccc agcagcatac cgcgcgcgc ttggtagcga agcactgct gatgagcga
4081 cgaggcggt gctgcgcac tggtagcga gctgagcgg cttgttttgg gccgcgcgc
4141 ggtcgtgcga gtcgacact agggacacca gcgagcggg ggcgcgcgc ggcagagct
4201 cgtgggccc gcgcaggcag ccaaagccct gcgcggtgc cgcggcgcc ggcggcgcc
4261 gcgcccagc ccagtcgggt ttggcgcca cgcggcgcc ggcggcgcc tggactcgc
4321 gcgcccctg cgggtagtgc tccgccatgt agggcgccag ctcggcctcg attacgtcag
4381 caataaactc ttgcagggc ccacggtcgc cgcgctgac gccgagggc gcgagcgcg
4441 gccgcaggga aacgcgcag ccgtgaaag cgcgcgggt gacggcgcc ttgcgtcaa
4501 aaaagctaac gtattcgcc ccaacgtgc cacgacgtg ctcgcggcg cgcggcgcc
4561 gtggcgggc gtggaagtgg aagtgggtgc ggtcgcgggt cgcggcgcc aaggcgcca
4621 cgtcgtcgca gcgctctgg accacgtaga agggcaggag ccaccgccc acgttgcttg
4681 cggcgctctg cttgcaaaaa aagggaac gcaggctgt cccgtgcgt tagacagcc
4741 cgtcaacgaa ggcaagtcg cgaagtagc ggtcatggc ctcggcgaag gggcgttcca

4801	gcatgacggc	atgctggacg	aggcgcgcg	tgccttgag	cgtggggccg	ccggcgataa
4861	tgtatggcgc	cgggagcgcc	acagccacgc	ggaagcccat	tttgtcgtcg	catccgcacg
4921	cggtcgtag	ggccgcccgc	cttcccgcgc	cctccgcgcc	gcccgtctct	tcaggccggg
4981	cgcccgcggg	gtcgtgacg	tcctcgcagc	tgtattgcgc	ctcgcctctg	cgcgcgaggg
5041	cgctctcgta	ctcgtccag	cccgcgtcgc	ggtcgggcgc	ggcccaggac	ggcgacgcgt
5101	cgccgtcgcc	taggttgcta	gcggcgccgc	aagggcacgc	gctcttgtag	aagaagcagg
5161	gggtgtcggg	ccaggcatcg	gcgggaacag	cggggaacag	cgccgcgagc	gcggcaagcg
5221	cgccgcgagc	gaagctgcgc	atggctccgt	gcaggtctcc	gcgggggagg	gggcgcttga
5281	ggcgaaagtc	cacgtccagg	acgatgttgg	ttacggcgag	gcgggcgttg	aacagctcgt
5341	tgcggttcac	gtagtactgg	tcgcgcggcg	cgccggggcc	caggctccgg	cggtccgagc
5401	ggccggcgcc	acaggccgcg	cgctcagtga	ggagcgcggt	tagccgcgcg	tctcgtcca
5461	caagcgcgtc	ccggccgctc	tctgcggcgg	cggcagcggc	cgccgcaacc	tcgaccgcca
5521	cttcgctcgg	gtctagggcg	gcgacgctcg	tgacggcggc	ccagtcgctg	ccgtcccgca
5581	cggcaaatgc	ctgggtggccg	cgcggtagct	ccactcggtg	gacggggcgtg	ggcgcccgcg
5641	tcccgcgcgc	gccaaagagc	ccgtccagcg	gatgcgcgcc	gtcgcgcgcg	gcggcgggccg
5701	ccagctcaag	tagccgcttg	gacaccccg	agcaggcggg	cgtcgcatca	ggggacgcac
5761	cgccgctccg	cgcgccaacg	cgaagcgcg	cgcttagccc	cgggccccgg	accgcgcttg
5821	cgcttggcgc	gcccgggtgcg	tgagcacccc	acccgaagcg	agccgccttg	ccctcgaggt
5881	gggtccagcgc	tgcgcgagcg	gcggccgcgc	cgtcgcagat	tgtgcgcccg	ggccatttag
5941	cggtcgcgcc	gagcaagcgc	gcgtacgctac	gcgcgcgcgc	gtaagcctcg	gctgttgccg
6001	ggggcgagccg	aacaacggcg	accgccacgt	tctgttcgat	gtagcttttg	acgttaaact
6061	gcgcgcgcac	gtgccgaaaa	aaagcgtcaa	cggcgcgctc	gcggaggcgc	gagacgcccg
6121	cgaggcgcg	cgcgagcgcc	tcgcccgcct	cgggggggctc	gggtggcggtg	acggcgcgca
6181	gggtgctcgg	gatctgcccg	cgattaaagc	cctcaaagta	ggccaagtat	acgtaggcca
6241	cgaactcccg	gtcggccact	ttaagactgc	gacggctcgtg	gtcgtatgtac	tcgcgcaggc
6301	agcgggacctc	ggcgaggctc	gcctcgatgc	gcgcggccac	gtacgcgggt	gccccggcg
6361	caaccgcgccc	gcgggctgag	ccgctgcggc	agcagaaggc	ggcaagcgcc	gcgaaggaaa
6421	ccaagtcggg	gaaggcgagt	cccagggggt	taggcggcgc	ggcgacggcg	tacgtggcca
6481	ggcagtcctc	cacggcctgc	aggtcgtagg	tagcggcgtc	gcccggcgcg	tcagcctgga
6541	acacgtagaa	gcgcgtggcc	aacaccaagg	ttttttcgcc	gggccccaac	ttggagagga
6601	accagaaggg	agtcgcaccg	ctgttgaggt	aaagccggcg	gtaggcgggc	accgttttgt
6661	gctcgtgggt	gatgtagagc	gaggttaggc	gcggcgggcc	ggccggggcg	gcgcgcaggg
6721	ccgagcgcac	tgtagtctgg	ccctcaacct	agcgggcgtc	gtctgcgggtg	cgccgggtgc
6781	gaggcgccag	ctgctccgtg	gccaccagca	gcgcgtgatc	atgtccgcgt	gcagcgcaaa
6841	ggtgacgtcc	tcggcgagggt	gctcgagcag	cacgcgcgcg	ggtagggcct	tgccgaggag
6901	cagtgcgtcg	gcgagcgcg	gcgcgcctcg	cgcgctgttg	aaggtgcaca	cgaagacggg
6961	ccaggcgcg	ggtcgcggcg	gcgcttccgc	ccggcgggcc	gcccagcaga	taaaacgcga
7021	cgagcgggcg	cgcatccgccc	agcgccagcg	ccacgtcgtt	tgggctttcg	ccaccaaggc
7081	acgcggcgag	ccgcccgggg	cagttgttagg	agaccacgta	ggcgccacgg	ccgggtccct
7141	cctggcccgt	gagcagcatc	agcgaaaacc	cgatcgcgca	gccgtcggtg	gcgtacagga
7201	tttggagcgc	gtcctcgagc	gcggctgggc	cgtccatggc	gctgcagcgg	ctggtcgggt
7261	ggctgtgcgg	gcgcggcggg	ggcacgcgag	acgctccgca	gtacgagccg	ctggcgcggc
7321	gcctgagcgg	accgacgcta	tttcgcctgc	aagaagcggt	ggtagccgtc	agcgcgctgc
7381	tgccggcgcc	gctgacagtg	gaggacgtgt	cgcgctcggc	agacggcacg	cgcggtcttg
7441	ccaaggcgca	gtcgttagcg	cggaacctat	acatctgcca	gcggaacatc	gagtgcctct
7501	caaagcacca	ggccgcgtgt	agtgacgcaa	gcatcacccg	cgctcgtgacg	aagcacatac
7561	aggatgctca	gcgcgatgcgc	gacacctgcc	tgccgccttt	gcttcaaattg	taccactcgg
7621	tgggcgctgt	ggagggcacg	acggacagca	tggtggacca	ggccatccgc	atggcgggcg
7681	aaagcaacat	tgtaatggcc	gacgttgccg	tgctggagcg	cgccctgggg	attcaggcgc
7741	agggcgcggg	cgcggaaggc	gcggccaggg	caagcccagc	ggccgttggt	gcccagggtc
7801	gggccccgcc	gcccctgccc	cggcagccgg	ccgcctcggc	gcccgtcgcc	gtgtctccgg
7861	caccgcgggt	ggcgcttgca	gagcgccgg	ccacaaaacc	acctagccgc	gcggggcgcg
7921	cgccggccgc	cgcttcttcc	cccgcggttt	tgacgcttgc	ggcgtagccc	gggtgaataa
7981	aagcaaaaata	agtatacgca	aaacacgtgt	gtgggtggagt	cggtgtactt	taatgtgctt
8041	tgttttacag	cccgttgagc	ccaaagccgc	gcggcccgcg	cgagaggggg	ggcaccgccc
8101	cggcgagatc	ggcgacgcgg	cgccagcgca	ggcgcggggg	cccagggggc	ggcggtgctg
8161	cgcgaggggt	agttgggaag	ggctcgcggt	cggtgaggcc	ggacggaagc	cactcgaggt
8221	gccgtgacag	cagaagcagc	tgccgacagc	gctggcctgc	ggcagcaacg	agcgggttct
8281	cgctgacgtt	tcgcaagaca	aagcggcagg	gctccccggg	gggccaggct	gtcggcagga
8341	cgatcagccc	ccgaagggtg	caggacgatc	gaccaaacc	gtagggcgcg	gcagcgtggg
8401	cgctgtccgc	gtaggctacg	ggcagccgca	cggtgaaatt	ttccccgggt	gccaaagcgg
8461	ccgtgtatgg	catggcaata	tcgtacccgg	cgctctcgct	gcgtttgggg	gcgaacgtgg
8521	caaagaaggg	cacttcgacg	cccgcctctg	tcccggcggt	tgctgcgtcg	tcgacggcga
8581	tgaggcgagg	cagcgtgggt	gttagccgcg	cgagcgctag	ccgcagcgca	agccccgcgg
8641	ggggagcggc	cgctgctggc	tcgggcgccc	agacgatggc	gcgcaagatc	cccagtagc
8701	ccgagtcgac	gatgccgacg	gccacggctg	gtgggcgggg	catgtgtgtg	tcacccgagc
8761	gcatttgcca	cattataatg	gcataatccg	cgggcgcggc	cgccctcatg	tttaaattaa
8821	tcagccgggt	ataaaggaga	gatcccagcg	gggctgtttc	atctcgcttt	gctgctggcg
8881	caattggggc	ccagagcgcc	agcgagtcgg	gctcacagca	gctttccaac	cgccaggggg
8941	ccgcctccgc	gttagctctc	acgacgagga	tgccgcgggt	gcccgtcatc	gttgcggttg
9001	tgcccgccgc	gctgtttgcc	atcgtgcgcg	gcccgcgacc	cctgctagac	gcgatgcggc
9061	gcgagggggc	aatggacttt	tggaagcgag	gctgctacgc	gcgcgggggtg	ccgctctcgg
9121	agccaccgca	ggccctgggt	gttttttacg	tgccctgac	cgcggtaatg	gtcgccgtgg
9181	ccctgtacgc	gtacgggctt	tgcttttaggc	tcattgggcgc	cagcgggccc	aataaaaagg
9241	agtcgcgggg	gcggggctga	ttgaccgcaa	cgctgcggag	taacttgtat	ataaagctcg
9301	cggtcccggc	gaccgctgcc	tttttcgcac	tcggcccgcg	ccgctttgag	ctgcacgccc

9361	gccggccgcg	cgactcgctt	gccatggccc	ggttccacag	gccctccgaa	gacgaggacg
9421	attacgagta	cagcgacctt	tgggtgcgag	aaaacagcct	ctatgactac	gagtccggct
9481	cggatgacca	cgtatacgaa	gagctgcgcg	ccgcgacgag	cggacccgag	ccgagcgggc
9541	ggcgcgctag	cgtccgtgcg	tgcgccagcg	ctgcagccgt	ccagcccgcg	gcccgcggcc
9601	gcgatcgagc	cgcagccgcg	gggacgaccg	tagctgcgcc	cgccgcgcg	ccggcccgcg
9661	gctcgagcag	ccgggcgtcc	tcgcgcccgc	cgcgagctgc	cgccgacccg	cccgtccctc
9721	ggccagccac	gcgcgggtcc	tcgggcggcg	ccggggcagt	cgccgtcggg	ccacctcgac
9781	ctcgcgcgcc	ccccgggtgt	aatgctgttg	cgtctggccg	gccgctggcg	ttcagcgcgg
9841	ctccgaaaac	gcccgaaggcg	ccctgggtgtg	gaccgacgca	cgccataaac	cgaacgatct
9901	tttgcgaggc	cgtcgcgctc	gtggccgcgcg	agtacgcccg	gcaggcgggt	gccagcgtct
9961	gggactcggg	ccccccaaag	agcaacgagc	gattggatcg	catgttgagg	tcggcggcaa
10021	ttcgcacctt	cgtgtgcgag	ggctccgggc	ttctcgccgc	cgcgaaacgac	atcttgccgcg
10081	cgcgggcccc	gcgccccgcg	gcgcgcggga	gcacaagcgg	cggggaaagc	cgcccttcgcg
10141	gcgagcgggc	ccggccgtag	cgcgagcggg	agggcttttt	cgacgcgcgc	ggcttaagca
10201	gcgcgctgct	gtgctagtat	gaaaataaac	gcttgtaaat	taaacacacc	aagccgagtt
10261	gcgttgctct	tgggatgagc	gggcgcataa	aaaccgcggg	ccgcgcgctc	gccagtcagt
10321	gcggcgggtg	tgcggcggca	accatggacc	cgtacgacgc	cattgaagcg	ttcgtatgact
10381	ccctgctcgg	gtcgccgctc	gcggcggggc	cgttttatga	cgcccgcgtc	cccgcgcggg
10441	tcgcgctgcc	gccccgcgcg	ccggctcccc	tggccgcgtt	gctggagcga	atgcaggccg
10501	agctgggtct	ccccgacggc	cccgcgctgc	tgcgggccat	ggagcgggtg	aacgaggact
10561	tattctcgtg	tctgccgacc	aacgcagacc	tgtacgcaga	cgccgcgctg	ctctcggcag
10621	acgcagacgc	ggtagtgggc	gccatgtacc	tagcgggtgc	tggggacgcg	gagcgtttgg
10681	acttgaacgc	gcacgcgaac	cagccgcttc	ccgcaccgcc	ggcctcgag	gagggcctcc
10741	cggagtatgt	ggccggcgta	caggcgcatt	ttctggcaga	gctgcgcgcg	cggaagagc
10801	ggtacgcggg	cctgtttttg	ggctactgcc	gcgcgctgct	gcagcacctg	cgcgcgacgg
10861	cggcgcgctg	ccgagggcgcg	gcgggcgcgg	gcgccagggc	agaccgcctg	cggcagctgg
10921	tggcgcgcg	gtactaccgc	gaggcgagcc	ggctggcgcg	gctggccttt	gcgcatatgt
10981	acgtggcgac	ggcgcgcgaa	gtctctttgg	gcctgcactc	ccagcagagc	caggcgcagg
11041	gcgtgttctg	ttcgtgttac	tatgcttggc	cgcagcggcg	gcagttcacc	tgctgtttcc
11101	accccgctgt	gttcaaccac	ggcgtcgtgg	cgtggaggga	cggttctttg	gacgcggcgg
11161	agctgcggcg	gctaaactac	cggcgtcggg	agctggggct	gccgctgggt	cgcgcggggc
11221	tggtcgaggt	tgaagtgggg	cctctggtag	aggagccgcc	gttttcggga	agcttgccgc
11281	gggcgctggg	cttcctgaat	taccaagtag	gcgcgaagat	gggcgcgcgc	gcccaggccg
11341	gcgggcggct	ggcgccggag	cgggagcact	cgtacgcgcg	gccgcgcggc	gcgatcaact
11401	acgggacgac	tccagaggcc	atgtttgcgg	ccccgtcgcc	gagcgaagtg	ctgccgtgcg
11461	accccgcgcc	agcggctacc	gtgcgcgtgg	cgagccccgc	cacacatctg	gctcaggcgc
11521	cttcagccaa	gggcgcgcgc	ccggccgagt	ttgccgcctt	ggctgggctt	gcaaagcccc
11581	gtccggcccc	gctcgcggcg	gccccggccc	aagccccggt	cgacgcggcc	ttggccttag
11641	ccgagcccg	ggcagccctg	gccccggccc	cgcttgccgc	ggccccagcc	gagcccgccg
11701	cggccgctgc	cgggccaagc	ccggcaaacc	cattcggcgg	cacgtatgac	gcgctgctgg
11761	gggaccgcct	caaccagctg	ctggacttct	aagggcgggc	gggcagtggc	gctttcgacc
11821	cggcgcgctg	cgtttgcgag	gcctccctct	ggcgtaaggc	ctctggcgcc	gccctgcggg
11881	cggcgcgagc	gtataaaaag	cacttgggtc	tacacgggat	ttagttttcg	cgcccgcggc
11941	tttctaggcg	cccttagacg	ccatggacgc	cgctagggat	gggcggcctg	agcgccgcgc
12001	ggccgtctcc	ggaacgtacc	gcacgcaccc	gttccagcgc	ccctctgccc	ggcgagcgcg
12061	tggacgccct	gcgcgctgcg	gacgcggagg	ccgcggagcg	ccgcgggtcc	ggcgcccgcg
12121	gccgtacttc	cagcggcccc	cggacgagga	caccagttag	gacgagaacg	tgtatgatta
12181	catcgacggc	gatagcagcg	acagcgccga	cgactacgat	agcgattatt	ttactgctaa
12241	ccgcggcccc	aatcacggcg	ccggcgatgc	tatggacaca	gacgcaccac	ccgagcgcgc
12301	cccgggaagg	ggtgccccgc	aagactactt	gacggccac	ctgcgcgcca	tcgaggtcct
12361	gcccaggtca	gcgccccacc	ggagcctgct	ggagcgcacg	gcccggaccg	tgtatgcgca
12421	gcagtttccc	ccgcgcgagt	tgagtcgggg	ctccaaggcg	ccggcacagc	gcgcgcggcg
12481	gagcctccgc	ggcttcccgc	gtggcgggcg	gggcggccaa	gaaccggggc	cagacgacga
12541	aggcgacgac	gccgcagacc	tgcgcgagga	ccttgtgcca	gacgaggcct	acgcgcacct
12601	agagcgcgac	gagcggctgt	cgggaaggcc	cccgtcctc	aacatggagg	cgccgcgtgc
12661	ggctgcgggg	gagaggagcg	tggtaggagga	gctgtttacg	tacgcccctg	cccagcctca
12721	ggtagagggt	ccgctgcccc	ggatttttga	gggcgggtg	cgcccagcg	ccttcttcgc
12781	gcagatgtcg	ctggagcgcg	tgtgcgcac	gcccggcaac	gatcagcgcg	tggcgcgaga
12841	gcggcgcgct	tgggagatgg	ccggtaacgc	gcattgggctc	ctaataacca	cgtggagcac
12901	ggtggaccgg	gaattctcga	tcggcggcat	gtacgtgggc	gcccctgagg	gcaccgggcc
12961	ccggctagtg	tggcggcgcg	cgatgaagca	ggccatggcg	ctgcagtacc	ggctgggggt
13021	ggggggcctg	tgccgagcag	tagacggcgc	agcatgccgc	ccactgaggc	gctgctcttt
13081	ttggcgtgac	gcgctgctgc	gcgagtgcgc	aactgccatt	ttttgtcgcg	gcccggggcg
13141	gcggggcgcg	ccgcgcgcgc	tgccgcggcc	ggcggttggg	ctgctggcag	ccacgcagtt
13201	cacggccacg	gacgcgtccc	cccacgcgac	gctctttcgc	ggctcaatgg	gttccctgat
13261	ttactggcac	gagctgcgcg	tgatgctgac	tgcggtgccg	gcccctgtgcg	cgcgctacgc
13321	gggcgcgggg	ctgcagtcgg	ccgagctgta	cctgctggcg	ctacggcact	cagaggcgcc
13381	cggctacacg	gcaaatagag	gctacgcgct	ctcggcgtag	ctgacgctgt	ttgtagcgt
13441	cgcggagcgg	ggcctgcgct	ggctgtatct	agcgggcgcg	cacctgctcg	ggccgcaccc
13501	cacagcggcg	gccttcccgc	aagtgcgcgc	caagatcccg	tacgagcggc	tgccgctagg
13561	cacgcgcgac	ctgcacgacg	ccgaagtggg	gacgggtggc	tcggccacct	tccaagaggc
13621	cctggctttt	agcgcgctgg	cacatgttta	cggggaggcc	tacgtagcgg	tgcggaaccgc
13681	gacgacgctg	ctgatggccg	agtacgcggg	ccacgctgag	cgccgggacg	tgcggcagat
13741	gacagcggcc	ttcctggggc	tggggctgat	cgcgacgcgg	ctgatgggca	gcctgaacct
13801	gctgctgaac	tgcgtagccg	gcgcagcggg	gtacgggggc	cggcgtgtga	cgggtgcgcga
13861	gggcacgcctc	gcgcgggtaca	gcctgcttagc	ggacgcggca	ctgccgctgg	tgcgcccggt

13921	gttcctggtg	gagttccggg	aggccccgca	cggcgtcatg	cgcgagctgc	ggctgcggcc
13981	cgtggcgagc	ccgcccctgg	ccggcaagcg	gcgggtcatg	gagctgtacc	tctcgtgga
14041	cagcatagag	gcgctggtcg	gccgcgagcc	gctaggttcg	cgcccggtgc	ttgggccgct
14101	cgtggacatc	gcggaggcgc	tggcggacca	cccgcacctc	gtcacgggcg	atgggcgggg
14161	cccgcgcctg	ggcggccgct	agggcgacgg	ccgcgcttac	gcggcgctgg	gtccgcccac
14221	atcagccacc	acgcccgcgc	gccccccccg	ccctcgtatg	cctatatagc	catcacgctt
14281	gaatgccaa	ggccactttc	ccgcgcggcg	gaaatggcgt	ggccggccgc	ctctcggggc
14341	ctcatcgagc	cgcatcgaga	gaagggtgc	ctgctgccga	cgctcgaga	tgccacggcc
14401	gcggccggtg	tggccttgca	ggaggcgacc	gagcctctgt	gcggggctcc	gctgtttggc
14461	gccgagcgcg	cggccgcgct	gctcggcggtg	cgctccaacg	ccgtcccgga	ggcgctggtt
14521	ctgtcggact	cggcgaaaga	cgccgacgac	gagtaccggc	tggagtatga	ccgcgccgca
14581	gcgcgggtgc	tggcgggcgc	gcggctctct	aaggacgccg	tctggcgcg	ggtcatcgcc
14641	tctgtactgga	agtacctgaa	ggcctcagag	ggcgctgacg	tgaacatcga	cggcgcgcc
14701	ggcggcgcg	cgatggagca	ggcgagctgc	acgaacgtga	tgctctttgc	gcccacatac
14761	gcgcggcggg	cctcgcgctc	gcggttcaag	cacaagcagg	acaacgcggc	gtacaaaacc
14821	gcagcggcgg	agctgcgcgg	cgccctgcgc	gcggtggaaa	agtatatgta	ttacatgcgg
14881	ccgggcgacc	ccatggtcga	aagccccgac	acggaagccc	gcctgcagga	aattttggcg
14941	tacgcccgca	cggcctaccg	ctggtctgtg	tggttcatgg	acgcgctcga	tggcacgggtg
15001	ctgcgcaagc	ttggcaagcg	ccccctggcc	gcggtggggc	cgcgcgagcc	gcggccgccc
15061	ggcgagctgt	gcgagcgcca	tctgaccggc	ggcccgggga	tcgcctgcgg	cagcggggcc
15121	gcgctcatgt	tgacggccct	gacggcgggc	gtgctggcct	tgctactgcg	cgtcggggcc
15181	gcttggacgg	aatcgtcatg	gaagagcaat	acgcaggggc	tgacgggagc	catcgctgcc
15241	gcggtcgagc	tggcgctggc	cgtacaccac	cacctgcagt	acctgctcaa	catggccttt
15301	gtgggggtacg	cctgctgggt	gcgcgcgggc	gtgcgcgacc	cgtacatgat	cgcgccatc
15361	cgcgcgagct	gcccgttcgc	tcacttttacg	gggcagctga	tgccgaccat	gacttccgcc
15421	agctgggcgg	ccctggagcg	cggcagggcg	agctggttta	agctggcgct	gctgaaaagc
15481	gtggcgcgcg	acggcgcgcg	gacgcgtac	tactccaaca	tcgtggagtc	gatgcggctc
15541	ggcgggagcc	gcgggctgct	ggcgccgggtg	cgcgcgggc	cgtcggggcg	cgcccgccgc
15601	tgcccgcaga	gtctggccgc	gcgccccttg	cccagcctgc	cgcccgcggc	cgccgccctt
15661	ccgggctcgg	gctcgggctc	gggctcgggc	tctgactctg	actccgacct	ggatctcggc
15721	tttgcccccg	ccgtcggcgt	ctatgcctcg	atgcgcaacc	tggaggggcg	ctatgccgac
15781	gcgggcggcc	cgcttttcgc	ggcggaagc	gcccgcggcg	gggaggcgcc	ggtgtacgaa
15841	aacgaaggcg	agggcgaaat	cgcgcccttg	ccctcggcgt	tcgccgaaga	cggcagctcc
15901	gacagcgccg	acgagctcgc	tatcgacggc	cccatgcctg	ccccgccgcc	ccgcgggtggc
15961	cgcggcggcg	acgagctcgc	catcgacggg	cccatgcctg	ccccgccgcc	ccgcggcgcc
16021	cgcggcggcg	acgagctcgc	catcgacggc	cccatgcctg	ccccgccgcc	ccgcggcgcc
16081	cgcggcgcct	ctgctggggc	cctccagtac	gctgattcgc	gcgccgtctc	gagtgcgac
16141	gacgaggacg	agggcaagga	cgaggacgag	aacaaggccg	gggcgaccgc	cccgttggcc
16201	gcggagcccc	aatcggaaat	ggcccgcgcc	atgcggcggt	gcagcctccg	cgcccgccgc
16261	tcggcccccg	ccccggcccc	ggccccgtgc	accgagcgcc	cgggtaatcc	aaccgggtct
16321	tactcgcgct	cgcgccctcg	gctccgcgcc	ctagacgacc	ggcacggcct	ggaggcgctg
16381	gcggctgccc	gtgccgctca	caccgcgcgc	cacaaccgcg	acgtgtggca	gcgcttttcc
16441	cgcgctctcg	aggccggcga	cgactacgaa	aactacgacg	aggcccgcgg	cgcagagcgc
16501	ggacacctct	cttgcgccctc	ccgcgcgcgg	cctgaggtgg	agagggtaac	gtcgtgttaa
16561	aggcgcccc	cgcaaacgct	gtaacacaca	cacaataaaa	agtttgtttt	agtttattat
16621	gaaattgtac	atgcgtgggtc	tttggggggg	ggcgcgggcg	ctttgccgtc	ggggccccgc
16681	gcctacaggc	gcgcccgggc	cttgcgccgc	aggcacgagg	ccgccaccag	caggagcccc
16741	acggcgccga	gaccgcaggc	gacggccacg	acgtgacga	ggacggggct	tccgattagg
16801	ccgggcgagg	cgctcgtagct	ggcggtcgcg	gagaactcgg	gcagcggtgc	cgggtagcca
16861	gtggcggtgc	aggtgtagtc	gacggggccg	tcggtttag	aaagcaggcg	cacgccgcgc
16921	aggtttacca	gcccggggcg	ctcggcgacg	acgccggtct	gctcagtgcg	cgacggggcg
16981	atgccgtcgc	gcaccggtcca	gcagcgggag	acgcgcccc	cggggacgca	gcgcgctcgc
17041	cagacggcct	cgccggccctc	gaagtacacg	cgacgctcgg	gcgggcggta	aacggccggc
17101	gtgccagccg	cgtaaaaagcg	gcgctccatg	ttagcgctct	ggaaccagga	gacgtcgcag
17161	cgaggttg	gcgggtgggc	ggttggcgtc	gcgtcctcga	gcgtaaggac	ggacgtgcgc
17221	gaaaagagcc	cggagtcgtc	gaccgtaaa	acgtcgcgcg	cgtgccgagc	ctccacgggg
17281	tagccgttgc	ggaaccagtg	caggcgcggtg	gagcgcgcg	ggtagtactc	ggcggcgcgg
17341	cacacgggcc	cgtagccggc	gccttcctagc	gctggctggg	gttcgacgga	aacagcgggc
17401	gcgcgggtcg	tcgtgacggg	cacgaccttg	cgctgtgact	tggtgcccat	gtcgcggcgc
17461	caagtgtaca	cgccctcggg	ggcgggcgtc	agggagcgca	cggtcagggg	caagttgcgg
17521	gggtcggcgg	gcgaagggaa	aatatagttg	tcgcccagct	ccgcgctacg	gtacgcgac
17581	gagccgttct	gggttacgaa	cagcagcacg	ggcgggggcc	gcggaaaagg	gttgcgcacg
17641	gcctcgtcgt	cgccgcgcgt	ggagcggaac	ctgcccacgc	gctgaaacca	gagctccagg
17701	cgcgaccgcg	cagtggcggt	gtcggccacg	ccgcagtgca	cgtacagcgg	ctcggcgctac
17761	gaggcgccca	cggcctcgcg	ctcgcagacg	atccacttgc	gctccttcgg	cggggctttg
17821	ctcggccgcg	gggggcgagg	ccgccccccg	ccgctagggtc	gccccatcgc	gctcgcgttg
17881	ccagcgccgc	cgggtcgcgc	gtcctcgggc	ggggcgggcg	gcggcggtgc	gttggtaacg
17941	ggcggtcgtg	gctcggacac	ggacggcggc	tccggcgctc	ccacgggcgt	agtagcaccg
18001	ggcggtcgtg	cctctggcgt	agcgtcgggg	ctgttggggc	tggggggcgt	tgcgccgggtg
18061	gtcccagcgg	agctttccgt	ctcgggtggg	gacggggagg	gcggaggcga	gggcgaggct
18121	tcgcgctcct	cggcgagccc	ccgcccggga	gacaggagcg	cccaggcgaa	aatagctcgc
18181	atcagccacg	ctcgccccag	cgggccccatg	gcggacgcgc	ggcgagggtct	cgggctggcg
18241	gtctctcggc	ggtcgtgcgc	gcgggtggat	ccaagatggc	cgcgaccgcg	gcgcggctac
18301	atttttaagg	gcgtccggtt	tgtgctttcg	tggtccggga	ttgagcacac	gcgcggctgc
18361	aggcgcgcta	ccgtcggcgg	cagccggttca	ttcgtcggcg	cagacccagc	aggccccgac
18421	gcagaagcac	agcgcggcgt	gcagggcctt	ggccacgtgc	gcccgcggca	gccgtgcggt

18481	gccgcgccccg	cagcgccgga	cccacacgca	ggccaccagc	gtgcccgcgg	ctgccgaggg
18541	cagcgctgcg	ggcgcgccgc	cgtccgcgcc	gcagagcggc	agcgctgcgc	ccagagcgca
18601	gatgcccacg	tgcgccatta	gcgcgcgcgt	cgcgggcgtc	gcgcgcgcgt	agcgcaggca
18661	gaggtgctcg	gcgagcgcg	cgccgtgccc	gcccgcgacg	ctgagcagaa	ccgcgccgcg
18721	cgtgcgccag	cgcccaccgc	cctcgagccc	aagcgcgcg	cccggggccc	agagcgccgc
18781	cgccgcggct	aaggcgggcg	ccgacagcgc	gagctccgcg	gcggcgggcg	gcgccagcgc
18841	gcgcattggg	acggcgctct	cgcgcgcgcc	gcacgggtca	cgggggcacg	ctgcctcgcc
18901	gagcgggccc	agagtcgcga	gcgcgcgta	ccgccagatc	ttgtagtggc	aggtgtcttc
18961	cagcgccgcc	gcggcgctcg	tggcgggcgc	gaccagcgcg	gccgcggcgc	ccgcggccgc
19021	cagcgccctg	ggccgcgcgc	cccagcgccc	ggccgaaagg	ccgagaagca	gcccgcaggt
19081	catggctcagt	agcgccgtgc	gaaagtgcgc	cccggtgccc	gaggctgccc	tcacaaagtg
19141	cgcgcgagtgc	accggcacac	cgcagacgac	gtaggcagcg	gccgcgcccc	ttgttaccce
19201	gcgcagcacg	gcggggggcg	ggctctgtgg	ccagacggcg	agtgccgctg	cgacagccag
19261	cgcctgcgcg	agccggccaa	gcggcgcgag	ccggcgggcg	agcgtctgtg	cgcgggggcg
19321	ccaacaaacg	agcgcgggcg	cgcccggtgg	tgtaaacgca	agcgccgcgg	ccgggtcttg
19381	cgcgcgcccc	acgggtggcca	gggcccgcgc	catcaagccg	gtgtgtgtgc	ccatggccac
19441	cagcgcgccc	gtggcgggcaa	gcgcacacgg	gcccagcccg	gctctcgccc	ccgcgcagcc
19501	gctcacccgc	acggacgcga	acatggatgg	tcccggttcc	ccaaataacg	caacgtggcc
19561	caggatcgct	ttttatcggc	ctttattgtt	tttcgcttaa	ggagtttcgc	ccccctcccc
19621	gccccgatcc	ggggccgagc	tcggggccgg	ggcgccggcg	tcggcgcgcg	gccgcttgcg
19681	ggccccggcg	ccggaaactg	cgaccgggtg	cgcgccgctg	gtttgaatgc	cggtctccggc
19741	cccgcgacga	ggttggccgg	acgcggcggg	ccgcttagcg	ggaaggcggg	gtgcgggctc
19801	ggcgcgagtca	tcagcatcgt	cggcggaggc	gggtggcggtg	gcggggcggc	agaaaaagaa
19861	cacagtcagc	ccctccggcg	ccgctgtgga	cacgctcatc	atggcgggcg	tggcgggcgc
19921	gaggtagaag	cgcacgaggg	cgtcgcgcgc	gacctgccgc	acctttttgca	gcagccggcg
19981	gaatcccag	ggggactcca	actccagccg	aaagtcaggc	gccccgccag	agcagcgcac
20041	ttccaatagg	gcggccctgc	ggccgcgcgc	ctgggcgcgg	gcaaaaatgc	gctcgtgccc
20101	tgcgctcggg	gcgagcgcca	gctggagctc	tgccccggac	tcgccgccct	catggcgcg
20161	ggcgaacgaa	gctcggcccc	atgcggactc	ggcgctcagg	caacggggcg	gccggtatgc
20221	gaataccacc	gcctcgttgg	gatctttggc	aactgcctgc	agctttgaga	gctgcggccg
20281	cgagagcgag	acggcgaggt	cggcgcgcgc	cgtcggaagc	atgattgagt	actcgcctag
20341	ctcgtgcttg	accaggctgg	cctgcaatag	ggcatcgccc	tcccgaaagt	aggtaacttg
20401	cgttagcacg	ctcgcgggtg	gctcacccgt	gattagaaaag	gccacgttct	gactgtccg
20461	tgtcttgctg	gcgcggaagg	cgtccagcag	gccgcggcgg	ctgtcgacgt	tggcgaggaa
20521	gacggctcgc	gcgtcgctgc	gggcgggggc	ccactggaag	gacgtgaact	tctcggcggg
20581	gacggccacg	tacacttgct	cgtcgtagag	gccgctgtgt	accagcatgc	cctcgcgggt
20641	aaagaccaa	aaggcgtttc	gcagcgaggc	gccaaagggg	ctcagcaggg	cgagacgctc
20701	cgccagctgg	cggccgataa	gcgagggcgt	cgcgattggg	ttgccgttgc	cgccgtcgga
20761	cagaccggcg	gtgaggcggg	gtcgagcttc	gtcggcgcgc	agatgcgagg	ggggctcgag
20821	catcgcgcg	ggtgcttcgg	cggcgcttcc	gctcgctctc	tacgcgcgcg	gtcgcaaagc
20881	gagtcctgcg	tgcggcgggc	ctctttatac	tgggcggacg	cccccgacgc	ggcaaaacac
20941	acactcggcg	gcctcagcgt	atcaaacggc	gacacgttta	agtttcgacg	cctataagcg
21001	ggcgcgcgca	ctaggccctcc	caatcggcac	cgcgcgcggc	tgtgcggggc	accctgcgca
21061	gagagagatg	gggctcttca	agctactgcg	ttacgcgtac	ggcaatcggc	tggtaaagca
21121	cgacgccatc	accacggcgc	cgggcgtgat	gaccccgatc	gcggtcgacc	tgtggaacgt
21181	gatgtatacg	ctcctggcag	gcttctgcgg	gcagcgcccc	ggcggcgtag	gagacgccgc
21241	cgcgaccgcg	cgctgcttcc	tctcgctgct	gcggatgctg	ctcaagcgct	cctactaccc
21301	gatctttgta	gcggaccgcg	gcatccacgg	ggaccggcgc	gccacgcggg	gtgccaaggc
21361	cattgtggcg	cagacgatgc	gcgccgtcgg	cggtcggggc	cgccctcgggc	ggctcgtcag
21421	cgacgattat	acctcggagg	acgaggtgct	gggcgcgtac	gagtaccccg	ttccgcacgc
21481	ggacgcggga	gccgacgacg	acgagggagc	aacggcgaa	gaatttgccg	ggcgcgcttc
21541	ggcgggggcc	gcgcggggcca	acgcgcccc	gctggcacat	cgcggtgtcg	tgagcctcat
21601	ccgctttttg	ggctacgcgt	acgtcgacgc	cgctgagatg	gaggcagacg	acgtctgcgc
21661	aaacctcttc	cacacaaaca	ccgtggcgca	catctacacg	acggacacgg	acatgatcct
21721	tatgggctgt	gacctgattt	tggacgcggc	gccgttggtc	cccccgacgc	tacgctgccg
21781	cgacgtgctg	gcgtcgctgg	ggctcacgta	cgccagtttc	ctcgcgacgt	tcgtgcgctg
21841	ccacaccgac	ttgcaccagc	cgccaatgct	gcgctcgggtg	cagcaggtgg	tgcgggggct
21901	gcggcgcgct	gccgagggcg	agcccgcgac	taccgagacg	gagtcctggc	ccgagcgcca
21961	gccggagtcc	gagctcgggtc	gtccggggcg	tgggcgcggg	cgccggttgc	cgcccgcggt
22021	cgacgacccg	ctgaaaacta	cgacgccggc	gaccgtggaa	gcgcacagcg	tgcgcatgaa
22081	gtatacatct	cggtaccctc	cgattgcgca	gacgtgcgcc	gacgcgctgc	ggctgctgcc
22141	ggcgtcccag	acgcgcggcg	gcgtgctgga	gcgcaaattt	gtaaagcacg	tggtagacac
22201	gatcgcgccg	cgaatgcgcg	ggcgctgggc	cgctgtgaag	cgctgcccc	tcgcacagga
22261	cgccccgac	cctcggctcg	tgtacgacac	catcgtagag	gccgtaggca	gcgcgcgcga
22321	ggccgacacg	ctgtatgggc	tcttctggaa	gcacatcccc	actccacccc	catttgccaa
22381	gggtgctggca	gactactggg	acgaggcccc	cgcgggggcg	gggtcgcgac	ggacaacccg
22441	ccaataaaaa	cgcgcgcata	cgcgagactg	gctttcgttg	acatggaaca	ttttttattc
22501	gcggcggtggg	ggtgagaagg	aggaggaaag	gcggggcgct	ctggcagggc	agcggggggtg
22561	ccctacaggt	cggtgattac	ggcgctgtg	tagttgggtg	tgcggcgctc	aaagaagttc
22621	gtgtgcttct	cggcagtcac	cagggccaaa	ggaaaatcgg	tcccaggagg	cggggtgcca
22681	aacagaggag	gcagctggat	agcagcgagc	aggcggtccg	cgctgtactc	gacgtacgca
22741	gaaatagcct	ccacgtcaag	tatatgactg	ccgcgcggcg	cgcaacccaa	taaactcgcg
22801	ctcaatttcc	acgcttcgcg	gaacagctcg	tagatgcggg	ccggcgggcg	ccgctccccg
22861	ccgaggtagt	tgtcgaagat	gcagcacgac	gcggccgtgt	gcacggcttc	gtcgcggctg
22921	atgaggtcgt	tggtttggca	cgtcacgacg	aaaaggttgt	gggtgcgacg	gtaggcaatc
22981	gccgcaaacg	aggaggagaa	aaaaatgccc	tcgattagaa	tcatgagcac	gtacttttcg

23041	gccaccgact	ctgccgcggc	cacgcgccgc	tcgagccagt	ccaccttgcg	cgggaccgcc
23101	gggtcgccga	gggcgccttc	tacgtagccc	gcgcgcgcc	ccgcgtcggt	tctaaagagc
23161	agcagctgta	tggcgctgta	caccgcgag	tgcaccactt	cgatggactc	ctgctcgata
23221	tagtaatgca	ggatgtcttt	ttgggtgaac	agctcggaca	ggtccccgag	gttgacgttc
23281	acgaggtcat	cggcggccga	gaggaacgcg	aacagaaagc	ggtaaaactc	cagctcggcg
23341	ccgctgagcc	gcgccacgtc	cttggcgctg	tccgctaggg	gaaactcggg	ctccagccag
23401	cggtttgcca	cgctgagcga	cgcgaagtga	tctaggtcgg	ggcactcggg	ctcgtaaaag
23461	tattttgtatt	tacgcgtgag	ggtcgcgcgc	tccgcgcctt	cggccatcgc	gctcggcgcg
23521	cgctcgtaca	ggtggcaccc	agagcacacg	aggtcgccgc	ccgtgaagac	gccgttggtg
23581	gtggccttgc	ggatcttgca	gtagtagagc	cccgtcttaa	ggcccttctt	ataggcgtag
23641	actaggaggt	tcatgatctg	ggaggcgggc	acctttccgt	ccattggctc	ggtcacgaag
23701	agcgacattg	actggctctg	gtccacgaac	ggggcgcggt	cggcgagag	gtcgatcagg
23761	cgctcttggg	cgtactcgaa	ggcgctcttg	aacttggcca	gcggtgccc	gggcgcgagg
23821	tcgcccagcg	cggcgccac	cgaccacttg	tccgggtcca	gcgcgcgcac	ggccccgagc
23881	cggctggcct	cgcgcgtaaa	gtgctttcgc	agcgcgcgca	tcagcggcag	gttcgggcgc
23941	agcagctcgc	cgctcatcgt	gaccttgctg	aacatgttgg	tgaagacggg	cgagaagccc
24001	tcgctgccct	ccgtcacctg	cgacgaggac	acggtcggca	taaggcgac	aaactgcgcg
24061	ttgtacagcc	cgtgccgcgc	gaccttctcg	cgcagccggg	cccaggcccg	cggcagcgag
24121	aggaccacgc	cctcgtagcc	gtcgaacggc	atgagcccgc	gcgcgaactt	gctgcgcgca
24181	aagtcctcga	acggcgcgca	ggcgactctg	cacagcgtgg	cgctgggtgg	catgacggcc
24241	aggagcaggc	gctcggcgat	ctccacgttc	agccgcgcgc	cggcgggcga	gagcatgtcc
24301	atgccgagct	ccaagaggag	cgtgtgcagg	ccctggaagc	cgatgcccag	cgagcgggtg
24361	cgcgccacgc	cgcgcgcggc	cttttcggta	gggtactgtc	cgcttagcat	catagcggtg
24421	acaaaaatgg	cggcgcgtgg	ggccgcctgt	gacagagcgg	caaagtcaaa	ggcgagcgcg
24481	ccgccctcac	cctcgcgcac	gcagcgcggc	aggttgacgc	tggccaagt	gcacacgccc
24541	tggcgctcgg	ggctcgcgcg	ctgcacgatt	tccgtgcaga	ggttggagcc	cgtagcgcgc
24601	tcggcgcccg	tgctccatgt	gtaattggcg	ttacacgcgt	ccttgaaat	gacgaagggg
24661	ctccccgtca	tgacgatgct	tcggacgatg	aggaaaagct	ggctctgcac	gggcacgggtc
24721	tcgacgccta	gccccctcgc	ctccagtcgc	tcgtactcgg	ccgtaaaggc	cgggccgtgc
24781	agccggctga	gggtgcgacgc	gcggctcgct	aagagcgctc	acacaacgcc	ctcgggcctt
24841	tcgaggtggg	cgaggtagcg	gtcaaagagc	aggtccggca	cccagaggca	gctgaacagg
24901	ttgtcgcagc	gcgtcgactc	gtcccgggag	agcaggccgc	gcattgtttg	cacggcccgc
24961	acgtcgcagt	ggcagggtct	gaggtacacg	cagatgcccg	tcgggcgctc	gctgtcgtg
25021	ttgatggcca	tggccatcga	gtccagcagc	ttcagcgccc	ccatgatgcc	acgcttgtag
25081	tcgcgcgaga	ccgcccggtc	gaagctctgg	aaggagattc	cgatccacc	gcggttgagc
25141	aagattcgcg	cgacctccgt	ggtgatcgcc	tccacggcct	ccgtactgct	ggacacctgc
25201	ggattgagca	ggtagcagct	ggccagcgag	ccccgcgcgc	ggccggcaaa	gagcatgatc
25261	ggcgctcgcg	ggacaacgag	ctgccggtag	agcgcgggtc	ggtaggcgtt	gaacaccgcg
25321	caccacgtgg	cgccctcgcc	gacgagggcg	cgcccaaagg	ccggctcccg	catcgtccac
25381	gtggcgcgcg	tcgcggcgat	cgcgacgaag	aactggccca	tagactcgat	cgccccgccc
25441	tcgagcttgg	ccaggtacat	ctcttcgtac	ttcagcgccg	actgcaggcc	gagcgcgcgc
25501	aggggtggcg	actcggtaag	ctcgaagtat	cggagcgaga	cctccacgaa	ggcgcggttg
25561	gcgcgcaccg	gctccgcgac	ctcggacacg	agcgcgagct	cggccgatgt	aagccagtcg
25621	tccagaggca	cgctccgagc	acgcacgcgc	aagtgcacga	gttgcccgcg	ctttacgtac
25681	acgcgttcgt	cggcccgcga	ctgcgtctct	atgcgatcca	cgacctcgcc	gacgtaagcc
25741	ggcaactgcg	cccgaagaag	acgagaagcg	gcggcgggcg	gcggcgggac	ggcaccgcag
25801	cccagctgcg	cccattccgc	gtgctcggcc	tcgagctgct	ccgccgcgtc	ggccgggcag
25861	gctgtctgca	tgaacgcgtc	gctcgccatc	ttgctcgccc	ccctcgcttg	cagcccgcgc
25921	ctgccgaccc	gctggctttt	tgtctttcgc	ccgccgaccc	gccggcgctt	ggtctgcccg
25981	atcgcacccc	ccccgacgcc	ttgggaacaa	gcgcgcggcc	ggctctgggt	ccccggagat
26041	aaaaaccgag	cgtatggcgg	cagcaaaagg	tgcgggccag	gtgctcgctc	ggcaggcaac
26101	ctgggcccgg	cagcatagat	atttaacggt	ggtttgaggg	gcgtggcggc	ccttccctgt
26161	tgattttatg	catcgcacac	aacgggtgtt	gcggaacaca	ttttatttaa	aacgacagcg
26221	cccccttgtg	tcagtaaaaag	cactccaccc	agtccccggt	tccccacacc	aagccctcga
26281	tcttgacgac	gggcacgtcg	caagactggg	agcgctcgct	gcggcaagtg	actcgcggcg
26341	agtcgtgggg	cagcgtcccc	aggcgcgcg	aggcggcgta	catgcagctc	tcccgggtgg
26401	gccgcccggc	agcgtccggc	gcccagcgcg	gcaggaacgc	cgctcgctcg	cagtcgcccc
26461	gccgcgagac	ggggcagcgt	taggcgcgcg	ggctgttcgc	cagcgcgggg	agcggaaact
26521	cgtccgcggc	cccggccact	tctgcacgct	cgcccccgct	cccccgagc	acgttttcgg
26581	cgcgctgctg	gtgcagcaag	tagctcagcc	cgctggcgaa	tgtggtttcg	taaagcttgc
26641	tgacggccac	gtgggcgcga	aagccctcgt	gctccaagcg	ctgcgtgtac	acgaagacca
26701	ggtacacaaa	tttgacgccg	gcgggctcca	gccgcagctc	ggcgctccac	tccaggaacg
26761	cgcaggcggg	cacgtgggcc	gtagagcgcg	ggtgcgcggc	ctggtcagtg	cgcgcgcctt
26821	cctgcgcgcc	gcagacgacg	gccgtgacgc	tggccagctt	gtcttgctg	gtccacgaga
26881	gcagtcggcc	caggcacccg	agtgccgtgat	gcgggaacgc	gcggcagcgg	atcatggcct
26941	gcaggcaggc	gtagaagcgg	tctagccgca	atgccatgcg	gcggtcgcgc	gagttggaaa
27001	tgaggtgcgc	gcgcagcgcg	tctgcggcgg	cgcggttgcc	gtactcggcg	gcgcaggcgg
27061	ctgccagaaa	ggaaaaggat	acaagagagg	cccgcagccc	cccgggcggc	accgcgcccc
27121	cgctggaggc	gtcgcggagg	tcgcgccaag	cctcttcgac	gtcgcgaaac	tgccgtccgg
27181	ggggcgagc	cgcggcgccc	agcccaataa	tgtcggcggg	gtgcttcagc	gttaggcagg
27241	gcgcgcgggg	gcgctcgagc	tgcgggtcgc	aaaagtccgt	cagggtaaac	tgccgcgaga
27301	gccggatgtg	aggctgcggg	aggggcgaga	ggacggcggt	gccggcgggc	gtgtccacgg
27361	caatctgccg	gggcgtgacg	atttgaatcc	ccgacatgtt	ctggatggtt	accgttgctg
27421	cagacacgtg	cagcatcccc	ccggcccaag	ggttgtagcc	ccggggtgcc	cggccgcgag
27481	cgccgccaac	cgcaggcgcc	gtcactgact	gcacgccggc	ttcggcggca	gaggcctcgg
27541	ccgccgcgcg	ggcggcgggc	gggacgcccc	agaacggcgg	cgcggcggct	gggagccgca

27601 tccgcaagtgt gttgccgatt tgaatgtaac tgcagctccc gtttaggcgcg gccatcgttc
27661 ctctgtccgct cggcactcgc gctcgggtcg ggtgttatag ggtggcggtat tgcagctgcc
27721 tttatagcgc cggcgacgc ggcgggggca agggcgctcag cggcggaagc cgcggcgcg
27781 gttgcggcgg ggggctgtgc ggggcgtaca ataaactgcg cggcggtgctc gggctctggc
27841 cattcgcgcc ccggcgacgc cgcggctgac atgagcggag acccctgctc gggcctgtgg
27901 gccgcgctcg agcgggttga tggcgaggtc gccggcccgg ccgctgttgc ggaggccagg
27961 cgggcccgtct cggagttcct cctcgcgtcc gggcccagct cgtagactt cgtggcgccg
28021 gcgtgggccc cgctgcagcg cgcggcgtgc cgcgcttacg agcgcctgca cacgccagac
28081 gcggcgctgc tggcgaaaaa cctgcccggg ctggtgctgt ggcgcctgcc cggggccgcg
28141 cgcgacaccg ccgatttcat ggccggcggt cgggacctgg ccaacagcat gatcgccgag
28201 gcgcccgttg gttacctggc ggccgcgcgc ctgcgccca cggcgcggtt cggcccgggtg
28261 aacatgcagc gcgtggtggt ggagtgggccc tcgctctttt tggagatcta cgcacgcgag
28321 gacgcggcgct gcgtgggtgt gtttagcccc gacctgctgc gccgctgcgc ggcgggcagc
28381 gcggccgtca tccgcccgtc cctgcagagc cgcttccgcc tgcgttatga catgcccttt
28441 tttcaggcgg ggcttagcgc cctggcgcac gccgccaact ggaaagtgcc tatggccgcc
28501 gtggcacgac gcgcccggga cgcgcggcg ccgcccgtag cgcgcgcgtt ttttgccgtg
28561 gcgcttgctc acgagtactt tcccagacca gacgacgagg acacggcgcc ggggctggct
28621 gaggcggttg cggaaattgc tgacttggtg ccgcccagag cgtagtgtcc cgcgggtgag
28681 gctaaccgtt ttgcgcgctc gtcgcacgac gtgcgctat cggcgcgctt ggcctaccgg
28741 gacccctttg tgcgcggcgc ggccgcgggc agcgtcgccg cgcgcgtgcg tgccgacgcg
28801 ggcccttctc cgcgacacac gttgtctggc cgggacgccc tcgcccgtca cgcaggcgcg
28861 gtggtgcggc tgctagaacg cgcggccgcg cgcgcgacgc cggcgcgctt ggggaggtt
28921 gcagagcacg cggccgcccgt ttgggacgcc gtgcaggcga gcgccacgcc agaccaagcc
28981 gtggagacgc tggccgcggc ggggtttacg ccgggaacct gcgccatgct agagcgcgcc
29041 gtgctggcgc agctatcgcg cccagagccg cgcgcgcccg cagacgtgct gcaggcggtg
29101 ggctgcgtgc cgggtggcggg cggcgctgctg tttaaactct ttgacgcgta cgggcccagt
29161 gcggactacc tcggcacta cacggcctat atcgcaaacc tgcaccgta ctacgcggac
29221 gtgctgccgt tgctggggct gcccgcgggc gggctggagc agacgatccg cactgcatg
29281 gcccgcggc cgcgcacgga ctacgtggcg gcgattcgcg cggcgctggc ggcagaggcc
29341 gcggccgcgg acaagcgagc cgcgagcgcg agtgcgcggg cggccgttga aaacagcggc
29401 gaccgcgcgg cggccggagc tgccgcgcgc gaggccctcc taacctggtt tgacctgcgc
29461 gccagcgagc gctggggcgt ggccgcgccc gcggccgaag cgcgcccgcg ggcgaggcg
29521 gcacgctctc cggccgcggg cggcgcttcg gccgcagagc tcgcccgcgc ggcgaggcg
29581 ctcgagttcc cccgcagga cgcgctgcgc gctgcccgtt tgcgagaccg ggcctttgcg
29641 cccacttcg ccgcccgtg gctgtcggac gtgctggtgg ctgaggacgc gctgcccctc
29701 agcgaacacg gcgtggcgca gctgatggcg ctgatcgctt gggcgcgaga ctgcccgcg
29761 ggagcggttg ccaacgtaga cggctaccgg acaaaactgt cggccctggc ggcgggctc
29821 tggccgtttg tggacgcgag cggcccggcg cccacgacga cgcaggtccg caacgcggag
29881 gctgtgctgg gcgagctgca cacgtagct acgaccgcgg cggagtgcct gccgccgaa
29941 gtgcgcccgc ctgtgcccgc gcgcccgcgg gtgggcggtt gtgtcttctt agcgagcatg
30001 tacctgcacg ccgcccctgc gcggctgcag ggctatgtcg ccgagacgga agcgtggcc
30061 gcgtctatgg ccgcccgtt gggcgacgtt gccggcgcgg tggcgcggtt gggagtgtg
30121 ttcgactgcc actttgcgtc ggtgcccggg cagcagatgc tggcgatata cgcgacgcgc
30181 ggcgcgccgt gcgcccgtg tgctggcgcc tcggcggacc tggccgacgc ggtgcccgtc
30241 gcgcgccggc aagccgcgcg cggcccggcc gagggtgcgc tgtcgtggc ggcgttgacg
30301 cgcgcccggc gcgagcgac acagagctg caggagtgtg aagctgcgga cgcgcccgc
30361 cccggcgggc ggctggacga cgagaccgc gcgttgctgg cgggcccact ggcgtgggtg
30421 cggcgcgaga cggcgctggc gctggcccgc ggcaagctcg tggcgggcg gggagcgccg
30481 gggctgcacg aggtgggccc ctttctgcag cgctgggacg cgatcgggc ggcctcggg
30541 cgcgcgctag acgacagtg cggcgagcgc gacgtcgccg agctcgtcgc gcggtccgc
30601 ggctgtggg acgaggtcca ggaggaccgc cgcgtagcgg ccccggggccc gccgcgcagc
30661 gccgcaaacg cggcgggcgc cgaagaggcg gtgctggcg tgttgaggg ctaccggag
30721 gttcggggag acgagggcag cccggcgctc ctggacgccc gcgaggacgt ggcgagtg
30781 gcgggctgag accgcggccc gctgcagcgc cgcgcgtctg cggcgcgga cgcgcccgc
30841 tctgccgccc cggcaaacac ggccggggg ccgtggctta cgacggaaga cctgctgcc
30901 gaagtcatg gcgtttgcgc cagtcgcccg gccgcagccc ggtgaggcgc gcgcccggg
30961 tgcggcgga ggccttcgca taaacggcgc tgcgcgcgcg gtgcccccta gtaccctgt
31021 ggagcagcga agcggcacca tgtccggcgt tgccggcgcg cgcgcgcgg caacgcggc
31081 cgacgtcgcg gtcgcccgtg tgggttttcg caaccagtac gacgcggcg tggggcggg
31141 cagcgcggtg gcatgccttc ggtcctcgt gtcgtttctg cggctggcct tcgcgggcg
31201 cgtcgacgcc gcgctgggcg ccgacgccat cgacgggtgt ctcgctgagg gcgcgcggtg
31261 ggcgcgcgaa agcggggcg gcccggaaat gtgctcgatc gtgcacctgc caaacgcac
31321 caccgaccag gcggggcgcg ggagcgggct ctgctgcgtg ttttcgcgcg tgtatgggga
31381 gtgcggcttc tacacgccgc cggcgagcgc cgccctgagc acccaagtc cagcgcgcga
31441 attc

L3 ANSWER 132 OF 199 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HSMULHOM GenBank (R)
GenBank ACC. NO. (GBN): L10283
GenBank VERSION (VER): L10283.1 GI:388703
CAS REGISTRY NO. (RN): 151210-86-5
SEQUENCE LENGTH (SQL): 8433
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Viruses
DATE (DATE): 29 oct 1993

DEFINITION (DEF): Gallid herpesvirus type 1 homologous sequence (UL50, UL49.5, UL49, UL48, UL47, UL46, and UL45) genes, complete cds.

SOURCE: Gallid herpesvirus type 1 (strain GA) DNA.

ORGANISM (ORGN): Gallid herpesvirus 1
Viruses; dsDNA viruses, no RNA stage; Herpesviridae; Alphaherpesvirinae; Infectious laryngotracheitis-like viruses

NUCLEIC ACID COUNT (NA): 2454 a 1751 c 1825 g 2403 t

REFERENCE: 1 (bases 1 to 8433)

AUTHOR (AU): Yanagida,N.; Yoshida,S.; Nazerian,K.; Lee,L.F.

TITLE (TI): Nucleotide and predicted amino acid sequences of Marek's disease virus homologues of herpes simplex virus major tegument proteins

JOURNAL (SO): J. Gen. Virol., 74 (Pt 9), 1837-1845 (***1993***)

OTHER SOURCE (OS): CA 120:3013

FEATURES (FEAT):		
Feature Key	Location	Qualifier
source	1..8433	/organism="Gallid herpesvirus 1" /strain="GA" /db-xref="taxon:10386"
gene	complement(<3..305)	/gene="UL50"
CDS	complement(<3..305)	/gene="UL50" /function="possible UTPase" /note="UL50h; MDV homologue of UL50 of HSV-1; putative" /codon-start=1 /protein-id="AAA03146.1" /db-xref="GI:388704" /translation="MNVHESHPRRDRDLENITLE ALTVPWRLQFRVDEALYAVNPNGW TCYIEERDQRCLRVTNCCVISLLKSDLKRKYQTC TLNIGIRVAVPQNYVVILAKLTD"
gene	285..572	/gene="UL49.5"
CDS	285..572	/gene="UL49.5" /note="hydrophobic protein; UL49.5h; MDV homologue of UL49.5 of HSV-1" /codon-start=1 /protein-id="AAA03147.1" /db-xref="GI:388705" /translation="MGLMDIHNAVCSLVIGVAIL IATSQATFVDWGSSITSMGDFWES TCSAVGVSIASFSSGFSVLFYMGMLVAVISALLAGS YHACFRLFTADMFKEEW"
CAAT-signal	628..634	
gene	718..1467	/gene="UL49"
CDS	718..1467	/gene="UL49" /note="UL49h; MDV homologue of UL49 of HSV-1 (VP22)" /codon-start=1 /protein-id="AAA03148.1" /db-xref="GI:388706" /translation="MGDSERRKSERRRSLGYPSA YDDVSIPARRPSTRTRQNLNQDDL SKHGPFTDHTQKHKSAAKAVSEDSSTTRGGFTN KPRTKPGVRAVQSNKFAFSTAPSS ASSTWRSNTVAFNQRMFCGAVATVAQYHAYQGAL ALWRQDPPRTNEELDAFLSRAVIK ITIQEGPNLMGEAETCARKLLEESGLSQGNENVK SKSERTTKSERTRRGGEIEIKSPD PGSHRTHNPRTPATSRRHSSARGYRSSDSE"
gene	1575..2858	/gene="UL48"
CDS	1575..2858	/gene="UL48" /note="UL48h; MDV homologue of UL48 of HSV-1 (VP16)" /codon-start=1 /protein-id="AAA03149.1" /db-xref="GI:388707" /translation="MEANMSFENDYYSPIQLFAE IEAYANTMDKSPDLDIRTIEEFD ETLLSEIEVVRTQSIPSLVAPSVTKMSLPSPSPA PPNSLYTRLLEHDFVEGPSILAR LEKINVDLFSCFPHNKHLYEHAKILSVSPSEVLE"

polyA-signal 2941..2946

terminator 2970..2976
gene 3097..5523
CDS 3097..5523

gene 5665..7371
CDS 5665..7371

ELSKNTWITYTALNNEHGEMALPM
PPTTKADLPSYVDDIQNFYLGELEAREKSYATMF
YGYCRALAEYIRQSAIKDLRDARV
EDKNIGACSKARQYIAERYREARFAKLLYVHL
YLSTTRDVSQRLEASQMGRQNIHV
YLKCEWLQERHFHCLFQPVIFNHGVVIVEGRVLT
APELRAQNYIRSEFGLPLIRCKLV
EEDPMDPLISPPFSGDAPRASVYLLQCIRSKLEV
YLSHPNPQLHVHKEHVHVQKLE
SPPNYGTTVEALLMDSSDRNSISPGDPVATTIST
L"

/note="terminator for UL49.5h,
UL49h, and UL48h (2.5 kb
transcript)"

/gene="UL47"

/gene="UL47"

/note="UL47h; MDV homologue of
UL47 of HSV-1 (VP13/14)"

/codon-start=1

/protein-id="AAA03150.1"

/db-xref="GI:388708"

/translation="MQMPSMHRYGHPGQNQRREN
QSIRNYLSTRSGSRNRISRSPHNM

ASVYTRAPAIAYDDDTYDTLEESEDNGFVKTIPTN

EEQFDNSRGRDRTRSGRSNGHSFL

GYLRDTFTERQPSGRRGSDTSRDMINASLKSRAR

SRRRSSRRRRHRNASMHMHFRGGS

RRSATGSQNLINHDRHRRISQSSLGSSREGEYNH

ASRSSRVRRRRSSRRRGPRAGG

HGDSFTSITPSGSAEHPISDIDQKRLRKNSDTSS

RGTRESPIDDSFGEDNYRLVSRNR

ATSIYTPSALYTRTESLKTYKRTTGDSKGTSPA

LASFLEHKTLADVINHIPLLRML

ESVPRSEAIREDELLYMSAKTFKYVSHWYSNSRP

DYANGKMYTSPPENALAWKRTAK

QAHALILHLGRDSLRSVMSLRELNQSNVLFLL

NSCLKIAICIHKNKMHKYGKVKIL

STMPHVRKGDQIFENSTIHTMRDPMSAARASY

GSLAYWPELRCALGSENKRIVRYA

IVAMLQAEIYLLTRISSQVRSMNKSELRISSCI

TMECVAACIAVQFLYTSWQILYS

SKINREYIWLKTASERSKKLPMASTDLLYAEGAC

LGRLESSLYGTEGTLGRTLVEAY

LATRSAFTELIYEFQSNSDLFEKQNVKLGEKLT

AAVIAATVVLQRLLGHLNIIIAQM

VIGSVYHKKDQDVWSETFKMYQYLSYVCKSLYRP

VTIDEYINDRDDTMEYLTLEFARG

DPPTGMAVSIYEDEKSEELESKLVPPPINYDIL

GNLVPLRNAIEDASDVIFEKRAVE

TARREPQRAN"

/gene="UL46"

/gene="UL46"

/note="UL46h; MDV homologue of
UL46 of HSV-1"

/codon-start=1

/protein-id="AAA03151.1"

/db-xref="GI:388709"

/translation="MKRLSSSEQSLELFDRDSPQ
EYSCILPNELTVSASALRAEDSL

IEKLPSGLTLGIRESVLCETLSNKVPESVIVHLA

LGDVRGEYISLYSANVKRRLKRAA

LTPAVVKDYYTDSYQRYVCKRRRIPCVDLPGTRE

PARSTVALLFYPAIQRNPLTQKPF

RLQKDNKMFVKCWAIEWDALNFIQKYVYYMRPDE

ITTPSLDTSARLELLFGYVKTYLM

WAMWMDLLDTRIVSNKFGTRVPISIDNIFSNTL

EVMGSLSSDKWMSTALLCRSIEHL

LSSLIHISSLWTCCQWRETKHGEMLRPIVSIVAL

VSLHHHCQYIINITFNQYARWLE

GGLGNPMLRSAIRQQKRFHYLGGLFPSIRPTAW

GELEFSIRAWFELALAKSMVIHGS

LLKKSIVSNVLEPLCKPRHTQIGERHDTFRTRS

TSMPSGGHISTLQNNQQAIVPE

CSSGQLSSIATALWSADELQNDYVEMKGGVLCPA

PQPADSITPNSSQTNGTASDGSP

polyA-signal	7465..7470	TRVTDASLDPTEVESSTTVAETPPVTVAVESVYV CRETARNKSPSSKVERILRRLRVA TD" /note="terminator for UL49.5h, UL49h, UL48h, UL47h, and UL46h (7.8, 4.6, and 2.0 kb transcripts)"
polyA-signal terminator	complement(7491..7496) 7500..7507	/note="terminator for UL45h"
gene	complement(7504..8139)	/gene="UL45"
CDS	complement(7504..8139)	/gene="UL45" /note="UL45h; MDV homologue of UL45 of HSV-1" /codon-start=1 /protein-id="AAA03152.1" /db-xref="GI:388710" /translation="MMSPTPEDDRDLVVVRGLR MMDNGAEHDRRERSYTAWPHLCCG CTIGIILTMFVIATTLTLLASLFAFSYMSLES GTC PKEWIGLGYSCMRVAGNNATELEA LDMCAQHNSKLVDFTNAKTLVEAIVPFGST NASF GNIFRLRDSRSTCILPTIGGPISV DCPRTCSVVCQRPRLSTAASIIRDARIYLR LER RDYYEVYSSILSNAIMK"

SEQUENCE (SEQ):

1	ggatccggtta	acttttgcaa	aatgaccacg	taattctgag	gaacggcaac	tcgtattccg
61	atattcaatg	tacacgtttg	atattttg	tttaaattccg	atttcagtaa	cgagatcaca
121	caattgttgg	taacgcgaag	acaacgctga	tcacgctctt	ctatataaca	ggtccaaccg
181	tttgggttta	ctgcatataa	cgcttcacg	acacggaatt	gcagacgcca	gggaactggt
241	agtgcctcca	acgttatatt	ctccaaatca	cgatctcgac	gaggatggga	ctcatggaca
301	ttcataatgc	agtctgtagt	ttagttatcg	gcgttgctat	tttgattgcc	acttcgcaag
361	cgacgtttgt	cgattgggga	agttcaatca	caagtatggg	agatttttgg	gagtcctacgt
421	gttctgcagt	aggcgtgtca	atagcttttt	catctggggt	ttctgtgctg	ttttatatgg
481	gtctggtggc	ggtaatctcc	gccctcttag	cgggttcgta	tcacgcatgc	tttcgactat
541	tcaccgcaga	tatgtttaaa	gaggagtggg	aaattatgtg	ggcgtggaca	aatctcttat
601	ctcttcataa	gagatttggt	gactttgaac	caatattcat	atggtggaga	cgccacacgg
661	tacaatagaa	ggtgcacttg	ttcatatctt	actgtttaat	attatatctt	agttatcatg
721	ggggattctg	aaaggcggaa	atcggaaacg	cgtcgttccc	ttggatatcc	ctctgcatat
781	gatgacgtct	cgattcctgc	tcgcagacca	tcaacacgta	ctcagcgaaa	tttaaaccag
841	gatgatttgt	caaaacatgg	accatttacc	gaccatccaa	cacaaaaaca	taaatcggcg
901	aaagccgtat	cggaagacgt	ttcgtctacc	acccgggggtg	gctttacaaa	caaaccccgt
961	accaagcccg	gggtcagagc	tgtacaaagt	aataaattcg	ctttcagtac	ggctccttca
1021	tcagcatcta	gcacttgagg	atcaaataca	gtggcattta	atcagcgtat	gttttgcgga
1081	gcggttgcaa	ctgtggctca	atatcacgca	taccaaggcg	cgctcgcctt	ttggcgtcaa
1141	gattcctccg	gaacaaatga	agaattagat	gcatttcttt	ccagagctgt	cattaaaatt
1201	accattcaag	aggggtccaaa	tttgatgggg	gaagccgaaa	cctgtgcccg	caaactattg
1261	gaagagtctg	gattatccca	ggggaacgag	aacgtaaagt	ccaaatctga	acgtacaacc
1321	aatctgaac	gtacaagacg	cggcggtgaa	attgaaatca	aatcgccaga	tccgggatct
1381	catcgtagac	ataaccctcg	cactcccgcg	acttcgcgct	gccatcattc	atccgcccgc
1441	ggatatcgta	gcagtgatag	cgaataatgt	aacataggaa	cagccctact	actgcaagta
1501	agtcgtcttt	tatagacatg	cgaattaaaa	actagtacat	atatacttta	tctactcatt
1561	attgtatgat	tggaatggag	gcaaatatga	gttttgaaaa	cgattactac	agtcctatcc
1621	aattattcgc	tgaaattgag	gcgtatgcga	atactatgga	taagtccccg	gatcttgata
1681	tcctacgaac	aattgaagaa	tttgatgaaa	cgcttctctc	tgaaattgaa	gtcagaaccc
1741	aatctattcc	atcgccctctg	gttgctccgt	ctgttactaa	aatgtcactt	ccatccccat
1801	ctccagctcc	tcccaattct	ctctacacta	gactgttgca	tgagttggat	tttgtcgaag
1861	gcccgtctat	attagcacgt	ctggaaaaaa	taaatgtaga	tctattctca	tgtttccctc
1921	ataataacata	cttatatgaa	catgcaaaaa	ttttatctgt	atctccttcg	gaagtattgg
1981	aagagtgtgc	gaagaataca	tggacgtata	cggcttttaa	tttaaatagaa	catggagaga
2041	tggccctgcc	catgcctccc	acaacaaagg	ccgatttacc	ttcttatgta	gacgacatac
2101	aaaacttcta	tttgggagaa	ttagaagcaa	gggagaaatc	atatgctact	atgttttatg
2161	gatactgtcg	tgctctggca	gagtatatta	gacagtcggc	gattaaagat	cttcggggacg
2221	ctcgagtcga	agataaaaaa	attgggtgctg	gtagtaaagc	acgacaatac	atcgccgaaa
2281	ggattattcg	agaagcggca	aggtttgcca	agctcttata	tgtgcactta	tacctttcta
2341	ccacgcggga	tgtatcacag	cgacttcgaag	catctcaaat	gggacgacaa	aatatatttg
2401	tatatattgaa	atgcgaatgg	ttacaagaaa	gacactttca	ttgtttatct	caacctgtaa
2461	tttttaacca	tggcgtagtt	attgtcgaag	ggcgtgtttt	gactgctcct	gaactccggg
2521	ctcagaatta	tatacgttcc	gagttcggtc	ttcctcta	acgatgtaaa	ttagtagaag
2581	agcctgacat	gccgttgatc	tgcggccccc	cgttttcagg	tgatgctcct	cgggcatcag
2641	tatatattat	gcagtgattt	agatcaaagt	tggaaagtata	ttctctatca	caccccccta
2701	atccgcaatt	gcagtgtgcat	aaggaacatg	tacatgttca	aaagctagaa	tcaccgcaa
2761	actatggaac	tactgtcgaa	gcattgttga	tggactcttc	agacagaaat	tcaatttccc
2821	ctggtgatcc	tgttgccact	accatcagta	ctttataagg	aggtatttgt	ctattagtat
2881	gatggtgagt	tggcagaacg	aaactatact	taaatgatat	tatacgtaaa	tgtgacgttt
2941	aataaacgaa	tttgtcgtat	tgcgtttgtc	tttgtttctc	acgtcccatc	aatgatgtaa
3001	tattattgat	gcaattacac	ttccgcggtt	agatcaatac	attataaaac	ggcgtagttt

3061	tgataacagt	atgctggtag	cacattccac	cgaagaatgc	aaatgccttc	tatgcatcgg
3121	tatggacatc	ctgggtcaaaa	tcaacgacgg	gaaaaccaat	caatcagaaa	ttacttgtcg
3181	actagaagtg	gatcacgcaa	tcgtatatcg	cgaagtccgc	ataatatggc	gagtgtgtat
3241	acaagagcac	cggcgattgc	ctatgatgac	gatacatacg	atacgctaga	ggagagcgag
3301	gataatgggt	ttgtaaaaac	catttccta	gaggaacaat	ttgacaattc	acgggggagg
3361	gaccgtacac	gatctggcag	aagcaatggg	catagttttc	taggtttatc	ccgagatact
3421	ttcactgaga	ggcaaccttc	gggtcgctgc	ggtagtgata	catctcgtga	tatgattaat
3481	gcatcattaa	aatcgagagc	gaggtctaga	agacgctcgt	catctagacg	acgccatcgt
3541	aatgccagca	tgcataatgca	ttttcgtggg	ggttccagac	gatctgcaac	gggttctcaa
3601	aatttgataa	atcacgatag	acatagaaga	atatcccaat	ctagtctagg	atcgtctaga
3661	gaaggagaat	ataatcatgc	atcacgatca	agccgtgtta	gaaggcgcca	ccgtaggtca
3721	tcacgaaggc	gaggacctag	ggccgggtgg	cacggagatt	cttttacatc	cattactccc
3781	agtgaagtgc	cagaacatcc	aatatccgat	atcgatcaaa	aacggttacg	aaaaaactca
3841	gatacatcgt	ctcggggcac	tcgtgaattc	cccatagatg	atagttttgg	agaagacaat
3901	taccgattag	tttctcgcaa	tagggccact	tcaattttata	caaccccttc	tgctttatat
3961	actagaacag	agtcgctaaa	aacctataag	cgtaccactg	gtgatagtaa	aggtacgagt
4021	ccggcctttg	cctcctttct	cgagcataaa	acacttagcg	cagatgtcat	caaccacatt
4081	ccattattgc	gaatgttaga	atctgtgccc	agatccgagg	ctatacgtga	agatgaatta
4141	ttgtatatgt	ctgcaaaaac	tttcaaata	gtgtcacatt	ggatttccaa	cagccggcca
4201	gattatgcca	atgggaagat	gtactattcc	ccccgcctg	agaatgctct	cgcttggaag
4261	cggaccgcga	aacaggccca	tgctcttatt	ctccatttag	gcagagattc	cttaagaagt
4321	tctgtaaatg	cattgctgta	gttgaatcaa	agcaatgcag	ttttattttt	acttaattcc
4381	tgtttaaaaa	tagcaatttg	tatacataaa	aataaaatgc	ataaatatgg	aaatgtaaaa
4441	atattatcca	caatgccaca	cgttcggaaa	ggtgatgctc	aaatattcga	aaatagtact
4501	atacatacca	tgcgagaccc	tatggcttcg	gctgcacgag	cttcctatgg	atcgcttgcg
4561	tattggccag	agcttcgctg	tgcatattgg	tctgagaaca	aacgaattgt	acgatatgcc
4621	attgtggcta	tggtgcaagc	agaaatatat	ctactttaca	ggatctcttc	ccaaagagtg
4681	tcaatgaata	agagtgaact	tagaatttta	tcctcgtgca	ttacgatgga	atgtgtggca
4741	gcatgtatag	ctgtgcaatt	tctatacact	tccttatggc	aaatacttta	cagttctaaa
4801	atcaatcgtg	aatacatatg	gctgaaaact	gccagcgaga	gaagtaaaaa	gttaccaatg
4861	gcaagtacgg	atctccttta	tgcaaggggg	gcctgccttg	ggagggttaga	gtcatctctg
4921	tatggtagac	agggtacacc	tctagggaga	acacttgtag	aagcgtatct	tgccacaaga
4981	tctgcattta	cggagttaat	atatgagttt	caatcaaaaca	gtgattttatt	tctagagaag
5041	cagaatgtca	agctgggaga	aaaattaacc	gctgccgtga	ttgctgcaac	tggtgtctta
5101	cagcgtttgc	tcggccattt	aaatatcatt	atcgcgcgaga	tggttattgg	atctgtatat
5161	cacaaaaaag	acgtggatgt	ttggtcagag	acattcaaga	tgtatcaata	tctatcgtat
5221	gtctgtaaaa	gtttatatag	accagtgacc	attgatgaat	acataaatga	ccgtgatgat
5281	actatggagt	atttaacact	tgaatttgca	cgaggcgatc	cacctactgg	catggcatca
5341	gtgattttatg	aagatgaaaa	aagtgaagaa	ctagaatctt	tgaaacttgt	accccgcccg
5401	attaatttatg	acattctagg	taatttagtt	cctttacgga	atgcgataga	agatgcgagt
5461	gatgtgatat	tcgagaaaag	agccgctcga	accgcccgcg	gtgagccaca	acgggcgaat
5521	tgacgtaggg	aagagggcgg	gacttttact	ccggatgtag	aataatggca	tttaagagtg
5581	gtacatgttt	aaaaccggga	ctcttgcaag	atcctgtact	atatttcagt	tttctctgta
5641	gtgtgtccat	ccatatgggt	tataatgaag	cggtcagct	cttctgaaca	gtcgttgga
5701	ctgtttgacc	gagattcgcc	acaagaatat	tcatgtatat	tacccaacga	attaactgta
5761	tctgcgtctg	cattaagagc	tcttgaggat	agccttatag	agaagttgcc	atccgggttg
5821	acattgggta	taagggaatc	ggtattgtgt	gaaactcttt	ccaataaggt	tccagaatct
5881	gttattgttc	atcttgcggt	gggagatgtt	agaggagagt	atatatccct	atacagcgca
5941	aatgtgaaac	gcagattgaa	acgggcggcg	ttgacacctg	cgggtggtaa	agactactac
6001	acagactcgt	atcagcgcta	tgtctgtaag	cggcggcgta	tacctgtgtg	tgatctcccg
6061	ggaactcgtg	aacctgccag	atccaccgtt	gcgttgctat	tttatccagc	tatacaacga
6121	aatcccttta	cacaaaaacc	atttcggctt	caaaaagata	acaaaatggt	cgtaaaatgc
6181	tgggcggaaa	tatgggatgc	gttaaaat	attcagaagt	atgtgtatta	tatgagacct
6241	gacgaaataa	caacacctag	tctcgatact	tccgctcgac	tggagttgtt	atttggttat
6301	gtgaagacac	tgtacatgtg	ggcaatgtgg	ttaatggact	tgctagatac	gcgaattgtt
6361	tctaacaaat	tcggcacccg	cgtacctatc	agcattgata	atataatttc	aaatcttact
6421	gaggttatgg	gttcgttatc	gtcagataag	tggatgagca	ctgcattgct	ctgtcgctcc
6481	atagaacacc	ttttgtcttc	acttatccat	attagttctc	tgtggacatg	ttgtcaatgg
6541	cgcgaaacca	aacatggaga	aatgttgctg	cctatagtta	gcattgtcgc	gttgggttct
6601	ctcttgacc	atcactgtca	atataattatc	aatattactt	ttaatggata	tgcaagatgg
6661	ttggaggggg	gtttgggtaa	tcctatgtta	agatcggcaa	ttcgacaaca	aaaacggttt
6721	gaacattatt	tgggaggact	tttcccattc	attcgcccca	cggcatgggg	agaacttgaa
6781	tttagcatca	gagcatgggt	tgaacttgca	ttagccaagt	caatggtaat	tcacggctct
6841	ttactcaaaa	agtccattgt	gagcaataat	gtccttgaac	ctttatgtaa	accaaggcat
6901	actcaaattg	gagaaaggca	tgataacgag	tttacacgat	ctaccagcat	gccgtcttct
6961	tcgggacata	tacacagtac	attacagaat	aatcaacaag	cgattgttcc	tgagtgttct
7021	tcgggacaac	tatcttcaat	cgctaccgct	ttgtggctcag	cggacgaact	ccaaaacgat
7081	tacgtggaaa	tgaaagggtg	agttttatgt	ccagccccac	agccagctga	ctcgatcact
7141	ccaaattcca	gtcaaaacaa	taatgggaca	gcttcagacg	gttctccaac	gagagtgacc
7201	gatgcgtccc	tcgatccaac	cgaagtgtga	tcatacaacta	cagttagctga	gacaccgcct
7261	gttacagtgg	ccgtcgcaatc	ggatatgtga	tcgagagaaa	ccgcacgaaa	caaatctcca
7321	tcatccaaag	tggaaacgaat	attgcgtagg	ttgaggggtg	ctaccgattg	atactatgtt
7381	caaacatata	tgtttttatc	tttagcgtaa	cgatttgtcc	caaacatgta	taccctttca
7441	cctttcatgc	tcgattatta	aagaaataaa	gaaccgcttt	aagaatagtg	tttatttttg
7501	tgtttatttc	ataattgctg	tcgagagaa	ggaactgtaa	acttcgtagt	aatcgcgctg
7561	ttctaaacga	agatagatac	gagcatctct	gattatagaa	gccgcgggtac	ttaatggctg


```

7621 ggggcggttg catacaacgc tgcattgtcct tggacaatcg accgatataag gacctccaat
7681 ggtgggtagt atacaggtag atctactgtc ccgtagtcta aatatatttc caaaggaagc
7741 attcgtggag ccgaatggga caattgcttc aaccaatgtt tttgcgttag taaaatctac
7801 gagtttactg ttatgctggg cacacatatc taatgcctcg agttctgtag cattgtttcc
7861 agccacgcgc atgcaactgt accctaattc aatccattcc ttagggcatg ttcccgaactc
7921 tagagacatg tacgagaatg caaacaatga tgctaataat aacgttgctg cgatgacgaa
7981 catagttaag ataattccga tggtagatcc acaacacaaa tggggccatg cgggtgatga
8041 tcgccgttct cgtatcattg cggcaccgtt atccatcatt cggagacgct cacgtactac
8101 cactaaatcg cgtatcctct cgggtgtagg cgacatcatt cttatagcat catgtctatg
8161 gagtacattc gtggttatat ttctgagtaa ctatatacga tcatatttag cgattgtacg
8221 gtatgcatgt tcgtattcga tttgtaaaat tgttatcgac gtattttgctg gtgggggccc
8281 gatccgtgca actcttttgt cataggttgg gaaactttcg atacttattt ttcccatatg
8341 acccgtaagt ctaatgcact atatcgaaag gtactgatag agtgtggctg gatgcaatga
8401 caaaactaat attcatagaa acgatatgaa ttc

```

L3 ANSWER 133 OF 199 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): ADECP GenBank (R)
GenBank ACC. NO. (GBN): M81775 M81776 M81777
GenBank VERSION (VER): M81775.1 GI:209738
CAS REGISTRY NO. (RN): 140600-01-7
SEQUENCE LENGTH (SQL): 1096
MOLECULE TYPE (CI): ss; RNA; linear
DIVISION CODE (CI): Viruses
DATE (DATE): 27 Apr 1993
DEFINITION (DEF): Andean potato mottle virus coat protein (***VP22***) mRNA, 3' end.
SOURCE: Andean potato mottle virus cDNA to genomic RNA.
ORGANISM (ORGN): Andean potato mottle virus
Viruses; ssRNA positive-strand viruses, no DNA stage;
Comoviridae; Comovirus
NUCLEIC ACID COUNT (NA): 304 a 161 c 240 g 391 t
REFERENCE: 1 (bases 1 to 1096)
AUTHOR (AU): Shindo,N.; Krengiel,R.; Brioso,P.S.; Vicente,A.C.;
Weyne,M.; de Oliveira,D.E.; Timmerman,B.
TITLE (TI): Complete nucleotide sequence of the 22 kDa coat protein
of Andean potato mottle virus
JOURNAL (SO): Plant Mol. Biol., 19 (3), 505-507 (***1992***)
OTHER SOURCE (OS): CA 118:249964

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..1096	/organism="Andean potato mottle virus" /db-xref="taxon:12259"
gene	1..594	/gene="VP22"
CDS	1..594	/partial /gene="VP22" /codon-start=1 /product="coat protein" /protein-id="AAA42420.1" /db-xref="GI:209739" /translation="FCSPCINWSEFCALDIPVV DTTKVNFAQYSLDLVNPTVSANAS GRNWRFLVLPSPMVYLLQTSWKRGLHFKLKIL GKSNVVRSEWSSTSRIDVRRAPGT EYLNATVFTAEHPHADEINFEIEICGPNNGFEMW NADFGNQLSWMANVVGNDQAGI HQWYVRPGENFEVAGNRMVQPLALSGEDGTGMLP ILK"

SEQUENCE (SEQ):

```

1 tttttagtgc catgtataaa tgtttggagt gagttttgtg cattagatat tcctgtttgtg
61 gacacaacta aggttaattt tgcccaatat tctctggatc ttgtgaatcc aacagtttct
121 gcaaatgcct ctgggcgtaa ttggagggtt gttcttatac cttctcccat ggtgtattta
181 cttcaaactt cagactggaa aagaggaaag ttgcatttta agcttaaaat actggggaaa
241 tccaatgtta aacgatctga atggagtagc acaagcagga tagatgtgag aagagcacct
301 ggtacagagt atttaaatgc tatcactgtt ttcactgctg agccacatgc agatgagata
361 aattttgaaa tagaaatttg tgggccaaac aacggatttg agatgtggaa tgctgatttt
421 ggaaaccaat tgtcttggat ggcaaatgtt gttattggaa atcctgatca agcgggtata
481 catcaatggg atgttaggcc aggagaaaat tttgaggttg caggaaatag gatgggtcaa
541 cctctagcgc tttctgggga ggatggtact ggtatgcttc caatactaaa gtagccaata
601 aatttggatt tgtgcgtgtt cttcttgaga aacgctctgg tgtgcattca ccacctagga
661 gctaggactc tgggttttaa tgcaaatgtt ttttaatttg ttatttaaat ggtttgcttt
721 aatttaagta gtcgtaatcg tttatctgga attttaacaa gtttttacgt tactgagctt

```


781 ctgcccttgt aagaacactt gtgtaaattt gtagtttata aactctagtt tgtatttctg
841 gatttgtgcg tgttccttct gagaaacgct ctggtgtgca ttcaccacct aggaggtagg
901 actctgggtt tcaatgcaaa ctgtttttta ttttgttact taaatagttt gcttttagttc
961 aagtaattat gatcgtttat ttggaatttc ataagttctt gcgtttctga gcttctgccc
1021 ttgtaagaac acttgtgtaa atttgtagtt tacaaacttt ggtttgcatt tgtgttttaa
1081 aaaaaaaaaa aaaaaa

L3 ANSWER 134 OF 199 LIFESCI COPYRIGHT 2004 CSA on STN
AN 2000:9036 LIFESCI
TI Protein therapy - delivery guaranteed
AU Bayley, H.
CS Department of medical biochemistry and genetics at the Texas A&M Health
Science Center, College Station, TX 77843-1114, USA; E-mail:
bayley@tamu.edu
SO Nature Biotechnology [Nat. Biotechnol.], (***19991100***) vol. 17, no.
11, pp. 1066-1067.
ISSN: 1087-0156.
DT Journal
TC General Review
FS W3
LA English

L3 ANSWER 135 OF 199 LIFESCI COPYRIGHT 2004 CSA on STN
AN 1998:92608 LIFESCI
TI Herpes simplex virus type 1 tegument protein ***VP22*** induces the
stabilization and hyperacetylation of microtubules
AU Elliott, G.; O'Hare, P.
CS Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 0TL, United
Kingdom.
SO J. Virol., (***19980800***) vol. 72, no. 8, pp. 6406-6413.
ISSN: 0022-538X.
DT Journal
FS V
LA English
SL English

L3 ANSWER 136 OF 199 MEDLINE on STN
AN 2000008734 MEDLINE
DN PubMed ID: 10543389
TI Can ***VP22*** resurrect gene therapy?
CM Comment on: J Mol Med. 1999 Aug;77(8):609-13. PubMed ID: 10543392
AU Luft F C
CS Franz-Volhard-Klinik, Humboldt University of Berlin, Berlin-Buch,
Germany.. luft@fvk-berlin.de
SO Journal of molecular medicine (Berlin, Germany), *** (1999 Aug) *** 77
(8) 575-6.
Journal code: 9504370. ISSN: 0946-2716.
CY GERMANY: Germany, Federal Republic of
DT Commentary
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199911
ED Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991118

L3 ANSWER 137 OF 199 MEDLINE on STN
AN 97414190 MEDLINE
DN PubMed ID: 9269047
TI Study of immunogenicity and virulence of bovine herpesvirus 1 mutants
deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in cattle.
AU Liang X; Chow B; Babiuk L A
CS Veterinary Infectious Disease Organization, University of Saskatchewan,
Saskatoon, Canada.
SO Vaccine, *** (1997 Jul) *** 15 (10) 1057-64.
Journal code: 8406899. ISSN: 0264-410X.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199710
ED Entered STN: 19971105
Last Updated on STN: 20020926
Entered Medline: 19971020

L3 ANSWER 138 OF 199 MEDLINE on STN
AN 95264482 MEDLINE
DN PubMed ID: 7745736
TI Characterization of bovine herpesvirus 1 UL49 homolog gene and product:
bovine herpesvirus 1 UL49 homolog is dispensable for virus growth.
AU Liang X; Chow B; Li Y; Raggo C; Yoo D; Attah-Poku S; Babiuk L A
CS Veterinary Infectious Diseases Organization, University of Saskatchewan,
Saskatoon, Canada.
SO Journal of virology, *** (1995 Jun)*** 69 (6) 3863-7.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-U21137
EM 199506
ED Entered STN: 19950621
Last Updated on STN: 19950621
Entered Medline: 19950613

L3 ANSWER 139 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1646911 PHARMAML
TI Cantab making "significant progress"
SO Marketletter May 20, 1999
DT Newsletter
WC 221

L3 ANSWER 140 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1644751 PHARMAML
TI Cantab On Track To Being A Fully Integrated Company
SO Marketletter December 3, 1998
DT Newsletter
WC 1651

L3 ANSWER 141 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1644315 PHARMAML
TI UK Biotech Firms Back In Vogue With Investors?
SO Marketletter November 5, 1998
DT Newsletter
WC 1448

L3 ANSWER 142 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1641854 PHARMAML
TI Cantab Reports Solid Progress During 1st Qtr
SO Marketletter May 28, 1998
DT Newsletter
WC 237

L3 ANSWER 143 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1641682 PHARMAML
TI Stock Commentary Europe
SO Marketletter May 14, 1998
DT Newsletter
WC 337

L3 ANSWER 144 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1641505 PHARMAML
TI Phogen Signs First Commercial Deal
SO Marketletter April 30, 1998
DT Newsletter
WC 59

L3 ANSWER 145 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1636166 PHARMAML
TI Cantab And Marie Curie Cancer Care Form New Biotech Company; Cantab
Shares
SO Marketletter March 10, 1997
DT Newsletter
WC 55

L3 ANSWER 146 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1635838 PHARMAML
TI New Discovery At Marie Curie Research Institute
SO Marketletter February 10, 1997
DT Newsletter
WC 57

L3 ANSWER 147 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1999:19715 PHIN
DN S00644158
DED 17 Nov 1999
TI Cantab ahead of budget at nine months
SO Scrip (***1999***) No. 2490 p15
DT Newsletter
FS FULL

L3 ANSWER 148 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1999:9623 PHIN
DN S00623580
DED 26 May 1999
TI Phogen joint venture to receive more funding
SO Scrip (***1999***) No. 2440 p14
DT Newsletter
FS FULL

L3 ANSWER 149 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1999:2652 PHIN
DN S00609030
DED 22 Jan 1999
TI New gene therapy techniques
SO Scrip (***1999***) No. 2405 p22
DT Newsletter
FS FULL

L3 ANSWER 150 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:15871 PHIN
DN B00592838
DED 1 Jul 1998
TI ReqMed Co.: Japanese Entrepreneurial Spirit Takes a First Step
SO Bioventure-View (***1998***) No. 1307 p18
DT Newsletter
FS FULL

L3 ANSWER 151 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:11262 PHIN
DN B00583792
DED 1 Jun 1998
TI Research and Clinical Progress: Phogen Ltd
SO Bioventure-View (***1998***) No. 1406 p30
DT Newsletter
FS FULL

L3 ANSWER 152 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:9688 PHIN
DN S00580586
DED 15 May 1998
TI Cantab's ***VP22*** shows early promise
SO Scrip (***1998***) No. 2335 p29
DT Newsletter
FS FULL

L3 ANSWER 153 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:13839 PHIN
DN B00546118
DED 1 Jul 1997
TI Biotech's Transatlantic Challenge BVV's Eurotour Continues
SO Bioventure-View (***1997***) No. 1207 p4
DT Newsletter
FS FULL

L3 ANSWER 154 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:8845 PHIN
DN B00535906
DED 1 Apr 1997

TI Agreements - Cantab Pharmaceuticals
SO Bioventure-View (***1997***) No. 1204 p18
DT Newsletter
FS BRIEF

L3 ANSWER 155 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:8623 PHIN
DN S00536364
DED 9 May 1997
TI PHARMAPROJECTS - New Formulations for week ending 2 May 1997
SO Scrip-Online-plus (***1997***)
DT Newsletter
FS FULL

L3 ANSWER 156 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:5606 PHIN
DN S00528886
DED 11 Mar 1997
TI Cantab Pharmaceuticals teams up with UK cancer charity
SO Scrip (***1997***) No. 2213 p10
DT Newsletter
FS FULL

L3 ANSWER 157 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:3906 PHIN
DN S00526786
DED 25 Feb 1997
TI Gene therapy update
SO Scrip (***1997***) No. 2209 p23
DT Newsletter
FS FULL

L3 ANSWER 158 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:732888 PROMT
TITLE: Cantab Reports Third Quarter Financial Results Ahead of Budget.
SOURCE: PR Newswire, (***10 Nov 1999***) pp. 1097.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1841
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 159 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:399865 PROMT
TITLE: Enhancement of Mucosal Immune Responses to HIV Gp160.
SOURCE: Vaccine Weekly, (***14 Jun 1999***) .
ISSN: 1074-2921.
PUBLISHER: Charles W. Henderson
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 417
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 160 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:340020 PROMT
TITLE: Cantab making "significant progress".
SOURCE: Marketletter, (***24 May 1999***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 228
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 161 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:331352 PROMT
TITLE: Phogen Receives Extended Funding to Continue Drug Delivery Program.

SOURCE: PR Newswire, (***20 May 1999***) pp. 4072.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 936
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 162 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:331351 PROMT
TITLE: Cantab Pharmaceuticals Reports First Quarter Financial Results and Significant Progress in Key Development Programs.
SOURCE: PR Newswire, (***20 May 1999***) pp. 4071.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1541
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 163 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:141589 PROMT
TITLE: Cantab Reports 1998 Fourth Quarter and Year End Financial Results and Corporate Review of Progress.
SOURCE: PR Newswire, (***9 Mar 1999***) pp. 1400.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1986
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 164 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:633293 PROMT
TITLE: Cantab On Track To Being A Fully Integrated Company.
SOURCE: Marketletter, (***7 Dec 1998***) pp. NA.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 1655
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 165 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:591203 PROMT
TITLE: Cantab Reports Third Quarter Financial Results - Company makes progress in key clinical programs -.
SOURCE: PR Newswire, (***12 Nov 1998***) pp. 1402.
LANGUAGE: English
WORD COUNT: 1591
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 166 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:577595 PROMT
TITLE: UK Biotech Firms Back In Vogue With Investors?
SOURCE: Marketletter, (***9 Nov 1998***) pp. NA.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 1444
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 167 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:497629 PROMT
TITLE: Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Herpes Lesions.
SOURCE: Vaccine Weekly, (***21 sep 1998***) pp. NA.
ISSN: 1074-2921.
LANGUAGE: English
WORD COUNT: 289
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 168 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:451675 PROMT
TITLE: Joined for strength
SOURCE: Med Ad News, (***Aug 1998***) pp. 26.
ISSN: 0745-0907.
LANGUAGE: English
WORD COUNT: 3198
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 169 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:382725 PROMT
TITLE: New Faces, New Names
SOURCE: BioPharm, (***Jul 1998***) pp. 10.
ISSN: 1040-8304.
LANGUAGE: English
WORD COUNT: 154
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 170 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:295529 PROMT
TITLE: Delivering p53 with Herpesvirus Protein
SOURCE: Applied Genetics News, (***1 Jun 1998***) pp. N/A.
ISSN: 0271-7107.
LANGUAGE: English
WORD COUNT: 334
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 171 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:264243 PROMT
TITLE: drug delivery system, ***VP22*** herpesvirus protein
Phogen preclinical data
Preclinical results of Phogen's treatment reported
SOURCE: R & D Focus Drug News, (***25 May 1998***) pp. N/A.
ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 196
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 172 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:262791 PROMT
TITLE: Cantab Reports Solid Progress During 1st Qtr
SOURCE: Marketletter, (***1 Jun 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 248
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 173 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:237169 PROMT
TITLE: Stock Commentary Europe
SOURCE: Marketletter, (***18 May 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 337
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 174 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:237110 PROMT
TITLE: Phogen Signs First Commercial Deal
SOURCE: Marketletter, (***4 May 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 59
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 175 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:208184 PROMT
TITLE: Phogen and Invitrogen Collaborate to Market ***VP22***
Reagents
SOURCE: PR Newswire, (***27 Apr 1998***) pp. 0427NYM008.

LANGUAGE: English
WORD COUNT: 806
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 176 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:175690 PROMT
TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :Cantab-Reports Year-End
Results - A Year Of Solid Progress
SOURCE: BioAccess, (***1 Apr 1998***) pp. N/A.
ISSN: 1356-3432.
LANGUAGE: English
WORD COUNT: 681
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 177 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:109999 PROMT
TITLE: Cantab Pharmaceuticals Reports Year-End Results; Company
Turns in a Year of Solid Progress Across All Business Areas
SOURCE: PR Newswire, (***2 Mar 1998***) pp. 0302NYM022.
LANGUAGE: English
WORD COUNT: 1474
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 178 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:496714 PROMT
TITLE: Biotech's Transatlantic Challenge (PART 1)
SOURCE: BioVenture View, (***1 Aug 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 2338
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 179 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:355215 PROMT
TITLE: Biotech's Transatlantic Challenge --BWV's Eurotour
Continues-Part 1
SOURCE: BioVenture View, (***1 Jul 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 4781
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 180 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:198204 PROMT
TITLE: Phogen JV exposes potential of herpesvirus drug delivery.
This biotech co formed to develop new drug delivery means
using ***VP22*** herpesvirus protein tech
SOURCE: Genetic Engineering News, (***15 Mar 1997***) pp. 4.
ISSN: 0270-6377.
LANGUAGE: English

L3 ANSWER 181 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:190488 PROMT
TITLE: Corporate Agreements:Cantab Pharmaceuticals plc
SOURCE: BioVenture View, (***1 Apr 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 153
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 182 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:166243 PROMT
TITLE: Cantab Pharmaceuticals Reports Fourth Quarter Results
SOURCE: PR Newswire, (***19 Mar 1997***) pp. 0319NYW026.
LANGUAGE: English
WORD COUNT: 1474
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 183 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:158009 PROMT
TITLE: Cantab joins forces with MCCC to form biotech company
SOURCE: Pharmaceutical Business News, (***12 Mar 1997***) pp.
N/A.
ISSN: 0956-0661.
LANGUAGE: English
WORD COUNT: 511
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 184 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:147009 PROMT
TITLE: Industry News (Joint Venture) New Company To Develop Drug
Delivery Technology Against Disease
SOURCE: Disease Weekly Plus, (***10 Mar 1997***) pp. N/A.
LANGUAGE: English
WORD COUNT: 617
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 185 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:135685 PROMT
TITLE: Industry News (Joint Venture) New Company To Develop Drug
Delivery Technology Against Disease
SOURCE: Cancer Weekly Plus, (***10 Mar 1997***) pp. N/A.
LANGUAGE: English
WORD COUNT: 617
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 186 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:122260 PROMT
TITLE: Cantab Pharmaceuticals and Marie Curie Cancer Care Form New
Biotechnology Company to Develop Drug Delivery Technology
SOURCE: PR Newswire, (***27 Feb 1997***) pp. 0227NYTH010.
LANGUAGE: English
WORD COUNT: 989
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 187 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:75700 PROMT
TITLE: New Discovery At Marie Curie Research Institute
SOURCE: Marketletter, (***10 Feb 1997***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 56
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 188 OF 199 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN

AN 1999:763858 SCISEARCH
GA The Genuine Article (R) Number: 226QX
TI Preliminary structural characterization of ***VP22*** , a protein
expressing novel intercellular trafficking activity
AU Kuelto L (Reprint); OHare P; Middaugh C R
CS UNIV KANSAS, DEPT PHARMACEUT CHEM, LAWRENCE, KS 66047; MARIE CURIE RES
INST, SURREY RH8 0TL, ENGLAND
CYA USA; ENGLAND
SO FASEB JOURNAL, (***23 APR 1999***) Vol. 13, No. 7, Supp. [S], pp.
A1393-A1393.
Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD
20814-3998.
ISSN: 0892-6638.
DT Conference; Journal
FS LIFE
LA English
REC Reference Count: 0

L3 ANSWER 189 OF 199 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN

AN 1999:137239 SCISEARCH
GA The Genuine Article (R) Number: 165CH
TI European drug news - In vivo potential for ***VP22*** in gene therapy
shown

AU Fox S
SO GENETIC ENGINEERING NEWS, (***1 FEB 1999***) Vol. 19, No. 3, pp. 20-&.
Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY
10538.
ISSN: 0270-6377.
DT Article; Journal
LA English
REC Reference Count: 0

L3 ANSWER 190 OF 199 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN

AN 1998:312179 SCISEARCH
GA The Genuine Article (R) Number: ZH354
TI C-type lectin-like receptors in peptide-specific HLA class I-restricted
cytotoxic T lymphocytes: differential expression and modulation of
effector functions in clones sharing identical TCR structure and epitope
specificity

AU Noppen C (Reprint); Schaefer C; Zajac P; Schutz A; Kocher T; Kloth J;
Heberer M; Colonna M; DeLibero G; Spagnoli G C
CS UNIV BASEL, DEPT SURG, DIV RES, HEBELSTR 20, CH-4031 BASEL, SWITZERLAND
(Reprint); BASEL INST IMMUNOL, BASEL, SWITZERLAND; UNIV BASEL, DEPT RES,
BASEL, SWITZERLAND

CYA SWITZERLAND
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (***APR 1998***) Vol. 28, No. 4, pp.
1134-1142.
Publisher: VCH PUBLISHERS INC, 303 NW 12TH AVE, DEERFIELD BEACH, FL
33442-1788.
ISSN: 0014-2980.

DT Article; Journal
FS LIFE
LA English
REC Reference Count: 29

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 191 OF 199 USPATFULL on STN

AN 2004:129601 USPATFULL

TI Nucleic acid transfer phage

IN Akuta, Teruo, Kumamoto, JAPAN

Yokoi, Haruhiko, Tokyo, JAPAN

Okuyama, Hajime, Hyogo, JAPAN

Takeda, Katsuo, late of Tokyo, JAPAN deceased

Eiko Takeda, United States legal representative

Hasegawa, Mamoru, Ibaraki, JAPAN

Nakanishi, Mahito, Osaka, JAPAN

PA Dनावेक Research, Inc., JAPAN (non-U.S. corporation)

PI US 6740524 B1 20040525

WO 9966061 19991223

<--

AI US 2001-720003 20010904 (9)

WO 1999-JP3272 19990618

PRAI JP 1998-189845 19980618

DT Utility

FS GRANTED

LN.CNT 887

INCL INCLM: 435/456.000

INCLS: 530/350.000; 435/320.100; 435/252.300; 435/252.330; 435/235.100;
435/069.700; 435/975.000; 536/023.400

NCL NCLM: 435/456.000

NCLS: 435/069.700; 435/235.100; 435/252.300; 435/252.330; 435/320.100;
435/975.000; 530/350.000; 536/023.400

IC [7]

ICM: C12N015-86

ICS: C12N015-62; C12N001-21; C12N005-10; C07K019-00

EXF 530/350; 435/235.1; 435/320.1; 435/252.33; 435/456; 435/69.7; 435/975;
536/23.4; 424/93.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 192 OF 199 USPATFULL on STN

AN 2003:228405 USPATFULL

TI Promoter for telomerase reverse transcriptase

IN Morin, Gregg B., Davis, CA, United States

Andrews, William H., Richmond, CA, United States

PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

PI US 6610839 B1 20030826

WO 9814593 19980409

<--

AI US 1999-402181 19990929 (9)

WO 1997-US17885 19971001

RLI Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997
Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997,
now abandoned Continuation-in-part of Ser. No. US 1997-915503, filed on
14 Aug 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 10430
INCL INCLM: 536/024.100
INCLS: 435/194.000; 435/320.100
NCL NCLM: 536/024.100
NCLS: 435/194.000; 435/320.100
IC [7]
ICM: C07H021-04
ICS: C12N009-12; C12N015-00
EXF 435/194; 435/320.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 193 OF 199 USPATFULL on STN
AN 1998:59111 USPATFULL
TI Programming which can make threshold voltages of programmed memory cells
have a narrow distribution in a nonvolatile semiconductor memory
IN Takeshima, Toshio, Tokyo, Japan
Sugawara, Hiroshi, Tokyo, Japan
PA NEC Corporation, Tokyo, Japan (non-U.S. corporation)
PI US 5757699 19980526 <--
AI US 1997-862965 19970603 (8)
PRAI JP 1996-140497 19960603
DT Utility
FS Granted
LN.CNT 817
INCL INCLM: 365/185.240
INCLS: 365/185.220; 365/185.190; 365/185.030
NCL NCLM: 365/185.240
NCLS: 365/185.030; 365/185.190; 365/185.220
IC [6]
ICM: G11C007-00
EXF 365/185.24; 365/185.21; 365/185.19; 365/185.03

L3 ANSWER 194 OF 199 USPATFULL on STN
AN 97:25432 USPATFULL
TI Display apparatus
IN Kawaguchi, Takafumi, Yamatotakada, Japan
Tomiyoshi, Akira, Nara, Japan
Takeda, Makoto, Nara, Japan
PA Sharp Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)
PI US 5614922 19970325 <--
AI US 1995-414717 19950331 (8)
PRAI JP 1994-66145 19940404
DT Utility
FS Granted
LN.CNT 1311
INCL INCLM: 345/089.000
INCLS: 345/094.000; 345/100.000
NCL NCLM: 345/089.000
NCLS: 345/094.000; 345/100.000
IC [6]
ICM: G09G003-36
EXF 345/87; 345/89; 345/94; 345/99; 345/100; 345/150; 345/208; 345/211;
359/55; 359/56

L3 ANSWER 195 OF 199 USPATFULL on STN
AN 94:29081 USPATFULL
TI Semiconductor IC device having sense amplifier circuit
IN Kawahara, Takayuki, Kokubunji, Japan
Akiba, Takesada, Kokubunji, Japan
Kitsukawa, Goro, Tokyo, Japan
Kawajiri, Yoshiki, Akishima, Japan
Itoh, Kiyoo, Higashikurume, Japan
Sakata, Takeshi, Kunitachi, Japan
PA Hitachi, Ltd., Tokyo, Japan (non-U.S. corporation)
Hitachi Device Engineering Co., Ltd., Mobara, Japan (non-U.S.
corporation)
PI US 5300839 19940405 <--
AI US 1992-865852 19920409 (7)
PRAI JP 1991-82228 19910415
JP 1992-11727 19920127

DT Utility
FS Granted
LN.CNT 1031
INCL INCLM: 307/530.000
INCLS: 365/203.000
NCL NCLM: 327/052.000
NCLS: 365/203.000; 365/208.000
IC [5]
ICM: G11C007-06
EXF 307/247.1; 307/350; 307/530; 365/189.06; 365/203; 365/205; 365/208

L3 ANSWER 196 OF 199 USPATFULL on STN
AN 91:55132 USPATFULL
TI Image forming apparatus with AC bias voltages for preventing developer mixture
IN Tajima, Hatsu, Matsudo, Japan
Kobayashi, Yoshiaki, Tokyo, Japan
PA Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)
PI US 5030996 19910709 <--
AI US 1990-574893 19900830 (7)
PRAI JP 1989-223196 19890831
DT Utility
FS Granted
LN.CNT 758
INCL INCLM: 355/246.000
INCLS: 118/645.000; 355/326.000
NCL NCLM: 399/232.000
NCLS: 399/270.000
IC [5]
ICM: G03G021-00
EXF 355/246; 355/214; 355/326; 355/327; 355/328; 355/261; 355/265; 355/266;
118/645; 118/647; 118/651; 118/653; 346/157

L3 ANSWER 197 OF 199 USPATFULL on STN
AN 79:17060 USPATFULL
TI Two-color electrostatic printing apparatus
IN Yamauchi, Mineo, Musashino, Japan
Sumi, Akira, Musashino, Japan
PA Yokogawa Electric Works, Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 4148043 19790403 <--
AI US 1977-782095 19770328 (5)
PRAI JP 1976-35640 19760331
DT Utility
FS Granted
LN.CNT 853
INCL INCLM: 346/157.000
INCLS: 346/154.000
NCL NCLM: 347/115.000
NCLS: 347/142.000
IC [2]
ICM: G03G015-02
EXF 346/157; 346/153; 346/154; 355/14

L3 ANSWER 198 OF 199 USPATFULL on STN
AN 77:17043 USPATFULL
TI Process for polymerizing tetrafluoroethylene in aqueous dispersion
IN Holmes, David Alan, Vienna, WV, United States
PA E. I. Du Pont de Nemours and Company, Wilmington, DE, United States
(U.S. corporation)
PI US 4016345 19770405 <--
AI US 1976-670075 19760324 (5)
RLI Continuation-in-part of Ser. No. US 1972-317804, filed on 22 Dec 1972,
now abandoned
DT Utility
FS Granted
LN.CNT 590
INCL INCLM: 526/206.000
INCLS: 526/255.000
NCL NCLM: 526/206.000
NCLS: 526/255.000
IC [2]
ICM: C08F014-26
EXF 526/229; 526/255; 526/206
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 199 OF 199 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

AN 1991-067287 [10] WPIDS
DNN N1991-052055
TI Colour image forming appts. - has image bearing element toner developer
and developing bias voltage applying device.
DC P84 S06
IN KOBAYASHI, Y; TAJIMA, H
PA (CANO) CANON KK
CYC 5
PI EP 415753 A 19910306 (199110)* <--
R: DE FR GB IT
US 5030996 A 19910709 (199130) <--
EP 415753 B1 19931201 (199348) EN 18 G03G015-01 <--
R: DE FR GB IT
DE 69004896 E 19940113 (199403) G03G015-01 <--
ADT EP 415753 A EP 1990-309486 19900830; US 5030996 A US 1990-574893 19900830;
EP 415753 B1 EP 1990-309486 19900830; DE 69004896 E DE 1990-604896
19900830, EP 1990-309486 19900830
FDT DE 69004896 E Based on EP 415753
PRAI JP 1989-223196 19890831
IC G03G015-01; G03G021-00
STN INTERNATIONAL LOGOFF AT 14:44:17 ON 22 SEP 2004

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 70 of 70 returned.

☐ 1. Document ID: US 20040157771 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 70

File: PGPB

Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040157771 A1

TITLE: Rank-ligand-induced sodium/proton antiporter polypeptides

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge	WA	US	
Tometsko, Mark E.	Seattle	WA	US	
Dougall, William C.	Seattle	WA	US	
Mosley, Bruce A.	Seattle	WA	US	

US-CL-CURRENT: [514/12](#); [435/320.1](#), [435/325](#), [435/69.1](#), [530/350](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 20040142892 A1

L2: Entry 2 of 70

File: PGPB

Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142892
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040142892 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: [514/44](#); [435/199](#), [435/320.1](#), [435/325](#), [435/69.1](#), [536/23.2](#)

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for expressing a product of interest in a cell that involve a secretable RNA Polymerase.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040132088 A1

L2: Entry 3 of 70

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 20040132033 A1

L2: Entry 4 of 70

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132033

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132033 A1

TITLE: Human heparanase gene regulatory sequences

<http://westbtrs.9000/bin/gate.exe?f=TOC&state=ofb0q.3&ref=2&dbname=PGPB,USPT,USOC...> 9/22/04

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Elizabeth J.	Orinda	CA	US	
Wolffe, Alan P.	Orinda	CA	US	
Qi, Hong	Cottonwood	CA	US	

US-CL-CURRENT: 435/6; 435/200, 435/320.1, 435/325, 435/69.1, 536/21, 536/23.2

ABSTRACT:

Nucleotide sequences comprising regulatory regions of the human heparanase gene are provided. Also provided are methods and compositions for regulating heparanase expression, as well as methods and compositions for using heparanase sequences to regulate a heterologous target gene.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 5. Document ID: US 20040115770 A1

L2: Entry 5 of 70

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma

membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20040063907 A1

L2: Entry 6 of 70

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20040058881 A1

L2: Entry 7 of 70

File: PGPB

Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058881

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040058881 A1

TITLE: Ii-key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert E.	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20040038338 A1

L2: Entry 8 of 70

File: PGPB...

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038338
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038338 A1

TITLE: Influence of LRP cytoplasmic domain on Abeta production

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koo, Edward H.	La Jolla	CA	US	
Pietrzik, Claus	Nierstein		DE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid .beta.-protein (A.beta.). Methods for preventing or treating diseases wherein

amyloid .beta.-protein (A.beta.) is a major constituent of amyloid plaques or amyloidosis by interfering with production of A.beta. are described, as is a high throughput assay for screening compounds that inhibit A.beta. production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 9. Document ID: US 20040034199 A1

L2: Entry 9 of 70

File: PGPB

Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040034199
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040034199 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A	Bainbridge Island		GB	
Cosman, David J.	Bainbridge Island		GB	

US-CL-CURRENT: 530/358; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 10. Document ID: US 20040002455 A1

L2: Entry 10 of 70

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	

Morse, Clarence C.	Asbury	NJ	US
Guo, Yong	Freshmeadows	NJ	US
Cheng, Su	Bridgewater		US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 20030235575 A1

L2: Entry 11 of 70

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235575

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235575 A1

TITLE: Identification of oligoadenylate synthetase-like genes

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Matzuk, Martin M.	Pearland	TX	US	
Bai, Yuchen	Newtown	PA	US	
Yan, Wei	Houston	TX	US	

US-CL-CURRENT: 424/94.61; 435/199, 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 12. Document ID: US 20030229019 A1

L2: Entry 12 of 70

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229019

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229019 A1

TITLE: Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burke, James R.	Chapel Hill	NC	US	
Strittmatter, Warren J.	Durham	NC	US	
Nagai, Yoshitaka	Osaka		JP	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 435/7.1, 514/44, 530/324, 536/23.1

ABSTRACT:

Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 13. Document ID: US 20030224444 A1

L2: Entry 13 of 70

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224444

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030224444 A1

TITLE: Antibodies to native conformations of membrane proteins

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.1; 435/326, 435/69.1, 530/387.1

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 14. Document ID: US 20030219859 A1

L2: Entry 14 of 70

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

☐ 15. Document ID: US 20030204069 A1

L2: Entry 15 of 70

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030204069

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030204069 A1

TITLE: Segments of the human gene for telomerase reverse transcriptase

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morin, Gregg B.	Toronto	NV	CA	
Andrews, William H.	Reno		US	

US-CL-CURRENT: 536/23.2; 435/199, 435/320.1, 435/325, 435/456, 435/6, 435/69.1

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.3&ref=2&dbname=PGPB,USPT,USOC...> 9/22/04

transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 16. Document ID: US 20030198626 A1

L2: Entry 16 of 70

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198626 A1

TITLE: Inhibition of Ii expression in mammalian cells

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xu, Minzhen	Northborough	MA	US	
Humphreys, Robert	Acton	MA	US	

US-CL-CURRENT: 424/93.21; 435/320.1, 435/366, 435/456, 435/69.1, 536/23.5

ABSTRACT:

The present invention is directed toward composition and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. More specifically, disclosed are compositions and methods which relate to MHC Class II molecule presentation of antigenic epitopes which, under normal circumstances, would not be presented in association with MHC Class II molecules. The invention relates to presentation in cells which normally express MHC Class II molecules, as well as cells which can be induced to express MHC Class II molecules.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 17. Document ID: US 20030194727 A1

L2: Entry 17 of 70

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Kim, Jin-Soo	Yuseong-gu	KR
Park, Kyung-Soon	Yuseong-gu	KR
Lee, Dong-Ki	Yuseong-gu	KR
Seol, Wongi	Yuseong-gu	KR
Lee, Horim	Chungcheongnam-do	KR
Lee, Seong-Il	Yuseong-gu	KR
Yang, Hyo-Young	Yuseong-gu	KR
Lee, Yangsoon	Yuseong-gu	KR
Jang, Young-Soon	Yuseong-gu	KR

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1, 435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 18. Document ID: US 20030175920 A1

L2: Entry 18 of 70

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175920

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030175920 A1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonny, Christophe	Morges		CH	

US-CL-CURRENT: 435/184; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 20030171318 A1

L2: Entry 19 of 70

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171318
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030171318 A1

TITLE: Composition and method for treating viral infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: 514/44; 424/186.1, 435/6, 435/69.1, 514/12

ABSTRACT:

Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells.

Full	Title	Citation	Front	Renew	Classification	Date	Reference	Sequences	Attachments	Claims	RWOC	Drawn Desc
------	-------	----------	-------	-------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 20. Document ID: US 20030170871 A1

L2: Entry 20 of 70

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170871
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170871 A1

TITLE: Alphavirus-based vectors for persistent infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dubensky, Thomas W. JR.	Piedmont	CA	US	
Polo, John M.	Hayward	CA	US	
Perri, Silvia	Castro Valley	CA	US	
Belli, Barbara	San Diego	CA	US	

US-CL-CURRENT: 435/235.1; 424/93.21, 435/325, 435/456, 435/69.1, 536/23.72

ABSTRACT:

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein 2 gene which, when operably incorporated into an alphavirus replicon particle, eukaryotic layered vector initiation system, alphavirus vector construct or

RNA vector replicon, provides a noncytopathic phenotype or confers the ability to establish persistent replication. Also disclosed are RNA vector replicons, alphavirus vector constructs, alphavirus replicon particles and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules, as well as methods of using such replicons, constructs, particles and eukaryotic layered vector initiation systems for expression of recombinant proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 21. Document ID: US 20030166141 A1

L2: Entry 21 of 70

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Cox, George N. III	Louisville	CO	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Liu, Qiang	Foster City	CA	US	
Rebar, Edward J.	El Cerrito	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 22. Document ID: US 20030166099 A1

L2: Entry 22 of 70

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166099
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166099 A1

TITLE: Minicells comprising membrane proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Sabbadini, Roger A.	Lakeside	CA	US
Surber, Mark W.	Coronado	CA	US
Berkley, Neil	San Diego	CA	US
Segall, Anca M.	San Diego	CA	US
Klepper, Robert	San Diego	CA	US

US-CL-CURRENT: 435/69.1; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnostic and therapeutic uses, as well as research tools and agents for drug discovery.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 23. Document ID: US 20030165945 A1

L2: Entry 23 of 70

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 24. Document ID: US 20030152945 A1

L2: Entry 24 of 70

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152945
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030152945 A1

TITLE: Cell cycle progression proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deak, Peter	Cambridge		GB	
Glover, David Moore	Sandy		GB	
Midgley, Carol	Milton Keynes		GB	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 25. Document ID: US 20030148265 A1

L2: Entry 25 of 70

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148265

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030148265 A1

TITLE: Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brooks, Timothy John Gilby	Wiltshire		GB	
Duggan, Jacqueline Marie	Wiltshire		GB	

US-CL-CURRENT: 435/5; 424/159.1, 435/235.1, 435/252.3, 435/320.1, 435/69.1, 530/388.3

ABSTRACT:

A protein conjugate comprising conjugate comprising a first region comprising a factor that permits translocation of a protein across a cell membrane; and a second region comprising a single-chain antibody fragment which has affinity for a viral protein, in particular a viral protein which is necessary for replication of a virus such as a flavivirus.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 26. Document ID: US 20030143681 A1

L2: Entry 26 of 70

File: PGPB

Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143681
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143681 A1

TITLE: Human ataxin-1-like polypeptide IMX97018

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, Dirk M.	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/199, 435/254.2, 435/320.1, 435/325, 435/6, 536/23.2

ABSTRACT:

This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 27. Document ID: US 20030119771 A1

L2: Entry 27 of 70

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	
Tomme, Peter Herwig Maria	Gent		BE	
Klaassen, Hubertus Johannes Matheus	Herent		BE	

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as

the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 28. Document ID: US 20030118611 A1

L2: Entry 28 of 70

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118611

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030118611 A1

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Corey, Lawrence	Seattle	WA	US	

US-CL-CURRENT: 424/231.1; 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1, 435/69.1, 435/69.7, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 29. Document ID: US 20030108886 A1

L2: Entry 29 of 70

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108886

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030108886 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: 435/6; 435/199, 435/252.3, 435/320.1, 435/69.1, 514/44, 536/23.2

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for expressing a product of interest in a cell that involve a secretable RNA Polymerase.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 30. Document ID: US 20030108880 A1

L2: Entry 30 of 70

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 31. Document ID: US 20030104526 A1

L2: Entry 31 of 70

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104526

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030104526 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/320.1, 435/325, 435/6, 536/23.2

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 32. Document ID: US 20030103992 A1

L2: Entry 32 of 70

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030103992

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030103992 A1

TITLE: Clasp membrane proteins

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 424/185.1; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to cell surface molecules, designated cadherin-like asymmetry proteins ("CLASPs"). In particular, it relates to CLASP polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 33. Document ID: US 20030100093 A1

L2: Entry 33 of 70

File: PGPB

May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100093
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030100093 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Pl. Croix-Blanche	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/199; 435/320.1, 435/325, 435/368, 435/69.1, 536/23.2

ABSTRACT:

The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 34. Document ID: US 20030096344 A1

L2: Entry 34 of 70

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096344
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096344 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Pl. Croix-Blanche 25	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	

US-CL-CURRENT: 435/69.1; 424/146.1, 435/199, 435/320.1, 435/325

ABSTRACT:

The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 35. Document ID: US 20030087411 A1

L2: Entry 35 of 70

File: PGPB

May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 36. Document ID: US 20030077827 A1

L2: Entry 36 of 70

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077827

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077827 A1

TITLE: Surface transfection and expression procedure

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uhler, Michael D.	Ann Arbor	MI	US	

US-CL-CURRENT: 435/455; 435/325, 435/6, 435/69.1

ABSTRACT:

The present invention relates to a method of transfecting cells comprising applying cells directly onto nucleic acids which are immobilized in transfection complexes on a surface and which transfect the cells. Preferably, the nucleic acids are immobilized in an array. In another aspect of the present invention, the method further includes expression of the nucleic acids in the transfected cells. In yet another aspect of the present invention, the method further comprises detecting the expression of the nucleic acids in the transfected cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 37. Document ID: US 20030068675 A1

L2: Entry 37 of 70

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068675

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030068675 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/6, 702/19

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 38. Document ID: US 20030049602 A1

L2: Entry 38 of 70

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 39. Document ID: US 20030044404 A1

L2: Entry 39 of 70

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044404

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044404 A1

TITLE: Regulation of angiogenesis with zinc finger proteins

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	
Liu, Qiang	Foster City	CA	US	
Liu, Pei-Qi	Richmond	CA	US	
Wolffe, Alan	Orinda	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric	Boulder	CO	US	

US-CL-CURRENT: 424/94.63; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.3&ref=2&dbname=PGPB,USPT,USOC...> 9/22/04

ABSTRACT:

Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 40. Document ID: US 20030040038 A1

L2: Entry 40 of 70

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040038

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030040038 A1

TITLE: INDUCIBLE REGULATORY SYSTEM AND USE THEREOF

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DOWDY, STEVEN F.	CLAYTON	MO	US	
JESSEE, JOEL A.	MOUNT AIRY	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455

ABSTRACT:

The present invention provides an inducible regulatory system in which transcription of a target nucleotide sequence in a host cell is activated by the introduction of a fusion protein having a transcription activator region and a protein transduction domain for entry of the fusion protein into the cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 41. Document ID: US 20030036163 A1

L2: Entry 41 of 70

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 42. Document ID: US 20030008324 A1

L2: Entry 42 of 70

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 43. Document ID: US 20020177152 A1

L2: Entry 43 of 70

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 44. Document ID: US 20020173026 A1

L2: Entry 44 of 70

File: PGPB

Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/199; 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or

preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 45. Document ID: US 20020169283 A1

L2: Entry 45 of 70

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 46. Document ID: US 20020168683 A1

L2: Entry 46 of 70

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 47. Document ID: US 20020155432 A1

L2: Entry 47 of 70

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	
Weichselbaum, Ralph R.	Chicago	IL	US	
Roizman, Bernard	Chicago	IL	US	

US-CL-CURRENT: 435/5; 424/199.1, 424/205.1, 424/229.1, 435/320.1, 435/69.1

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one additional pharmacological agent or surgical procedure.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 48. Document ID: US 20020146788 A1

L2: Entry 48 of 70

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146788

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020146788 A1

TITLE: Artificial endonuclease

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franklin, Sonya	Iowa City	IA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/6, 435/69.1

ABSTRACT:

The present invention provides artificial endonucleases and methods to prepare and use those endonucleases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 49. Document ID: US 20020106676 A1

L2: Entry 49 of 70

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106676

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020106676 A1

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/368, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 50. Document ID: US 20020102267 A1

PGPUB-DOCUMENT-NUMBER: 20020102267
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102267 A1

TITLE: CLASP-5 transmembrane protein

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-5 ("CLASP-5"). In particular, it relates to CLASP-5 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-5 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMBC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 51. Document ID: US 20020086382 A1

L2: Entry 51 of 70

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086382
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086382 A1

TITLE: Clasp-3 transmembrane protein

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-3 ("CLASP-3"). In particular, it relates to CLASP-3 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-3

function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 52. Document ID: US 20020086361 A1

L2: Entry 52 of 70

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086361

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086361 A1

TITLE: Modulators of antiestrogen pharmacology

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Montano, Monica	Shaker Heights	OH	US	
Sutton, Amelia	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/456, 435/458, 530/350, 536/23.5

ABSTRACT:

A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 53. Document ID: US 20020061296 A1

L2: Entry 53 of 70

File: PGPB

May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061296

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020061296 A1

TITLE: Delivery method for the tumor specific apoptosis inducing activity of apoptin

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Noteborn, Mathieu H.M.	Leiderdrop		NL	
Voorhoeve, Pieter M.	Amsterdam		NL	

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.3&ref=2&dbname=PGPB,USPT,USOC...> 9/22/04

Zhang, Ying-Hui
Leliveld, Sirik R.

Leiden
Leiden

NL
NL

US-CL-CURRENT: 424/93.21; 424/94.63, 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example novel therapeutic proteinaceous compounds that can contain apoptin alone or jointly with other proteinaceous protein or protein fragments, especially in those cases when cells are derailed such as cancer-, auto-immune-derived cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 54. Document ID: US 20020039765 A1

L2: Entry 54 of 70

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 55. Document ID: US 20020001805 A1

L2: Entry 55 of 70

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 56. Document ID: US 6780986 B1

L2: Entry 56 of 70

File: USPT

Aug 24, 2004

US-PAT-NO: 6780986

DOCUMENT-IDENTIFIER: US 6780986 B1

TITLE: RIP60 nucleic acid and polypeptide sequences and uses therefor

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heintz; Nicholas H.	Jericho	VT		
Houchens; Christopher R.	Baltimore	MD		

US-CL-CURRENT: 536/23.5; 435/455, 435/69.1, 435/71.1, 435/91.4, 536/23.1

ABSTRACT:

The invention relates to nucleic acids and encoded polypeptides from the human zinc finger protein RIP60. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, fragments of the foregoing including functional fragments and variants. Kits containing the foregoing molecules additionally are provided.

7 Claims, 6 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

☐ 57. Document ID: US 6777185 B2

L2: Entry 57 of 70

File: USPT

Aug 17, 2004

US-PAT-NO: 6777185
DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

☐ 58. Document ID: US 6723512 B2

L2: Entry 58 of 70

File: USPT

Apr 20, 2004

US-PAT-NO: 6723512
DOCUMENT-IDENTIFIER: US 6723512 B2

TITLE: METHODS USING GENETIC PACKAGE DISPLAY FOR DETECTING AND IDENTIFYING PROTEIN-PROTEIN INTERACTIONS THAT FACILITATE INTERNALIZATION AND TRANSGENE EXPRESSION AND CELLS OR TISSUES COMPETENT FOR THE SAME AND METHODS FOR EVOLVING GENE DELIVERY VECTORS

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larocca; David	Encinitas	CA		

Kassner; Paul San Mateo CA
Baird; Andrew San Diego CA

US-CL-CURRENT: 435/6; 435/320.1, 435/5, 435/69.1, 435/DIG.14, 435/DIG.15, 435/DIG.2,
435/DIG.35, 435/DIG.4, 536/23.1

ABSTRACT:

A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, transduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package. Also provided are methods for evolving a ligand displaying package to facilitate gene delivery or delivery of any desired agent (e.g., pharmaceutical, polypeptide, peptide, etc.) into a cell and/or targeting cellular compartments such as the nucleus, endosome, chloroplast, mitochondria, etc.

33 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Reform	Classification	Date	Reference			Claims	RMBC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 59. Document ID: US 6703487 B2

L2: Entry 59 of 70

File: USPT

Mar 9, 2004

US-PAT-NO: 6703487
DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324,
530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 60. Document ID: US 6660259 B2

L2: Entry 60 of 70

File: USPT

Dec 9, 2003

US-PAT-NO: 6660259

DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Laquerre; Sylvie	Walnut Creek	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICPO polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

☐ 61. Document ID: US 6653102 B2

L2: Entry 61 of 70

File: USPT

Nov 25, 2003

US-PAT-NO: 6653102

DOCUMENT-IDENTIFIER: US 6653102 B2

TITLE: Nucleic acid encoding a phosphatase 2C that interacts with Fe 65

DATE-ISSUED: November 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roch; Jean-Marc	Salt Lake City	UT		
Bartel; Paul L.	Salt Lake City	UT		
Heichman; Karen	Salt Lake City	UT		
Mauck; Kimberly	Sandy	UT		
Dufford; Max	Salt Lake City	UT		

US-CL-CURRENT: 435/69.1; 435/183, 435/252.3, 435/254.11, 435/254.2, 435/320.1,
435/325, 536/23.5

ABSTRACT:

The present invention relates to the discovery of protein--protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 62. Document ID: US 6649158 B1

L2: Entry 62 of 70

File: USPT

Nov 18, 2003

US-PAT-NO: 6649158
DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 63. Document ID: US 6635244 B2

L2: Entry 63 of 70

File: USPT

Oct 21, 2003

US-PAT-NO: 6635244

DOCUMENT-IDENTIFIER: US 6635244 B2

TITLE: Adenovirus E1B-55K single amino acid mutants and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shen; Yuqiao	Richmond	CA		
Nye; Julie	Berkeley	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 424/93.1, 424/93.6, 435/235.1, 435/320.1, 435/455, 435/456, 435/69.1, 435/91.4, 435/91.41, 536/23.1

ABSTRACT:

Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.

7 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMK	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 64. Document ID: US 6485977 B1

L2: Entry 64 of 70

File: USPT

Nov 26, 2002

US-PAT-NO: 6485977

DOCUMENT-IDENTIFIER: US 6485977 B1

TITLE: Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collmer; Alan	Ithaca	NY		
Beer; Steven V.	Ithaca	NY		

US-CL-CURRENT: 435/455; 435/320.1, 435/325, 435/456, 435/69.1, 435/69.7, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.

11 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 65. Document ID: US 6475789 B1

L2: Entry 65 of 70

File: USPT

Nov 5, 2002

US-PAT-NO: 6475789

DOCUMENT-IDENTIFIER: US 6475789 B1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cech; Thomas R.	Boulder	CO		
Lingner; Joachim	Epalinges			CH
Nakamura; Toru	Boulder	CO		
Chapman; Karen B.	Sausalito	CA		
Morin; Gregg B.	Palo Alto	CA		
Harley; Calvin B.	Palo Alto	CA		
Andrews; William H.	Richmond	CA		

US-CL-CURRENT: 435/366; 424/94.1, 435/320.1, 435/69.1, 536/23.2

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

8 Claims, 40 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 66. Document ID: US 6472176 B2

L2: Entry 66 of 70

File: USPT

Oct 29, 2002

US-PAT-NO: 6472176

DOCUMENT-IDENTIFIER: US 6472176 B2

TITLE: Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof

DATE-ISSUED: October 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kovesdi; Imre	Rockville	MD		
Bruder; Joseph T.	Ijamsville	MD		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 435/69.7, 435/69.8, 536/23.1, 536/23.2, 536/23.4, 536/23.5, 536/23.7, 536/24.1

ABSTRACT:

The invention pertains to a polynucleotide encoding a chimeric protein comprising an endoplasmic reticulum localization signal peptide, a transport moiety, and a moiety of interest, wherein the endoplasmic reticulum localization signal peptide, the transport moiety, and the moiety of interest are operably linked with each other, a vector comprising the polynucleotide, a cell comprising such a vector, and a method of expressing a protein comprising the transport moiety and the moiety of interest.

25 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 67. Document ID: US 6451579 B1

L2: Entry 67 of 70

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6,
435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Keyword	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	---------	-------------

☐ 68. Document ID: US 6413518 B1

L2: Entry 68 of 70

File: USPT

Jul 2, 2002

US-PAT-NO: 6413518

DOCUMENT-IDENTIFIER: US 6413518 B1

**** See image for Certificate of Correction ****

TITLE: Immunologically significant herpes simplex virus antigens and methods for identifying and using same

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koelle; David M.	Seattle	WA		
Chen; Hongbo	Shoreline	WA		
Corey; Lawrence	Mercer Island	WA		
Hosken; Nancy Ann	Seattle	WA		
McGowan; Patrick	Seattle	WA		
Fling; Steven P.	Bainbridge Island	WA		
Posavad; Christine M.	Seattle	WA		

US-CL-CURRENT: 424/186.1; 424/184.1, 424/192.1, 424/231.1, 435/69.1, 435/69.3,
435/91.1, 435/91.4, 536/23.5

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

12 Claims, 56 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 69. Document ID: US 6350572 B1

L2: Entry 69 of 70

File: USPT

Feb 26, 2002

US-PAT-NO: 6350572
DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijssen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4, 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 70. Document ID: US 6313269 B1

L2: Entry 70 of 70

File: USPT

Nov 6, 2001

US-PAT-NO: 6313269
DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.3&ref=2&dbname=PGPB,USPT,USOC...> 9/22/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Full	Full	Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	------	------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L1 AND VP22	70

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 79 of 79 returned.

☐ 1. Document ID: US 20040157771 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 79

File: PGPB

Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157771

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040157771 A1

TITLE: Rank-ligand-induced sodium/proton antiporter polypeptides

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge	WA	US	
Tometsko, Mark E.	Seattle	WA	US	
Dougall, William C.	Seattle	WA	US	
Mosley, Bruce A.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040151739 A1

L4: Entry 2 of 79

File: PGPB

Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151739

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040151739 A1

TITLE: Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Monnier, Philippe P.	Tubingen		DE	
Mueller, Bernhard K.	Tubingen		DE	
Schwab, Jan	Tubingen		DE	

US-CL-CURRENT: 424/239.1; 514/12, 530/350

ABSTRACT:

The invention relates to the use of a composition, comprising a fusion protein and at least one transporter for the in-vivo inhibition of scar tissue formation, the in-vivo reduction of secondary damage and/or the in-vivo accumulation of macrophages. The fusion protein contains at least one binding domain for the transporter and at least one modulation domain for the covalent modification of small GTP-binding proteins. The transporter permits the uptake of the fusion protein in a target cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 3. Document ID: US 20040132969 A1

L4: Entry 3 of 79

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132969

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132969 A1

TITLE: Antibodies, peptides, analogs and uses thereof

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Melvin, William Thomas	Aberdeen		GB	
Thompson, William Douglas	Inverurie		GB	
Stirk, Christina Maureen	Stonghaven		GB	

US-CL-CURRENT: 530/350

ABSTRACT:

Fibrin degradation products stimulate cell proliferation and angiogenesis. The present invention provides peptides, analogs and antibodies which are useful in the modulation of fibrin fragment E activities such as modulation of cell proliferation.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 4. Document ID: US 20040132088 A1

L4: Entry 4 of 79

File: PGPB

Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20040115770 A1

L4: Entry 5 of 79

File: PGPB

Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or

recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 6. Document ID: US 20040072270 A1

L4: Entry 6 of 79

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072270
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072270 A1

TITLE: Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fernandez-Salas, Ester	Fullerton	CA	US	
Steward, Lance E.	Irvine	CA	US	
Aoki, Kei Roger	Coto de Caza	CA	US	

US-CL-CURRENT: 435/7.32; 435/23, 530/350

ABSTRACT:

The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 7. Document ID: US 20040063907 A1

L4: Entry 7 of 79

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20040058881 A1

L4: Entry 8 of 79

File: PGPB

Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058881
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058881 A1

TITLE: Ii-key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert E.	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 9. Document ID: US 20040038338 A1

L4: Entry 9 of 79

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038338
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038338 A1

TITLE: Influence of LRP cytoplasmic domain on Abeta production

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koo, Edward H.	La Jolla	CA	US	
Pietrzik, Claus	Nierstein		DE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid .beta.-protein (A.beta.). Methods for preventing or treating diseases wherein amyloid .beta.-protein (A.beta.) is a major constituent of amyloid plaques or amyloidosis by interfering with production of A.beta. are described, as is a high throughput assay for screening compounds that inhibit A.beta. production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 10. Document ID: US 20040038303 A1

PGPUB-DOCUMENT-NUMBER: 20040038303
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040038303 A1

TITLE: Biologic modulations with nanoparticles

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Unger, Gretchen M.	Chaska	MN	US	

US-CL-CURRENT: 435/7.1; 530/350, 530/387.1, 530/396, 536/123

ABSTRACT:

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Desc.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 11. Document ID: US 20040002455 A1

L4: Entry 11 of 79

File: PGPB

Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20030235594 A1

L4: Entry 12 of 79

File: PGPB

Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235594

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030235594 A1

TITLE: Ii-Key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 424/192.1; 435/320.1, 435/325, 435/69.3, 530/350, 536/23.5

ABSTRACT:

Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 13. Document ID: US 20030229202 A1

L4: Entry 13 of 79

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229202

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229202 A1

TITLE: Membrane penetrating peptides and uses thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guo, Yong	Fresh Meadows	NY	US	
Morse, Clarence C.	Asbury	NJ	US	
Yao, Zhengbin	Sugar Land	TX	US	
Keesler, George A.	Hillsborough	NJ	US	

US-CL-CURRENT: 530/350; 435/455

ABSTRACT:

The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 14. Document ID: US 20030228634 A1

L4: Entry 14 of 79

File: PGPB

Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030228634

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030228634 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/7.2; 435/320.1, 530/350

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the

proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The housekeeping epitope(s) can be derived from a target-associated antigen, and the housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 15. Document ID: US 20030220480 A1

L4: Entry 15 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220480

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220480 A1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonny, Christophe	Morges		CH	

US-CL-CURRENT: 530/350

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 16. Document ID: US 20030220474 A1

L4: Entry 16 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220474

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220474 A1

TITLE: Conjugate of biodegradable aliphatic polyester with Tat49-57 peptide or peptide chain containing Tat49-57 peptide and nanoparticle manufactured using the same

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Park, Ju Young	Yongin-si		KR	
Nam, Yoon Sung	Yongin-si		KR	

Han, Sang Hoon Suwon-si KR
Chang, Ih Seop Yongin-si KR

US-CL-CURRENT: 530/350; 436/518, 436/531

ABSTRACT:

Conjugates of a biodegradable aliphatic polyester-based polymer with Tat.sub.49-57 peptide or a peptide chain containing the Tat.sub.49-57 peptide, and nanoparticles manufactured using the same. Intracellular permeability of the Tat.sub.49-57 peptide can be enhanced by exposing Tat peptide moieties to the surface of the nanoparticles.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 17. Document ID: US 20030220264 A1

L4: Entry 17 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220264

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030220264 A1

TITLE: Reversible modification of membrane interaction

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rozema, David B.	Madison	WI	US	
Wakefield, Darren	Madison	WI	US	
Wolff, Jon A.	Madison	WI	US	
Ekena, Kirk	Madison	WI	US	
Hagstrom, James E.	Middleton	WI	US	

US-CL-CURRENT: 514/12; 530/350, 530/406

ABSTRACT:

An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 18. Document ID: US 20030219859 A1

L4: Entry 18 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 19. Document ID: US 20030219378 A1

L4: Entry 19 of 79

File: PGPB

Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219378
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219378 A1

TITLE: Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Piwnica-Worms, David	Ladue	MO	US	

US-CL-CURRENT: 424/1.69; 424/188.1, 424/9.34, 424/9.6, 530/350

ABSTRACT:

Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 20. Document ID: US 20030190324 A1

L4: Entry 20 of 79

File: PGPB

Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190324 A1

TITLE: Immunologically significant herpes simplex virus antigens and methods for using same

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Hosken, Nancy A.	Seattle	WA	US	
Posavad, Christine M.	Seattle	WA	US	
Chen, Hongbo	Shoreline	WA	US	
McGowan, Patrick	Seattle	WA	US	

US-CL-CURRENT: 424/186.1; 435/235.1, 435/320.1, 435/325, 435/5, 435/69.3, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 21. Document ID: US 20030175807 A1

L4: Entry 21 of 79

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175807
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175807 A1

TITLE: Chimeric GFP-aequorin as bioluminescent Ca²⁺ at the single cell level

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baubet, Valerie	Kansas City	MO	US	
Le Mouellic, Herve	Paris		FR	

US-CL-CURRENT: 435/7.1; 530/350, 536/23.2

ABSTRACT:

A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 22. Document ID: US 20030170826 A1

L4: Entry 22 of 79

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170826

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170826 A1

TITLE: Peptides for facilitating composite receptor expression and translocation of macromolecules

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rabinovich, Peter	Madison	CT	US	
Bray-Ward, Patricia	Madison	CT	US	
Ward, David C.	Madison	CT	US	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/7.5, 530/350, 536/23.5

ABSTRACT:

The invention relates to compositions and methods for expressing a composite receptor on the cell surface. The composite receptor can be integrated into a cell membrane via a fusion peptide which includes a cell penetrating domain linked to a transmembrane domain. In a preferred embodiment, the composite receptor further comprises a ligand binding domain. In yet another embodiment the invention relates to compositions and methods for translocating a nucleic acid or other molecule across the cell membrane into the cell. In a preferred embodiment, the nucleic acid or other molecule is linked to a fusion peptide comprising an adapter domain which is linked to a cell penetrating domain.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 23. Document ID: US 20030166160 A1

L4: Entry 23 of 79

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166160

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166160 A1

TITLE: Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hawley, Stephen B.	San Diego	CA	US	
Chapin, Steven	San Diego	CA	US	
Sheridan, Philip L.	San Diego	CA	US	
Houston, L. L.	Del Mar	CA	US	
Glynn, Jacqueline M.	San Diego	CA	US	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and/or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from the properties of monomers, complexes and compounds having only one targeting element directed to a paracellular and/or transcytotic ligand. The complexes and compounds of the invention undergo endocytosis, transcytosis and exocytosis; following endocytosis, the complexes or compounds may be transported into the cytosol or an organelle of a cell. In polarized cells, transcytosis can proceed in a "forward" or "reverse" direction. Reverse transcytosis is used for the non-invasive delivery of biologically active agents from the lumen of, e.g., the gastrointestinal tract or the airways of lungs, to the circulatory system. The complexes and compounds are incorporated in various compositions and medical devices suitable for medicinal or veterinary use.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 24. Document ID: US 20030165945 A1

L4: Entry 24 of 79

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 25. Document ID: US 20030119771 A1

L4: Entry 25 of 79

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	
Tomme, Peter Herwig Maria	Gent		BE	
Klaassen, Hubertus Johannes Matheus	Herent		BE	

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 26. Document ID: US 20030118611 A1

L4: Entry 26 of 79

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118611
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118611 A1

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Corey, Lawrence	Seattle	WA	US	

US-CL-CURRENT: 424/231.1; 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1,
435/69.1, 435/69.7, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 27. Document ID: US 20030118600 A1

L4: Entry 27 of 79

File: PGPB

Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118600
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118600 A1

TITLE: Transfer compounds, production and use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gerdes, Johannes	Feldhorst		DE	
Scholzen, Thomas	Neritz		DE	
Wohlenberg, Claudia	Hamburg		DE	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.3, 514/44, 530/350, 536/23.2

ABSTRACT:

The invention relates to the use of a carboxy-terminal fragment of the Ki-67 protein or of an active part, fragment or homologue thereof as a compound that can be used

for intracellular transfer and for the introduction in and the release by the cells. The invention further relates to transfer compounds that contain the above-mentioned Ki-67 protein and to the vectors encoding the same. The invention also relates to corresponding pharmaceutical compositions and to the use of the transfer protein as an excipient or active agent in the treatment of diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 28. Document ID: US 20030105277 A1

L4: Entry 28 of 79

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030105277

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030105277 A1

TITLE: Compositions and therapeutic methods for viral infection

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: 530/300; 424/186.1, 530/350

ABSTRACT:

Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the infected host cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 29. Document ID: US 20030066095 A1

L4: Entry 29 of 79

File: PGPB

Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030066095

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030066095 A1

TITLE: Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baubet, Valerie	Paris		FR	

LeMouellic, Herve Paris FR
Brulet, Philippe Paris FR

US-CL-CURRENT: 800/3; 424/9.6, 435/4, 530/350, 536/23.5

ABSTRACT:

A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 30. Document ID: US 20030055219 A1

L4: Entry 30 of 79

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055219

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030055219 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/7.1, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 31. Document ID: US 20030054409 A1

L4: Entry 31 of 79

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054409
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054409 A1

TITLE: Novel complex-forming proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jerome, Valerie	Coelbe		DE	
Sedlacek, Hans-Harald	Marburg		DE	
Mueller, Rolf	Marburg		DE	

US-CL-CURRENT: 435/7.1; 435/183, 435/320.1, 435/325, 435/69.5, 435/69.7, 530/350, 530/351

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGs	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 32. Document ID: US 20030054000 A1

L4: Entry 32 of 79

File: PGPB

Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054000
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054000 A1

TITLE: Anti-pathogen system and methods of use thereof

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dowdy, Steven F.	Clayton	MO	US	

US-CL-CURRENT: 424/94.63; 435/226, 530/327, 530/350, 536/23.4, 536/24.33

ABSTRACT:

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 33. Document ID: US 20030044427 A1

L4: Entry 33 of 79

File: PGPB

Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044427

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030044427 A1

TITLE: Compositions and methods for treating Papillomavirus-infected cells

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howley, Peter M.	Wellesley	MA	US	
Benson, John	Brookline	MA	US	
Kasukawa, Hiroaki	Princeton	NJ	US	

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 34. Document ID: US 20030036163 A1

L4: Entry 34 of 79

File: PGPB

Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 35. Document ID: US 20030032592 A1

L4: Entry 35 of 79

File: PGPB

Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030032592

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030032592 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: February 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 435/7.1, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 36. Document ID: US 20030017174 A1

L4: Entry 36 of 79

File: PGPB

Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030017174

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030017174 A1

TITLE: HERPES SIMPLEX VIRUS VP22 VACCINES AND METHODS OF USE

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BURKE, RAE LYNN	SAN FRANCISCO	CA	US	
TIGGES, MICHAEL A.	OAKLAND	CA	US	

US-CL-CURRENT: 424/231.1; 424/204.1, 530/300, 530/350, 530/826

ABSTRACT:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

☐ 37. Document ID: US 20020177692 A1

L4: Entry 37 of 79

File: PGPB

Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177692

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020177692 A1

TITLE: BCL-XL-interacting protein and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/184, 435/287.2, 435/320.1, 435/325, 435/69.7

ABSTRACT:

Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the

protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 38. Document ID: US 20020169283 A1

L4: Entry 38 of 79

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 39. Document ID: US 20020168683 A1

L4: Entry 39 of 79

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 40. Document ID: US 20020165352 A1

L4: Entry 40 of 79

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165352

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020165352 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 41. Document ID: US 20020164666 A1

L4: Entry 41 of 79

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164666

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164666 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.23; 435/183, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 42. Document ID: US 20020147306 A1

L4: Entry 42 of 79

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147306
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147306 A1

TITLE: Peptides that modulate the interaction of B class ephrins and PDZ domains

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lin, Danny	Scarborough		CA	
Pawson, Anthony	Toronto		CA	
Gish, Gerald	East York		CA	

US-CL-CURRENT: 530/350; 530/324

ABSTRACT:

The invention relates to complexes comprising a B class ephrin and a PDZ domain containing protein; peptides that interfere with the interaction of a B class ephrin

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

with a PDZ domain binding site, and a PDZ domain containing protein; and, uses of the peptides and complexes. Methods for modulating the interaction of a B class ephrin and a PDZ domain containing protein, and methods for evaluating compounds for their ability to modulate the interaction are also described.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 43. Document ID: US 20020115607 A1

L4: Entry 43 of 79

File: PGPB

Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115607

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020115607 A1

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 424/146.1, 435/194, 435/226, 530/350

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 44. Document ID: US 20020106378 A1

L4: Entry 44 of 79

File: PGPB

Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106378

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020106378 A1

TITLE: Materials and methods for intracellular transport and their uses

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Oxted		GB	
Elliott, Gillian Daphne	Oxted		GB	

US-CL-CURRENT: 424/186.1; 530/350

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 45. Document ID: US 20020086361 A1

L4: Entry 45 of 79

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086361

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086361 A1

TITLE: Modulators of antiestrogen pharmacology

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Montano, Monica	Shaker Heights	OH	US	
Sutton, Amelia	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/456, 435/458, 530/350, 536/23.5

ABSTRACT:

A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 46. Document ID: US 20020068302 A1

L4: Entry 46 of 79

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068302
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020068302 A1

TITLE: Clasp-4 transmembrane protein

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 435/7.1; 530/350, 536/23.1

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-4 ("CLASP-4"). In particular, it relates to CLASP-4 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-4 function.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 47. Document ID: US 20020039765 A1

L4: Entry 47 of 79

File: PGPB

Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 48. Document ID: US 20020032154 A1

L4: Entry 48 of 79

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020032154

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020032154 A1

TITLE: Interferon-suppressing placental lactogen peptides

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Peyman, John A.	New Haven	CT	US	

US-CL-CURRENT: 514/12; 435/184, 530/350

ABSTRACT:

Interferon-Suppressing Placental Lactogen Peptides (ISPLP) are disclosed which block actions of the human cytokine interferon-gamma. In addition, methods are disclosed for the treatment with ISPLP of certain disorders associated with increased expression of interferon-gamma-stimulated major histocompatibility complex antigens, such as autoimmune diseases, inflammatory diseases, and transplant rejection.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 49. Document ID: US 20020001805 A1

L4: Entry 49 of 79

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 50. Document ID: US 20010044417 A1

L4: Entry 50 of 79

File: PGPB

Nov 22, 2001

PGPUB-DOCUMENT-NUMBER: 20010044417

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010044417 A1

TITLE: Compound containing a labile disulfide bond

PUBLICATION-DATE: November 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolff, Jon A.	Madison	WI	US	
Monahan, Sean D.	Madison	WI	US	
Budker, Vladimir G.	Middleton	WI	US	
Slattum, Paul M.	Madison	WI	US	
Rozema, David B.	Madison	WI	US	

US-CL-CURRENT: 514/44; 514/2, 530/350, 536/23.1

ABSTRACT:

A labile disulfide-containing compound under physiological conditions containing a labile disulfide bond and a transduction signal.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 51. Document ID: US 6787326 B1

L4: Entry 51 of 79

File: USPT

Sep 7, 2004

US-PAT-NO: 6787326

DOCUMENT-IDENTIFIER: US 6787326 B1

TITLE: Interaction between the VHL tumor suppressor and hypoxia inducible factor, and

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

assay methods relating thereto

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ratcliffe; Peter John	Oxford			GB
Maxwell; Patrick Henry	Oxford			GB
Pugh; Christopher William	Oxford			GB

US-CL-CURRENT: 435/14; 435/6, 435/7.1, 435/8, 530/350

ABSTRACT:

The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor .alpha. subunits, by targeting HIF .alpha. for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF .alpha. subunit sequence which may modulate this interaction.

16 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 52. Document ID: US 6780970 B2

L4: Entry 52 of 79

File: USPT

Aug 24, 2004

US-PAT-NO: 6780970

DOCUMENT-IDENTIFIER: US 6780970 B2

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonny; Christophe	Morges			CH

US-CL-CURRENT: 530/324; 530/300, 530/325, 530/326, 530/332

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

13 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 53. Document ID: US 6773920 B1

L4: Entry 53 of 79

File: USPT

Aug 10, 2004

US-PAT-NO: 6773920

DOCUMENT-IDENTIFIER: US 6773920 B1

TITLE: Delivery of functional protein sequences by translocating polypeptides

DATE-ISSUED: August 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dalby; Brian	Carlsbad	CA		
Bennett; Robert P.	Encinitas	CA		

US-CL-CURRENT: 435/462; 435/455, 435/468, 435/471, 530/300, 530/350

ABSTRACT:

The invention provides methods for modulating a cellular process by contacting a cell in culture with a cell process-modifying molecule attached to a translocating polypeptide. For example, in one embodiment, a cell in culture is transfected with a target gene by contacting the cell in culture with a polynucleotide (that contains the target gene) attached to a translocating polypeptide. In another embodiment, expression of a target gene product in a cell in culture that contains a target gene under control of one or more regulatory elements is modulated by contacting the cell in culture with one or more regulatory agents attached to a translocating polypeptide. The one or more regulatory agents are translocated into the cell in culture and interact therein with the one or more regulatory elements to modulate expression of the target gene product by the cell.

37 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Index	Drawing
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	---------

☐ 54. Document ID: US 6740524 B1

L4: Entry 54 of 79

File: USPT

May 25, 2004

US-PAT-NO: 6740524

DOCUMENT-IDENTIFIER: US 6740524 B1

TITLE: Nucleic acid transfer phage

DATE-ISSUED: May 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Akuta; Teruo	Kumamoto			JP
Yokoi; Haruhiko	Tokyo			JP
Okuyama; Hajime	Hyogo			JP

Takeda; Katsuo	late of Tokyo	JP
Hasegawa; Mamoru	Ibaraki	JP
Nakanishi; Mahito	Osaka	JP

US-CL-CURRENT: 435/456; 435/235.1, 435/252.3, 435/252.33, 435/320.1, 435/69.7,
435/975, 530/350, 536/23.4

ABSTRACT:

The present invention provides a novel phage expressing in its head a bi-functional protein that has nuclear translocation and cell adhesion activities. The phage is used to package a foreign substance such as a gene. As a bi-functional protein, TAT protein of HIV can be used. The phage is useful in gene therapy.

18 Claims, 8 Drawing figures
 Exemplary Claim Number: 1,15
 Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMCC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 55. Document ID: US 6734167 B2

L4: Entry 55 of 79

File: USPT

May 11, 2004

US-PAT-NO: 6734167

DOCUMENT-IDENTIFIER: US 6734167 B2

TITLE: Uses of transport proteins

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Surry			GB
Normand; Nadia Michelle	Boulogne-Billancourt			FR
Brewis; Neil Douglas	Surry			GB
Phelan; Anne	Kent			GB

US-CL-CURRENT: 514/12; 424/204.1, 424/231.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

11 Claims, 0 Drawing figures
 Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMCC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 56. Document ID: US 6703487 B2

US-PAT-NO: 6703487

DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324, 530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 57. Document ID: US 6683048 B1

L4: Entry 57 of 79

File: USPT

Jan 27, 2004

US-PAT-NO: 6683048

DOCUMENT-IDENTIFIER: US 6683048 B1

TITLE: Compounds and methods for stimulating gene expression and cellular differentiation

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blaschuk; Orest W.	Westmount			CA
Gour; Barbara J.	Montreal			CA

US-CL-CURRENT: 514/2; 514/11, 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/9, 530/300, 530/326, 530/328, 530/329, 530/330

ABSTRACT:

Modulating agents for inhibiting an interaction between .alpha.-catenin and .beta.-catenin are provided. The modulating agents comprise one or more of: (a) a .beta.-catenin HAV motif; (b) a peptide analogue or mimetic of a .beta.-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a .beta.-catenin HAV motif. Methods for using such modulating agents for inhibiting

cadherin-mediated cell adhesion in a variety of contexts are also provided.

16 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 58. Document ID: US 6677116 B1

L4: Entry 58 of 79

File: USPT

Jan 13, 2004

US-PAT-NO: 6677116

DOCUMENT-IDENTIFIER: US 6677116 B1

TITLE: Methods for treating cancer by modulating .beta.-catenin mediated gene expression

DATE-ISSUED: January 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blaschuk; Orest W.	Westmount			CA
Byers; Stephen	Washington	DC		
Gour; Barbara J.	Kemptonville			CA

US-CL-CURRENT: 435/6; 514/14, 514/2, 514/9, 530/300, 536/22.1

ABSTRACT:

Modulating agents for inhibiting .beta.-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating .beta.-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.

13 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 59. Document ID: US 6673354 B2

L4: Entry 59 of 79

File: USPT

Jan 6, 2004

US-PAT-NO: 6673354

DOCUMENT-IDENTIFIER: US 6673354 B2

TITLE: Compositions and methods for treating papillomavirus-infected cells

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howley; Peter M.	Wellesley	MA		
Benson; John	Brookline	MA		
Kasukawa; Hiroaki	Princeton	NJ		

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

17 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Index	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-------	----------

☐ 60. Document ID: US 6669951 B2

L4: Entry 60 of 79

File: USPT

Dec 30, 2003

US-PAT-NO: 6669951

DOCUMENT-IDENTIFIER: US 6669951 B2

TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothbard; Jonathan B.	Cupertino	CA		
Wender; Paul A.	Menlo Park	CA		
McGrane; P. Leo	Mountain View	CA		
Sista; Lalitha V. S.	Sunnyvale	CA		
Kirschberg; Thorsten A.	Mountain View	CA		

US-CL-CURRENT: 424/436; 514/11, 514/16, 514/169, 514/2, 514/634, 514/636, 530/300, 530/329, 564/236, 564/243

ABSTRACT:

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that

has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

88 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 34

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 61. Document ID: US 6664040 B2

L4: Entry 61 of 79

File: USPT

Dec 16, 2003

US-PAT-NO: 6664040
DOCUMENT-IDENTIFIER: US 6664040 B2

TITLE: Compositions and methods for delivery of a molecule into a cell

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sherman; Michael P.	San Francisco	CA		
Greene; Warner C.	San Francisco	CA		
de Noronha; Carlos M.C.	San Francisco	CA		
Schubert; Ulrich	Bethesda	MA		
Henklein; Peter	Berlin			GB

US-CL-CURRENT: 435/5; 435/29, 435/325, 435/41, 530/300, 530/350, 530/395

ABSTRACT:

Provided is a composition comprising a Vpr polypeptide conjugated to a therapeutic molecule. Preferably, the Vpr comprises synthetic Vpr. The therapeutic molecule can comprise any molecule capable of being conjugated to Vpr or a fragment thereof, including a polypeptide, a polynucleotide, and/or a toxin. The invention additionally provides a method for delivering a molecule into a cell. The method comprises contacting the cell with a conjugate comprising a Vpr polypeptide conjugated to the molecule. The invention further provides a method for modulating the expression of a transgene in a cell, a method for killing a target cell population in a subject, a method for increasing the sensitivity of cells to radiation therapy, and a method for inhibiting cell proliferation.

14 Claims, 83 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 29

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 62. Document ID: US 6635258 B2

US-PAT-NO: 6635258

DOCUMENT-IDENTIFIER: US 6635258 B2

TITLE: Herpes simplex virus VP22 vaccines and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke; Rae Lyn	San Francisco	CA		
Tigges; Michael A.	Oakland	CA		

US-CL-CURRENT: 424/231.1; 424/185.1, 424/204.1, 424/229.1, 530/350

ABSTRACT:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

24 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 63. Document ID: US 6632616 B2

L4: Entry 63 of 79

File: USPT

Oct 14, 2003

US-PAT-NO: 6632616

DOCUMENT-IDENTIFIER: US 6632616 B2

**** See image for Certificate of Correction ****

TITLE: Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke; James R.	Chapel Hill	NC		
Strittmatter; Warren J.	Durham	NC		
Nagai; Yoshitaka	Osaka			JP

US-CL-CURRENT: 435/7.1; 435/4, 435/6, 530/350

ABSTRACT:

Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

6 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 64. Document ID: US 6610820 B1

L4: Entry 64 of 79

File: USPT

Aug 26, 2003

US-PAT-NO: 6610820

DOCUMENT-IDENTIFIER: US 6610820 B1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonny; Christophe	Morges			CH

US-CL-CURRENT: 530/300; 530/324, 530/326, 530/328

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

20 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 65. Document ID: US 6610542 B1

L4: Entry 65 of 79

File: USPT

Aug 26, 2003

US-PAT-NO: 6610542

DOCUMENT-IDENTIFIER: US 6610542 B1

**** See image for Certificate of Correction ****

TITLE: Efficient ex vivo expansion of cd4+ and cd8- T-cells from HIV infected subjects

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bell; David N.	Oakville			CA
Rosenthal; Kenneth Lee	Ancaster			CA

US-CL-CURRENT: 435/377; 424/93.2, 424/93.21, 435/320.1, 435/325, 435/455, 514/44, 530/350, 530/351

ABSTRACT:

Methods for the expansion of CD4, CD8, and DP T-cells from HIV infected patients are disclosed which allow the maintenance of low levels of HIV. The invention further discloses methods for the inhibition of HIV gene expression. Also disclosed are methods for the rapid and efficient screening of cells derived from HIV-infected patients to assess the suitability of various antiviral treatments. The invention further provides a means for the generation of cell banks for use in immune reconstitution and means of treating or modifying expanded cell populations prior to infusion to enhance or modulate therapeutic effectiveness.

33 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 66. Document ID: US 6593292 B1

L4: Entry 66 of 79

File: USPT

Jul 15, 2003

US-PAT-NO: 6593292

DOCUMENT-IDENTIFIER: US 6593292 B1

TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothbard; Jonathan B.	Cupertino	CA		
Wender; Paul A.	Menlo Park	CA		
McGrane; P. Leo	Mountain View	CA		
Sista; Lalitha V. S.	Sunnyvale	CA		
Kirschberg; Thorsten A.	Mountain View	CA		

US-CL-CURRENT: 514/2; 514/11, 514/12, 514/15, 514/159, 514/16, 514/169, 514/17, 514/254.07, 514/263.31, 514/291, 514/423, 514/456, 514/458, 514/634, 514/635, 514/636, 530/300, 530/321, 530/328, 530/329, 530/330, 544/366

ABSTRACT:

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient

guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

134 Claims, 41 Drawing figures
Exemplary Claim Number: 61
Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 67. Document ID: US 6461822 B2

L4: Entry 67 of 79

File: USPT

Oct 8, 2002

US-PAT-NO: 6461822
DOCUMENT-IDENTIFIER: US 6461822 B2

TITLE: Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gabel; Christopher A.	Ledyard	CT		
Griffiths; Richard J.	East Lyme	CT		
Eggler; James F.	Stonington	CT		
Dombroski; Mark A.	Waterford	CT		
Geoghegan; Kieran	Mystic	CT		

US-CL-CURRENT: 435/7.2; 435/7.1, 530/350, 536/23.5, 564/305

ABSTRACT:

The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1.beta..

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 68. Document ID: US 6451601 B1

L4: Entry 68 of 79

File: USPT

Sep 17, 2002

US-PAT-NO: 6451601
DOCUMENT-IDENTIFIER: US 6451601 B1

TITLE: Transiently immortalized cells for use in gene therapy

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baetge; Edward E.	St. Sulpice			CH
Wong; Shou	Verona	WI		
Dupraz; Philippe	Crissier			CH
Thorens; Bernard	Epalinges			CH

US-CL-CURRENT: 435/366; 435/377, 435/405, 530/350, 536/23.4

ABSTRACT:

The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

12 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMHC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 69. Document ID: US 6451579 B1

L4: Entry 69 of 79

File: USPT

Sep 17, 2002

US-PAT-NO: 6451579

DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and

subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 70. Document ID: US 6399075 B1

L4: Entry 70 of 79

File: USPT

Jun 4, 2002

US-PAT-NO: 6399075
DOCUMENT-IDENTIFIER: US 6399075 B1

TITLE: Compositions and methods for treating Papillomavirus-infected cells

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howley; Peter M.	Wellesley	MA		
Benson; John	Brookline	MA		
Kasukawa; Hiroaki	Princeton	NJ		

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

32 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 71. Document ID: US 6375952 B1

L4: Entry 71 of 79

File: USPT

Apr 23, 2002

US-PAT-NO: 6375952
DOCUMENT-IDENTIFIER: US 6375952 B1

**** See image for Certificate of Correction ****

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koelle; David M.	Seattle	WA		
Corey; Lawrence	Seattle	WA		

US-CL-CURRENT: 424/186.1; 424/192.1, 424/199.1, 424/231.1, 435/235.1, 435/252.3,
435/320.1, 435/325, 435/69.3, 435/69.7 , 530/350, 536/23.4, 536/23.7

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

39 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Index	Abstract	Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-------	----------	--------	------	------------

☐ 72. Document ID: US 6358739 B1

L4: Entry 72 of 79

File: USPT

Mar 19, 2002

US-PAT-NO: 6358739

DOCUMENT-IDENTIFIER: US 6358739 B1

**** See image for Certificate of Correction ****

TITLE: Transiently immortalized cells

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baetge; Edward E.	St. Sulpice			CH
Wong; Shou	Lausanne			CH
Dupraz; Philippe	Crissier			CH
Thorens; Bernard	Epalinges			CH

US-CL-CURRENT: 435/377; 530/350

ABSTRACT:

The invention provides methods and compositions for expanding cells that are not

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

12 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 73. Document ID: US 6316252 B1

L4: Entry 73 of 79

File: USPT

Nov 13, 2001

US-PAT-NO: 6316252
DOCUMENT-IDENTIFIER: US 6316252 B1

TITLE: Biotherapeutic delivery system

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Harms; Jerome S.	Madison	WI		
Splitter; Gary A.	Brooklyn	WI		

US-CL-CURRENT: 435/320.1; 435/69.7, 530/350, 530/826, 536/23.4, 536/23.72

ABSTRACT:

Disclosed herein are fusion proteins, nucleotide sequences for creating them, and vectors containing the nucleotide sequences. The fusion proteins have a bovine herpesvirus protein linked to a biotherapeutic protein or reporter protein. They rapidly spread biotherapeutic or reporter protein throughout mammalian cells.

4 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 74. Document ID: US 6313269 B1

L4: Entry 74 of 79

File: USPT

Nov 6, 2001

US-PAT-NO: 6313269
DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atherosclerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 75. Document ID: US 6251398 B1

L4: Entry 75 of 79

File: USPT

Jun 26, 2001

US-PAT-NO: 6251398

DOCUMENT-IDENTIFIER: US 6251398 B1

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxtd			GB
Elliott; Gillian Daphne	Oxtd			GB

US-CL-CURRENT: 424/186.1; 424/192.1, 424/204.1, 424/208.1, 424/248.1, 424/263.1, 435/235.1, 435/252.3, 435/317.1, 435/325, 530/350, 530/826, 536/23.4

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ofb0q.5&ref=4&dbname=PGPB,USPT,USOC...> 9/22/04

proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 76. Document ID: US 6200577 B1

L4: Entry 76 of 79

File: USPT

Mar 13, 2001

US-PAT-NO: 6200577

DOCUMENT-IDENTIFIER: US 6200577 B1

TITLE: Anti-herpesviral agents and assays therefor

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McLauchlan; John	Glasgow			GB
McGeoch; Duncan James	Glasgow			GB
Hope; Ralph Graham	Glasgow			GB
Rixon; Helen Winton McLaren	Strathblane			GB

US-CL-CURRENT: 424/229.1; 424/204.1, 424/231.1, 435/5, 435/7.93, 435/975, 530/300, 536/23.72

ABSTRACT:

There is described an antiviral agent capable of disrupting the association of two viral structural proteins required for maturation, replication and infection of herpesviruses. The agents are based upon VP22 and disrupt the normal association of that protein with VP16 and/or gB. Suitable agents are peptides having the amino acid sequences TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLW or ITTIRVTVCEGKNLLQRANE. The agents are suitable for combatting infection of herpesviruses and thus for the treatment of cold sores, genital herpes, chickenpox and shingles. An assay to test for agents able to disrupt VP22/VP16 and/or VP22/gB association is also described.

13 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 77. Document ID: US 6184038 B1

L4: Entry 77 of 79

File: USPT

Feb 6, 2001

US-PAT-NO: 6184038

DOCUMENT-IDENTIFIER: US 6184038 B1

**** See image for Certificate of Correction ****

TITLE: Transport proteins and their uses

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/455; 435/468, 435/471, 530/300, 530/350

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

8 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 78. Document ID: US 6086900 A

L4: Entry 78 of 79

File: USPT

Jul 11, 2000

US-PAT-NO: 6086900

DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3, 435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 79. Document ID: US 6017735 A

L4: Entry 79 of 79

File: USPT

Jan 25, 2000

US-PAT-NO: 6017735

DOCUMENT-IDENTIFIER: US 6017735 A

**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxtd			GB
Elliott; Gillian Daphne	Oxtd			GB

US-CL-CURRENT: 435/69.7; 435/252.3, 435/317.1, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.4, 536/23.5

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.

19 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L3 AND VP22	79

Display Format:

